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I Introduction 
1.1 Platelet-derived extracellular vesicles in platelet storage lesion and platelet 
senescence 
Anucleated platelets are small (0.5 - 1 µm), discoid blood cells with a lifespan up to 10 days in 
the human circulatory system (1, 2). They play an essential role in primary hemostasis and are 
filled with α-granules, dense granules and lysosomes (3). Intracellular α-granules are 
surrounded by membranes which contain proteins, chemokines, growth factors and immune 
mediators. Immune mediators constitute a large group of active molecules which includes, 
among the others, glycoprotein (GP) IIb-IIIa (integrin αIIbβ3), p-selectin, factor V (FV), factor IX 
(FIX), protein S, tissue factor (TF), plasminogen, plasminogen activator inhibitor 1 (PAI-1), 
fibrinogen, von Willebrand factor (vWF), thrombospondin, growth factors (epidermal, insulin-like, 
vascular endothelium, fibroblast, platelet-derived), complement C3, complement C4, C1 
inhibitor, β1H globulin (factor H) and immunoglobulin G (IgG). Dense granules contain Ca
2+
, 
Mg
2+
 and K
+
, polyphosphate, pyrophosphate, serotonin, histamine and nucleotides (e.g. ADP 
and ATP). Platelet lysosomes are filled with enzymes degrading proteins (e.g. cathepsin, 
elastase and collagenase), carbohydrates (e.g. glucosidase, fucosidase and galactosidase) and 
lipids (e.g. acid phosphatase). 
Additionally to granules and cytoskeletal components, platelets also contain other organelles 
such as mitochondria and the dense tubular system which is analogous to the endoplasmic 
reticulum connected to the open canalicular system and glycogen stores.  
Circulating platelets undergo senescence prior to clearance; the cells are not capable of 
division, they are metabolically active, though. Ex-vivo resting platelets undergo platelet storage 
lesion and they are subjected to either activation-mediated death or to storage-induced death. 
The storage “phenotype” of platelets, which translates to cell death, may also be responsible for 
necrotic or apoptotic changes (1), as well as for activation (2).  
Platelet storage lesion (PSL) or platelet storage defect (PSD) comprise platelets which lost their 
typical functional characteristics. This means loss of membrane integrity, p-selectin release, 
shedding of surface proteins (receptors), diminished mitochondrial membrane potential, 
increase of the intracellular calcium level with a secondary activation of proteases (caspases), 
externalization of phosphatidylserine (PS) and secretion of platelet-derived extracellular vesicles 
(PL-EVs) (2), see Figure I-1. The presence of PSL justifiably corresponds to the reductions of in 
vivo survival and haemostatic activity after transfusion (4). Changes in PSL platelets are 
influenced by alterations during collection, processing and storage in platelet concentrates 
(PCs) (5).  
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Figure I-1: Summary of changes related to platelet storage lesion (PSL) and formation of 
platelet-derived extracellular vesicles (PL-EVs) 
The figure demonstrates the effects of storage conditions ex vivo (left) and the modulation of 
platelet morphology, physiology and function (right). 
 
Storage of platelet concentrates is performed under continuous agitation under standard blood 
banking conditions at 22°C ± 2°C for 5 days, including the day of apheresis. Agitation is carried 
out in bags with oxygen exchange in order to maintain the aerobic adenosine triphosphate 
(ATP) formation. Obviously, there are several factors which influence PSL such as temperature, 
storage duration, form and intensity of agitation, volume of suspending plasma, permeability of 
the membranes of a storage container and a leukodepletion technique (5). Exemplarily, storage 
carried out almost at physiological temperatures (37°C) improves the viability of platelets due to 
a decrease of a rapid ATP turnover and a lower metabolic activity of stored platelets (5, 6). 
Additionally, a 16%-release of α-granules within seven days of storage was described and the 
release was independent from different rotators used. This leads to a loss of functional proteins, 
essential for the adequate coagulation response after transfusion in vivo (7). To control the 
effects of these factors during storage of PCs, several techniques were used and incorporated 
into the quality control process (explained in detail in chapter 1.2, page 7). 
PL-EVs were described first in 1967 as a coagulable “platelet dust” (8). They are also 
connected with the term of platelet factor 3 (PF3) activity and its role in coagulation (9). Platelet 
vesiculation led back to the observation of a 10-fold rise in the PF3 activity during platelet 
storage (10). The raise in PF3 activity is accompanied by a stable platelet count. Nearly three 
decades ago, an active PF3 was regarded as a part of PSL in a process of platelet activation 
and damage (11). The presence of PL-EVs or platelet-derived microvesicles (PL-MVs) in stored 
PCs has been well demonstrated. Already in 1986/87, Solberg et al. recognized it and found a 
correlation between the presence of PL-MVs and PF3 activity (12, 13). Formation of platelet-
derived vesicles particularly elevates in PCs exhibiting high pH, associated with LDH release.  
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In 1988, George et al. showed rotation dependency on PL-MV level over 7 days storage as a 
shear stress model. Inappropriate shear stress and/ or activation of platelets during storage 
result in elevated vesicle levels (7). During a study on supplementation of platelets with 
activation inhibitors that protect platelets from damage, the group of Bode demonstrated in 1991 
that solely partial inhibition of vesiculation occurred (40%), resulting in a hypothesis that not only 
activated platelets shed MVs. However, MVs seemed to appear already at physiological 
concentrations in matured platelets (14). The group of Bode delineated two populations of 
microparticles (MPs): one population corresponding to fluorescent beads smaller than 0.5 µm 
and another one corresponding to fluorescent beads, larger than 0.5 µm.  
Nowadays, it is well known that strongly procoagulant PL-MVs or PL-EVs released from 
membranes of intact platelets are present in PCs but there are many questions in platelet 
transfusion medicine which still remain unanswered. 
Various functions of PL-MVs in PCs can be ascribed to four pathologic conditions (Figure I-2). 
The first condition is related to mechanical injury and shear stress during collection and 
processing. It is not distinguishable to which extent PL-MV components are released from donor 
platelets in vivo and ”collected” in the suspended donor plasma as compared to the release via 
the non-physiological shear force of the apheresis systems. Rank et al. isolated annexin V 
positive microvesicles which reached the concentrates and the group compared the vesicle 
content of PCs to the MV content in the donor plasma (15). PL-MVs in PCs (93% of all MVs) 
differed by 39% from the PL-MV amount obtained from donor plasma (1.6 to 1), suggesting that 
plateletpheresis concentrates contain more PL-MVs than the donor´s pre-donation samples and 
they seem to be constant in PL-MV enrichment during storage over 5 days. Rank et al. 
assumed that the most abundant amount of PL-MVs in PCs results from the collection process 
and not from the donor plasma. PL-MVs originate to a lesser extent from activated platelets (p-
selectin positive PL-MVs in 4.8%) rather than from resting platelets with stable annexin V 
positive MVs. However, the group of Rank found increased degranulation of p-selectin in PL-
MVs dependent on the storage time. Furthermore, the results indicated that CD63 positive 
platelet-derived exosomes (PL-EXs) are present in isolated MVs. Additionally, exosomes 
showed a significant increase on the fifth day of storage thus representing a minor fraction 
(2.6%) in comparison to the dominant larger PL-MVs (15).  
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Figure I-2: Potential mechanisms behind the presence of platelet-derived extracellular vesicles 
(PL-EVs) in plateletpheresis concentrates (PCs) 
 
Sloand et al. observed that the application of different preparation techniques (e.g. apheresis 
versus whole blood-derived PCs) and different anticoagulants (e.g. ACD versus CPDA-1) result 
in different amounts of PL-MVs (16). These findings support the hypothesis that the abundant 
amount of PL-MV in PCs is dependent on the conditions of collection and not necessarily on the 
donor plasma at the time of apheresis. However, at this point it cannot be excluded that there 
are donors, who have more sensitive platelet membranes and therefore generate more PL-MVs 
during plateletpheresis. 
In addition, activation of stored platelets due to their contact with the plastic surface of a storage 
container takes place in the vesiculation fraction of PCs. Reduction of the surface-to-volume 
ratio (S/V) in PCs resulted in a lower LDH release and it significantly correlated to the total MP 
count, suggesting that the cytoplasmic content of all vesicles is regulated by the vesiculation of 
platelets (14). With the decrease in the adhesion of the platelets to the surface of the storage 
container, fewer platelets become activated thus being more prone to form platelet-derived 
vesicles.  
Since 1997, various mechanisms have already been observed which “lead to microvesiculation 
of platelets during storage” (17), see Table I-1. Seghatchian et al. described available methods 
for quantification and characterization of PL-MVs. Nowadays, these methods overlap such 
evaluation approaches as flow cytometric analysis of specific markers (GPIb, GPIIb/IIIa) using 
monoclonal antibodies (moAbs) or analysis of PS exposure by annexin V labeling. Although, 
since then flow cytometry has been the favored method, the comparison of standard flow 
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cytometers with advanced new high-resolution flow cytometers indicates more possibilities in 
detection of vesicles as far as their lower size and higher sensitivity are concerned. 
 
Table I-1: Potential mechanisms of PL-EV formation during collection and storage 
Mechanical disruption and excessive shear stress, e.g. passage through low gauge needles 
or leukocyte filters, high g force, rigorous agitation 
Activation by platelet aggregation agonists, e.g. ADP, thrombin, during collection and storage 
Activation and secretion of platelets caused by poor handling and prolonged exposure to low 
temperatures (4°C) and high pH > 7.6 
Lysis of platelets caused by freezing-thawing, lyophilization and rehydration; prolonged 
exposure to low pH <6.2 
Exposure to activated complement components, leukocyte- and platelet-derived cytokines 
and enzymes, e.g. calpain, histamine 
 (Table adjusted to (17)) 
 
Senescence and apoptosis of platelets in PCs stored for five days could induce increased 
vesicle formation. With the purpose of explaining to which extent PL-MVs or PL-EXs originate 
from senescent or apoptotic platelets, it is essential to better define the “phenotype” of these 
vesicles compared to the vesicles from activated platelets. However, no evidence has been yet 
found to prove any principal differences between these vesicle groups. On the other hand, 
understanding of the process of vesicle formation during senescence and/ or apoptosis in PCs 
is indispensable and needs reinvestigation with the help of currently available more 
sophisticated methods. Though, despite of the fact that mechanisms of PSL and senescence 
may overlap, PSL and the apoptotic program are two distinct processes, even if some authors 
use the names of PSL and senescence interchangeably (1, 18).  
As aforementioned, when inhibitors applied only, the reduction of activation-dependent 
generation of PL-EVs in stored platelets averages approximately 40%. Nevertheless, 
significantly lower PL-EV levels within the storage time of 9 days versus control (14) suggest 
that remaining PL-EVs originate from resting/ senescent platelets. “In vitro experiments 
demonstrate that platelet apoptosis can be induced by calcium ionophores, other platelet 
agonists [during] storage at room temperature under blood banking conditions” (5). It is evident 
that platelets undergo apoptosis at 37°C, accompanied by a loss of platelet viability and a 
gradual rise in caspase-3 and caspase-9 activities (19). The inhibition of platelet apoptosis by 
Introduction  6 
  
cell-permeable caspase-inhibitors could improve the viability of platelets but this approach 
turned out to be ineffective in this study. Under this condition, gelsolin, a caspase-3 substrate 
affected in apoptosis, was cleaved as caspase-3 activity rose. This process, also observed by 
Thiele et al., became acknowledged as a cytosolic protein biomarker of apoptosis of platelets 
subjected to 9-day storage (20). Whereas 97% of cytosolic proteins remained unchanged, 
gelsolin and septin 2 belong to the group of 3% of proteins which undergo changes as analyzed 
by differential gel electrophoresis (DIGE) and mass spectrometry. 
Thiele et al. also found proteins involved in the early storage lesion, e.g. the focal adhesion 
signaling integrin αIIbβ3 (21), which plays a role as a proteomic biomarker of platelet quality. 
The investigation of changes of cytosolic proteins during storage, especially of the proteins 
connected to signaling pathways underlying storage lesion development (22), may at least 
partially correspond to activation, senescence and apoptosis of platelets and the underlying 
vesiculation. 
PS exposure, detectable by annexin V binding and release of p-selectin provide evidence for an 
effect of apoptosis on platelet viability.  
Although platelet mitochondria maintain their transmembrane potential (Δψ(m)) upon storage 
over 7 days, which does not correlate to the downstream protein markers, selected stressors 
(i.e. calcium ionophore stimulation) lead to higher degrees of mitochondrial depolarization (23). 
The preparation techniques also affect the Δψ(m) of platelets and the percentage of platelets 
with depolarized Δψ(m) significantly increases in buffy-coat PCs as compared with PCs 
produced by apheresis (24).  
In addition to the observed mitochondrial changes, the group of Albanyan showed growing 
values, both percentage and absolute, of the immature platelet fraction (IPF) as determined by 
Sysmex XE-2100 in PCs over 7-day storage (25). Simultaneously, the platelet count remained 
stable, whereas mean platelet volume (MPV) and platelet distribution width (PDW) exhibited a 
small increase. The fluorescent dye Thiazole Orange, used for detection of immature platelets 
with residuals of nucleic acid shows non-specific binding to basic proteins and anionic 
phospholipids which appear on the platelet surface during senescence. Dense granular or other 
platelet structures may become also unspecifically dyed because of their nucleotides or 
messenger RNA (mRNA) which affect the elevation of IPF levels. Thus far, no investigation has 
confirmed the presence of mRNA or micro RNA (miRNA) in PL-EVs. Yet, their presence is very 
likely to the expression of miRNA, detected in human peripheral blood vesicles (26-28) and 
most vesicles in circulating blood originate from platelets (or megakaryocytes, see chapter 
1.4.2, page 25). It cannot be excluded that platelet-derived vesicles, which contain mRNA or 
miRNA, contribute to unspecific staining. 
Gamma irradiation of platelet concentrates prevents transfusion-associated graft-versus-host 
disease (TA-GvHD) and may lead to an increase of vesiculation. Upon application of the 
required irradiation dose of 25 Gray (Gy), as assessed by Food and Drug Administration (FDA), 
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no differences were found between irradiated and non-irradiated PCs, including swirling, 
hypotonic shock response (HSR), the percentage of GPIb-expressing cells and pH during 7 
days of storage (29). On the other hand, development of elasticity points to a slower 
progression after storage in the irradiated group leading to the assumption, that vesiculation 
increases under the condition of the loss of membrane elasticity. Gamma irradiation applied on 
the first day of storage causes pronounced proteome changes, responsible for specific catalytic 
activities and/ or protein/ nucleic acid binding capacity, involved in the platelet storage lesion in 
PCs (30). 
 
1.2 Plateletpheresis concentrate quality 
It is essential to carry out laboratory tests in order to guarantee consistent and uniform quality of 
plateletpheresis concentrates. However, there is no single laboratory test which would reflect 
potential hemostatic effects of platelets in vivo and there is no established benchmark which 
can be used to translate the measured loss of platelet function to an appropriate graduation of 
PC quality (17). Many applicable tests were validated for identifying PSL of platelets. 
Nevertheless, there are established standards for platelet concentrate quality within quality 
control (QC) programs to detect problems during collection, processing or storage (5) according 
to the corresponding guidelines. There are currently several protocols for quality control used; 
the most popular are as follows: (i) the AABB (American Association of Blood Banks) technical 
manual (31) for the United States, (ii) the Guide to preparation, use and quality assurance of 
blood components (32) for Europe and (iii) the German guidelines for production and application 
of blood and blood components (33). 
These guidelines recommend determination of platelet count (number), concentrate volume, 
supernatant pH and residual leukocytes in clinical practice, although single test criteria deviate, 
e.g. the required pH in the United States is lower than 6.2, whereas in Germany it varies 
between 6.4 and 7.8. Routinely applied tests in PCs reflect only a minor part of the platelet 
changes during storage, also mentioned as the PSL. In addition, all these tests (see Table I-2) 
only determine the viability and function of platelets in vitro. Many investigators favor the 
measurement of the percentage recovery and in vivo survival of radiolabeled (generally with 
51
chromium or with
 111
indium), autologous platelets as a gold standard (34). This fact should be 
considered if altered or new storage conditions and/ or platelet substituents are evaluated (5). In 
healthy individuals, the mean in vivo recovery of fresh platelets from platelet rich plasma (PRP) 
amounts to 60-70%, whereas, after 5 days of storage, the mean recovery amounts to 45-50%. 
Higher recovery rates were observed for apheresis concentrates on the 5
th
 day.  
However, an acceptable “standard for approval” by FDA does not exist for platelet recovery and 
a standardization of practical implementation has not yet been established as compared with 
the standardized techniques for vesicle measurement (see chapter 1.4.6; page 29). 
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Table I-2: In vitro tests of platelet concentrate quality monitoring 
Platelet structure Cellular content (platelet count) 
Visual inspection of swirling phenomena 
Platelet morphology by microscopy 
Platelet size distribution by automated counters (PMV, PDW) 
Measurement of reticulated platelets  
Immature platelet fraction (IPF) 
Functional tests Platelet aggregation, spontaneous and agonist-directed 
Hypotonic shock response (HSP) 
Extent of shape change 
Thrombin-stimulated ATP release 
Metabolic status Supernatant pH, pO2, pO2, HCO3 
Glucose consumption 
Lactate production 
Platelet activation p-selectin (CD62P) surface expression 
Soluble p-selectin release into supernatant 
Platelet factor 4 and β-thromboglobulin 
Annexin V binding to estimate the reorganization of 
phosphatidylserine (PS) exposure 
Lactate dehydrogenase (LDH) release into supernatant 
Platelet microparticle formation 
Possibility of transfusion 
reactions (TR) 
Bacteriological growth 
Cytokines 
Activated complement components, i.e. C3a 
Otherwise Residual leukocytes 
Residual red blood cells (RBC) 
(Table adjusted to (17, 23)) 
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Two in vitro tests should be explained as examples for all tests listed in Table I-2. The simplest 
evaluations include visual examination of PCs before they are applied to patients. Upon 
exposing of the storage bag to any light source, a “swirling” phenomenon occurs due to the fact 
that resting platelets are discoid and refract light within the moved storage bag. If pH of stored 
PCs drops below the value of 6.2 or platelets underlie activation, the former discoid/ spherical 
shape of platelets undergoes morphological changes with formation of pseudopodia. Shape 
change causes the disappearance of the “swirling” phenomenon caused by the fact that shape-
changed platelets are not able to refract light (5). The weaker “swirling” phenomenon correlates 
to a lower platelet increment in vivo which is measurable after transfusion (5, 35). This happens 
because pH lower than 6.3 translates to diminished in vivo survival after transfusion (5). The 
subsequent discoid/ spherical conversion and microvesiculation result in decrease of mean 
platelet volume (MPV) (17). MPV is a common parameter, which is measured by automated 
hematology blood counters and could be easily implemented in the running procedures of 
clinical practice to maintain the visualized “swirling” phenomenon, which considerably depends 
on individuals and status of training.  
The analysis of platelet activation during manufacturing by flow cytometry and evaluation of the 
p-selectin (CD62P) exposure at the platelet surface (36) is another useful measurement of PC-
QC and it is applied as the most common measurement of platelet activation in PCs (5). In 
contrast to the physiological behavior of activated platelets, ex vivo p-selectin expression on the 
platelet surface upon activation by cold or pH below 6.2 is not reversible (37). In whole blood 
and platelet-rich-plasma (PRP), p-selectin expression amounted to 2-10% versus 20-30% in 
PCs (37). The percentage of CD62P positive platelets significantly increased within five days of 
storage, whereas the mean fluorescent intensity (MFI) values of labeled lysosome-associated 
membrane proteins 1 and 2 (LAMP-1, LAMP-2) decreased. Simultaneously, the reduction of 
CD62P positive platelets, LAMP-1 and LAMP-2 on the sixths day of storage was observed (36). 
The relative microparticle count and p-selectin expression on platelets surface were also 
determined and an increased MV number over the storage time in correlation to free and 
membrane-bound p-selectin was demonstrated. In general, the activation of platelets entails the 
occurrence of adverse effects during storage, but it is hardly evident that the rate of activation is 
associated with post-transfusion recovery (5). Several studies reported that p-selectin 
expression does not affect platelet clearance (38, 39) and may not reflect platelet survival and 
function in vivo (5). 
To highlight the importance of the applied tests for plateletpheresis concentrate quality 
monitoring, all subsequent parameters, which are beyond standard quality control (see Table 
I-3) for testing platelet viability at the university hospital of Regensburg, are described later 
(chapter 4.6; page 51). More parameters are necessary to guarantee platelet integrity in 
concentrates and to promote the improvement of cell component based quality control at the 
cellular, biochemical and molecular level.  
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Table I-3: Parameters and criteria of quality control in manufacturing of plateletpheresis 
concentrates in Germany 
Test parameters Test criteria Time of testing 
Volume according to specifications after preparation 
Platelet count per unit >2 x10
11
/ unit after preparation and  
at the end of expiry 
Platelet count per mL according to approval after preparation 
Residual erythrocytes <1 x10
6
/ unit after preparation 
Residual leukocytes <3 x10
9
/ unit after preparation 
pH value 6.4 - 7.8 at the end of expiry 
Visual valuation undamaged PC container and 
swirling  
at the end of expiry and 
before application 
Sterility sterile at the end of expiry 
The same criteria are applicable to irradiated plateletpheresis concentrates with 30 Gy. 
Table has been adjusted to “Richtl inien zur Gewinnung von Blut und Blutbestandteilen 
und zur Anwendung von Blutprodukten (Hämotherapie)“ (33).  
 
1.3 Extracellular vesicles in general 
1.3.1.  Definition 
Under physiological or pathological conditions, all human body fluids, such as plasma (40), 
serum (41), breast milk (42), amniotic fluid (43) or urine (44) in vivo, as well as media from 
cultured cells in vitro (45) contain cell-derived vesicles. Cell membrane vesicles, which undergo 
secretion, constitute spherical or tubular structures surrounded by a phospholipid bilayer. 
Vesicular membranes expose receptors that are constructed as transmembrane proteins with 
cytosolic components, i.e. soluble hydrophilic or hydrophobic molecules. Because the 
membrane orientation of cell-derived vesicles is the same as that of the donor cells, vesicles 
can be considered as non-nucleated miniature versions of a cell (46). Both, eukaryotic and 
prokaryotic cells have the ability to release such vesicles. The characteristics of vesicles are 
determined by size, density, visibility under the microscope, sedimentation, lipid composition, 
main protein markers and intracellular membranes or organelles of subcellular origin (46, 47). 
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Cell-derived vesicles possess different physiochemical features. Therefore, there is currently no 
consensus about a uniform nomenclature for all cell-derived vesicles. While scientists still 
debate the nomenclature, the term “extracellular vesicles (EVs)” has been proposed as a 
general term covering the complete diversity of vesicles. In relation to the current nomenclature, 
the International Society for Extracellular Vesicles (ISEV) meanders through multiple definitions 
of vesicles and offers suggestions for scientists and authors. In addition, a general term of EVs 
used for subgroups should base on logical arguments referring to physiochemical and functional 
characteristics and should clearly define the methods for isolation and measurement (48). 
There are two subgroups of EVs, i.e. exosomes and microvesicles. Apoptotic vesicles form a 
third, separate class (46, 47). There are more types of vesicles described, such as endosomes, 
ectosomes, membrane particles or exosome-like vesicles (46). This division is based on 
different characteristics explained above. The association of the latter four types with platelet-
derived vesicles is currently unknown and therefore not discussed in this study. The size of the 
largest subgroup of vesicles, i.e. apoptotic bodies, released during apoptotic cell death, ranges 
from 500 nm to 5 µm (46); (see Figure I-3 and Table I-4). 
Microvesicles of a size ranging between 100 nm to 1000 nm (46) are released from the plasma 
membrane during cell stress. The smallest vesicles, also known as exosomes, vary in their size 
from 50 to 100 nm (46). They are formed from intracellular multivesicular bodies (MVB; 
sometimes also used as multivesicular endosomes, MVE) in a process described as the “classic 
pathway” (47) or produced in a direct pathway (46, 49).  
The characteristics of these three subtypes (apoptotic vesicles, microvesicles and exosomes) 
are summarized in Table I-4. The efficient purification of vesicle subgroups is limited (50) and 
depends on isolation strategies. As a means to interpret the analytical results, it is necessary to 
assume a small contamination of vesicles neighbored to the refined vesicle subgroup. Rather, 
the vesicle subgroups represent a “continuum of vesicle types with overlapping properties 
[which are almost entirely] present in body fluids” (47). It should be considered that “ex vivo 
purified vesicles” can be “artificially generated during manual dissociation of tissues” (46) and 
that exosomes could represent intracellular multivesicular bodies, released from ruptured 
vesicles and non-secreted exosomes. 
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Figure I-3: Scheme of eukaryotic cell forming microvesicles, exosomes and apoptotic bodies 
Cells release small exosomes (EXs) via a classic pathway involving formation of intraluminal 
vesicles (ILV) within multivesicular endosomes (MVE) and via a direct pathway from the plasma 
membrane. Larger, secreted microvesicles (MVs) can be formed at the plasma membrane by 
direct budding. Apoptotic bodies including cellular compartments appear during apoptosis. 
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Table I-4: Overview of three subgroups of extracellular vesicles 
 Exosomes Microvesicles Apoptotic vesicles 
Size of diameter 
[nm] 
50 - 100 100 - 1000
 
or 
20 - 1000
 
50 - 500
 
or 
1000 - 5000
 
Density in 
sucrose [g/ ml] 
1.13 - 1.19 unknown 1.16 - 1.28 
Sedimentation 100,000 g 10,000 g 1,200 g, 10,000 g or 
100,000 g 
Morphology by 
EM* 
cup-shaped,  
homogenous 
irregular shape, 
electron-dense 
heterogeneous 
Cellular origin most cell types most cell types all cell types 
Cell origin 
 
multivesicular bodies plasma membrane plasma membrane 
and endoplasmic 
reticulum during cell 
death 
Composition cholesterol, 
sphingomyelin, ceramide, 
lipid rafts, 
glycerophospholipids, 
phophatidylserine-
exposure, Rab proteins, 
annexin, flotillin, intergins 
and tetraspanins (CD63, 
CD9, CD81, CD82), Alix, 
TSG101, HSP (hsc70, 
hsc90), mRNA, microRNA 
phosphatidylserine-
exposure, intergrins, 
selectins and CD40 
ligand; insufficiently 
known 
histone, DNA, 
organelles
 
References (27, 46, 47, 51-54) (46, 47, 54, 55) (46, 47, 56-59) 
*EM: electron microscopy; (adapted to (46, 49)) 
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1.3.2. Function of extracellular vesicles 
The EV subgroups are released by cells during different stages of cell life. Thereby, EVs reflect 
dissimilar formation processes and are related to different mechanisms of shedding of 
intracellular and/ or plasma membrane components into the intercellular environment. Released 
EVs are recognized by acceptor cells. It is obvious, that both, donor and acceptor cells benefit 
from the transposition of these cell fragments, where donor cells release vesicles, whereas 
target cells, which are brought into contact with the released vesicles, are acceptors. There is 
an increasing interest in functions of EVs and the most relevant properties of EVs shall be 
elucidated. 
In general, cell-derived vesicles may act as “multi-purpose” carriers (45), (see Figure I-4) to 
express the main functions of extracellular vesicles discussed in this work.  
 
 
Figure I-4: Summary of the main functions of extracellular vesicles (EVs) 
 
As indicated, the process of intercellular signaling via vesicles as potential communicators and, 
thus, understanding the function of cell-derived vesicles is an important current topic. The 
transport of receptors or cytokines was characterized and found to be similar to the transfer of 
the TF receptor and p-selectin glycoprotein ligand-1 (PSGL-1) between leukocyte-derived 
vesicles and activated platelets. As a result of this transfer, proteolytic activity of the TF-VIIa 
complex increases after fusion of leukocyte-derived microvesicles and platelets (60).  
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The transfer of ligands, e.g. CD95L (FASL), located on tumor cell-derived vesicles induced 
apoptosis of T cells (61) which is a proof for immunosuppressive effects of the intercellular 
communication.  
The mechanism of promotion of humoral immune response via CD40L (CD154) of platelet-
derived vesicles followed by B cell activation and production of immunoglobulin G can be 
considered as sufficiently understood (62). The communication aspect involves an 
“orchestrating function” of immune response including antigen presentation and the transfer of 
cellular components.  
A further possibility of the communication between released vesicles and cells is defined 
through the exchange of genetic information. This was shown in many tumor cell lines, e.g. 
transfer of functional mRNA and miRNA in vesicles from glioblastoma cells (63), or mRNA in 
colorectal cancer cell line-derived vesicles (64) and in physiological cells, e.g. miRNA from T 
cells (65) or miRNA from dendritic cells (DCs) (66). The exchange of functional miRNA among 
DCs results in the repression of target mRNA in acceptor cells. This may be an important key 
mechanism in saving the function of non-coding regulatory miRNA of cellular origin outside the 
cell, in which it was produced, because, as in the case of vesicles, miRNA is protected from 
degradation carried out by RNases (67). The ability of vesicles to facilitate the transfer of 
functional genetic information was pictured in exosomes of mouse and human mast cell lines 
and primary bone marrow-derived mouse mast cells. Exosomes contain functional mRNA of 
approximately 1300 genes undetected in the cytoplasm of the donor cells and miRNA called 
"exosomal shuttle RNA" (esRNA) (27). Induced expression of target proteins was also 
observed. Lässer´s work presented detectable levels of RNA in vesicles of several body fluids, 
e.g. human saliva, plasma or milk (68). These findings indicate a flow of information through 
RNA transfer. 
“Cellular waste management” or “protection against intra- and extracellular stress”(45) using the 
extracorporeal release of harmful substances in vesicles may be a survival strategy of cells. 
External stress, e.g. complement C5b-9 complex incubated with platelets, causes the release of 
vesicles enriched with this complex to protect the platelets from complement-induced lysis (69). 
Reticulocyte-derived transferrin receptor (TFR) or tumor cell-derived shedded vesicles, which 
contain chemotherapeutics, are active in the process of survival or drug resistance mechanisms 
(70) and were described as extracellular stress protectors.  
Active caspase 3 is the main executioner of apoptosis. Caspase 3 is abundant in vesicles of 
different cell types and it is assumed that it acts as a protection against internal stress and 
nemesis of cells (71, 72).  
Vesicles also play a role in cell adhesion, vascular integrity and repair which results from their 
expression of adhesion molecules and from the increasingly significant relation of the surface to 
cell compartment. “All membrane vesicles of any cellular origin express adhesion molecules on 
their surface, which could favor their capture by recipient cells” (46).  
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Platelet-derived vesicles were observed how they bind to fibrinogen-, fibronectin-, and collagen-
coated surfaces and minimally to vitronectin and von Willebrand factor (73). In a rabbit model, 
an increased vesicle binding to injured endothelium in vivo, but not to uninjured surfaces, was 
observed and elevated binding of platelets to immobilized vesicles was shown. This behavior 
was interpreted as a mechanism by which vesicles promote thrombus formation.  
Another example of exosome-mediated adhesion was described for integrins on B cell-derived 
exosomes, which interact with extracellular matrix components to mediate adhesion to  
collagen-I, fibronectin and surface adhesion molecules of tumor necrosis factor (TNF)-α-
activated fibroblasts (74). Similar to the mechanism of protection against intracellular stress 
through caspase 3 activity, an increased release of endothelial-derived vesicles antagonize 
apoptotic blebs. Tumor susceptibility gene 101 and translation controlled tumor protein (TCTP), 
which are abundant in vesicles, trigger an extracellular signal-regulated kinase 1/2 (ERK1/2)-
dependent antiapoptotic phenotype in vascular smooth muscle cells (VSMCs) (75). In contrast 
to the antiapoptotic effect, the vesicles from endotoxin-stimulated monocytes trigger caspase 1-
dependent apoptosis of vascular smooth muscle cells.  
These observations suggest functions beyond the communication between cells and vesicles, 
and underline the role of vesicles in damage control of vasculature and a potential role of 
vesicles in coagulation. Section 1.4.1 summarizes historical information on potential coagulatory 
features under clinical aspects of vesicles.  
Two topics referring to coagulation should be discussed. The first topic should concentrate on 
vesicles as specific or unspecific procoagulants and the second topic should refer to vesicles 
with anticoagulant activity. In the context of microvesicle-related coagulability, the results of 
analyses of the material of patients with Castaman syndrome are of interest (76, 77). In four 
unrelated patients with life-long bleeding tendency, a reduced formation of platelet 
microvesicles was found. These patients were without von Willebrand factor defect and with no 
evidence of any other platelet function abnormalities accompanied by normal prothrombin 
consumption. Castaman syndrome, which is at variance with Scott syndrome (see in 1.3.3), was 
described as disorder in vesicle formation and the EV generation was closely connected with 
coagulability under physiological conditions. In addition, the procoagulant activity of EVs results 
from the molecular composition of the vesicle membrane including presentation of anionic 
phospholipids, e.g. phosphatidylserine, in the outer monolayer (78). This corresponds to 
positively charged γ-carboxyglutamic acid (GLA) domains in proteins of the clotting system, 
such as factors VII, IX, X and II (prothrombin) (79). There is no consensus concerning PS 
exposure on exosomes and microvesicles. However, PS-positive EVs (51, 80) and PS-negative 
EVs (54, 81, 82) were reported in context of several diseases.  
Tissue factor, as a cofactor of the initiation of the extrinsic coagulation cascade by factor VIIa, is 
also present as a procoagulant on the surface of EVs. The TF/FVIIa complex, however, is 
counter-regulated by tissue factor pathway inhibitor (TFPI), suggesting that not all TF/FVIIa 
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complexes on EVs remain active (or become activated) (79, 83, 84). Similarly to PS exposing 
EVs, the procoagulant activity of TF bearing EVs remains also controversial. The pro- or anti-
coagulant activity of exosomes and, most likely, of microvesicles depend on physiologic or 
pathologic conditions (85). It was reported that TF exposing exosomes and microparticles from 
human saliva, promotes a shortened clotting time in human pericardial wound blood (85). 
Microvesicles triggered coagulation in a TF-depending pathway. The same working group 
showed that microvesicles from platelets, erythrocytes and granulocytes in blood samples also 
support coagulation via a TF-independent way. Antibodies against TF or FVII were ineffective to 
stop coagulation, suggesting PS-exposure as an initial step of coagulation.  
Further, an anticoagulant function was concluded. An inverse correlation of annexin V-positive 
microparticles and thrombin generation to levels of thrombin-antithrombin-complexes was 
found. Thrombin in a lower concentration activated protein C and led to an anticoagulant effect 
of microvesicles (86). PS-positive vesicles present in blood of healthy individuals predominantly 
originate from platelets, megakaryocytes, and the surface of platelet-derived vesicles showed 
50- to 100-fold higher procoagulant activity than that of a single platelet (87). Monocytes, 
however, are likely to be the major donor cells of TF-positive vesicles (79). Moreover, in several 
diseases, the procoagulant activity of vesicles, e.g. tumor-derived vesicles exposing TF, was 
found associated with an increased risk of venous thromboembolism (VTE) (79, 88). An 
increased incidence of thrombotic events was observed in patients with paroxysmal nocturnal 
hemoglobinuria (PNH) with ascending concentrations of microparticles (89). In contrast to these 
procoagulant activities, the results of TF-exposing microparticles in patients with multiple organ 
dysfunction syndrome (MODS) and sepsis indicate an inverse effect. Lower numbers of vesicles 
in these patients could explain this effect (82). Altogether, PS- and TF-bearing EVs play an 
undisputed role in hemostasis and thrombosis, but the contribution of exosomes or 
microvesicles is still unclear. 
1.3.3. Microvesicle formation 
Lipid translocases, ions and their plasma membrane channels, as well as such processes as 
cytoskeletal reorganization, signal transduction, lipid translocase-independent and apoptotic 
mechanisms are all involved in vesicle formation (78). The role of translocases in vesicle 
formation and shedding is coupled to the loss of asymmetric distribution of lipids in the outer 
and inner plasma membrane (90). Exposure of PS towards the outer cell membrane by an ATP-
dependent protein “floppase” (91) is an initial event in shedding of membrane vesicles (92). A 
normal bilayer membrane consists of positively charged polar phospholipids, such as 
phosphatidylcholine and sphingomyelin in the outer leaflet, and negatively charged anionic 
phospholipids in the inner leaflet, e.g. aminophospholipids, phophatidylserine (PS) or 
phosphatidylethanolamine (PE) (93). Aminophospholipid translocases with “flippase” activity 
direct PS and PE back to the inner leaflet of the cell membrane, whereas lipid scramblase is 
responsible for a bi-directional transfer of phospholipids and thus maintaining membrane 
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integrity (91). Scramblase is also the base of a rapid PS exposure towards the cell surface as a 
part of the physiologic hemostasis in coagulation response (94, 95). 
As far as the lipid transport mechanisms are concerned, stimulation-dependent increase in 
cytosolic Ca
2+
 provokes a disruption of membrane lipid distribution by activation of scramblases 
and floppases, whereas flippase activity is inhibited (96). Scott Syndrome is a bleeding disorder 
characterized by a deficiency in floppase activity, impaired shedding of vesicles and decreased 
PS expression on vascular cells (97, 98). Sorting of membrane compartments into the vesicle 
bleb may be regulated by lipid rafts of the cell membrane (99). The activation of the Ca
2+ 
-
dependent protease calpain after intracellular influx of calcium ions induces a release of 
microvesicles from platelets (78) and also promotes proteolysis of the cytoskeleton, which 
subsequently induces the formation of vesicles (92). The entry of calcium seems to be a 
common mechanism in platelet activation, while in the resting state of platelets a steady calcium 
[Ca
2+
]i is maintained by the endoplasmic reticulum (ER) as a calcium store.  
 
 
Figure I-5: The formation of microvesicles from the cell membrane 
Upon stimulation of resting cells, the cytosolic Ca
2+
 level increases, the activation of floppases 
and scramblases and inhibition of flippases result in the externalization of phophatidylserine on 
the outer leaflet of the cell membrane. Lipid and protein rafts may control the sorting of 
membrane compartments, which are excluded from the vesicle blebs (figure from (100)). 
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There are two mechanisms which regulate cytosolic calcium [Ca
2+
]i in platelets. The first 
mechanism is based on the calcium release from the cytosol and on the influx of Ca
2+
 through 
the cell membrane mediated by store-operated calcium entry (SOCE). The second mechanism 
involves the ligand-gated ion channel P2X1 (purinergic receptor P2X1) (101). In monocytes, 
P2X7 receptor (purinergic receptor P2X, ligand-gated ion channel 7) can be activated by 
extracellular ATP (102).  
The calcium entry via SOCE mechanism may act as a modulator of PS exposure and of a 
refilling of the ER calcium stores (103, 104). To maintain thousand fold lower concentration of 
[Ca
2+
]i than in the extracellular space or in the intracellular Ca
2+ 
pools, Ca
2+
-ATPases 
translocate Ca
2+
 across the cell membrane using the energy of ATP hydrolysis. In platelets, 
different isoforms of sarco/ endoplasmic reticulum Ca
2+
-ATPases (SERCAs) have been found. 
They become activated through the intracellular Ca
2+
 influx and pump Ca
2+
 back into the 
intracellular Ca
2+
 pools (105). Other key proteins acting as ion channels are involved in the 
store-operated calcium entry (SOCE). As store-operated calcium (SOC) channels, the stromal 
interaction molecule 1 (STIM1) and further in the system of tubular denses the Orai1 (also 
known as CRACM1 = calcium release-activated calcium channel protein/ modulator 1) were 
detected (106). Both, the STIM1/Orai1 pathway and the thrombin receptor pathway (54) operate 
in platelets on Ca
2+
 influx and PS externalization, together with SOCE-independent and cell-
type specific Ca
2+
 signaling, as well as other ions such as K
+
, Cl
-
, H
+
, and Na
+ 
(78).  
Destabilization of the actin cytoskeleton in platelets is stimulated by the αIIbβ3 signaling 
pathway and by calpain activation accompanied by high concentrations of Ca
2+
 (107). 
Caspases, as dominant regulators of the apoptosis cascade, are involved in the reorganization 
of the cytoskeleton (78). Proteases, caspases and calpain dominate the proteolysis of filamin-1, 
talin and myosin (108). Recent studies suggest that Rho-associated coiled-coil-containing 
protein kinase (ROCK) II, activated by caspase-2 in endothelial cells, is linked to the 
cytoskeletal reorganization, release of microvesicles (109, 110) and may be related to 
inflammation.  
Signal transduction pathways regulate formation and secretion of microvesicles from activated 
cells. Examples are provided in a comprehensive review of Morel who demonstrated that 
platelet-derived microvesicle formation is associated with phosphorylation of platelet proteins by 
calmodulin, myosin light chain kinase, and other calmodulin-regulated effectors. This 
microvesicle formation process was found to be similar to the pathway of activation-induced 
protein tyrosine dephosphorylation (78). Results from a study on endothelial cells showed 
reduced microvesicle formation induced by TNF-α through inhibition of p38 mitogen-activated 
protein kinase (111). In fact, the release of microvesicles is regulated by stimuli which activate 
cell specific receptors, e.g. Toll-like receptor 4 (TLR4), the receptor for gram-negative bacterial 
lipopolysaccharide (LPS) on DCs (112) or on platelets (113), which may influence vesicle 
formation.  
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Platelets bound to LPS via TLR4 show increased phosphorylation of p38 mitogen-activated 
protein kinase and decreased production of prothrombotic PS and CD62P-positive 
microparticles in response to thrombin receptor agonist peptide (TRAP). Therefore, a direct 
activation by TLR4 reduces the TRAP-stimulated platelet vesicle formation in vitro. An 
enhanced thrombotic risk of bacterial infections is likely to reflect the TLR4 activation of other 
cells which indirectly stimulate platelets through chemokines/ cytokines (113). Pathways 
involved in microvesicle formation are determined by a cell lineage and a type of cellular stress 
(78). 
In addition, translocase-independent mechanisms of vesicle and transient pore formation in the 
cell membrane and blebbing mechanisms may be responsible for Ca
2+
-
 
, PS -independent 
formation of MV (114, 115). 
During apoptosis, PS occurrence is one of the first changes, prior to DNA fragmentation, 
leading to the loss of asymmetry of cell membranes (116, 117). 
In apoptotic cell death, several regulators, including caspases (118), which affect apoptosis in 
nucleated cells, and various events such as loss of mitochondrial membrane potential, PS 
exposure and contraction of cells, are assumed to trigger apoptosis (119). In platelets, members 
of the Bcl-2 apoptosis inhibitory protein family are also present and Bcl-xl, a member of the Bcl-
2 protein family, plays a role in procoagulant activity of platelets and their viability (119). 
However, the extent to which the effects of apoptosis and activation affect formation of vesicles 
is poorly understood. The process of membrane blebbing is associated with phosphorylation of 
myosin light chain and ROCK I activation due to the cleavage by caspase-3 during apoptosis 
(120). 
1.3.4. Formation of exosomes 
Exosomes mainly originate from the lumen of multivesicular endosomes (MVE) as forms of 
intraluminal vesicles (ILV) which are released from MVEs after fusion of their membrane with 
the cell membrane. Different types of MVEs exist. Some MVEs are subjected to degradation 
and subsequently lysed by fusion with lysosomes; other MVEs fuse with the outer cell 
membrane to release their ILVs as exosomes. This MVE secretion pathway was described as 
the “classical pathway of exosome formation” (47) but consecutive sorting mechanisms have 
not been elucidated. The endosomal sorting complexes required for transport (ESCRT) execute 
sorting of transmembrane receptors for vesicles which are predetermined for degradation (121, 
122). In dendritic cells, Hrs, an ESCRT-0 protein, was involved in the formation of DC-derived 
endosomes (123). On the other hand, data from a mouse oligodendrogial cell line provide 
evidence for an ESCRT-independent pathway of MVE and exosome formation, which may 
depend on ceramide microdomains (124). Further differences in the degradation and secretion 
pathways are evident. Cholesterol labeling was found only in the plasma membrane of 
lymphoblastoid cells and in MVEs, and in exosomes after secretion (125), but it was absent in 
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Golgi cisternae and the surrounding membrane of MVBs. The late endosomal marker bis-
(monoacyl)-glycerophosphate (BMP) is also involved in the formation of vesicles predestined for 
degradation in intraluminal MVEs, but is not involved in the sorting of exosomes (126). BMP-
negative MVBs are exosomal targets for epidermal growth factor (EGF) and the EGF receptor 
(EGFR) (127), whereas MVEs containing BMP are not trafficking EGF and EGFR and are 
assigned for lysosomal degradation.  
More cytosolic and membrane proteins and lipids are thought to play a role in sorting of 
exosomes. Endosomes, for example, are formed in an ESCRT-independent manner (128) 
through other proteins, e.g. tetraspanins CD63 and CD9, or without ubiquination of major 
histocompatibility complex (MHC) class II molecules on DCs (129). In conclusion, various 
mechanisms are involved in vesicle sorting. Based on the stimulus-dependent secretion or 
recycling to MVEs, exosomes employ different sorting ways in different cell types, cell 
compartments and at various stages of cell maturation.  
Trafficking and fusion with the plasma membrane require small guanosine triphosphate (GTP)-
ases of the Ras-related in brain (Rab) protein family. Rab11 and calcium are involved in MVE 
fusion from K562 erythroleukaemia cells (130). Rab27a and Rab27b were found in the plasma 
membrane docking mechanism in HeLa cells (131) and GTP-dependent Rab35 was present on 
the surface of oligodendrogial cells with an impaired secretion of exosomes (132). The soluble 
N-ethylmaleimide-sensitive-factor attachment receptor (SNARE) proteins may be involved in the 
fusion of MVBs for exosome release, this pathway, however, is specific for lysosomal secretion 
(133).  
Beside the classical pathway, exosome release is mediated by a direct fusion of small vesicles 
with the cell membrane. In this case, exosomes do not originate from MVEs (47). In relation to 
this phenomenon, the difference between exosomes originating from MVEs or exosomes 
released directly from the cell membrane is unidentifiable. It was observed, that the HIV 
accessory protein negative factor (Nef) (134) and diverse Gag (group-specific antigen) proteins 
(135, 136) possess sorting information on exosome release in Jurkat T cells and T cells. “The 
extent to which such exosomes are also released from other cells or in vivo (e.g., in biological 
fluids) is unknown” (47). 
 
1.4 Platelet-derived extracellular vesicles 
1.4.1. Background and clinical potential 
At least since the 1940s, platelets have been considered to play an important role in 
hemostasis. According to newer reports, however, a thromboplastic protein fraction, 
sedimentable by high-speed centrifugation, was also discussed as a potential stimulus of 
coagulation (137). 
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In 1967, PL-EVs were observed for the first time and called “platelet dust” (8). The procoagulant 
effects of platelet-derived subcellular fragments, distinguishable from effects of platelets, were 
investigated by means of clotting time. The capability of clotting serum was attributed to PL-
EVs, which were obtained from platelet-poor plasma separated by ultracentrifugation (UC).  
In 1972, Warren et al. observed platelet-derived vesicles which originated from “multivesicular 
membrane sacs” of dendritic platelet pseudopodia. The way of formation was identified with the 
help of electron microscopy during adhesion of platelets to the subendothelial layer of coronary 
arteries in man (138). The investigation confirmed the hypothesis, supported by the results of 
fixation techniques, that “during the activation of human platelets, the release of membrane-
associated multivesicular structures may occur concurrently with other mechanisms of secretory 
granule content release” (139).  
Until now, these extracellular vesicles (48), (in this case, derived from platelets and hence 
named platelet-derived extracellular vesicles (PL-EVs) (9)), have proven their thrombogenic 
properties (9, 47, 82, 86, 140-142). Moreover, studies that are more recent, demonstrated that 
platelet-derived vesicles might transport and deliver various molecules among cells (9, 143, 
144). Platelet-derived vesicles also participate in innate (145, 146) and adapted (62, 147) 
immunity, in inflammation (148), malignancies (149) and in hematopoietic stem cell engraftment 
(150). They promote endothelial repair and support angiogenesis (151). The participation in 
several biological pathways was confirmed mainly in healthy individuals or in patients with 
cardiovascular and inflammatory diseases or cancer (see Table I-5).  
 
 
Table I-5: Platelet-derived vesicles in several diseases 
Diseases Changes in the level of PL-EVs References 
Cardiovascular diseases 
 
Coronary heart disease ↑ (152) 
Acute coronary syndrome (ACS) ↑ (153-155) 
Peripheral arterial disease ↑ (156, 157) 
Severe hypertension ↑ (158) 
Pulmonary hypertension ↑ (159) 
Acute pulmonary embolism ↑ (160) 
Valvular atrial fibrillation ↑ (161) 
Deep vein thrombosis (DVT) ↑ (162) 
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continuation of Table I-5: Platelet-derived vesicles in several diseases 
Diseases Changes in the level of PL-EVs References 
Cerebrovascular diseases 
 
Ischemic stroke ↑ (163, 164) 
Cerebral vasospasm ↑ (165) 
Lacunar infarcts ↑ (163) 
Multi-infarct dementia ↑ (163) 
Carotid atherosclerosis ↑ (9) 
Hematologic diseases 
 
Immune thrombocytopenia 
purpura (ITP) 
↑ (166-168) 
Thrombotic thrombocytopenic 
purpura (TTP)  
↑ (167) 
hemolytic uremic syndrome 
(HUS) 
↑ (167) 
Paroxysmal nocturnal 
hemoglobinuria (PNH) 
↑ (89, 169) 
Heparin-induced 
thrombocytopenia 
↑ (170, 171) 
Castaman syndrome ↓ (76, 77) 
Glanzman syndrome ↓ (172) 
Scott syndrome ↓ (173) 
Stormorken syndrome ↑ (174) 
Sickle cell disease ↑ (175, 176) 
Cancer 
 
Gastric cancer ↑ (177) 
Lung cancer ND (178) 
Breast cancer ↑ (179, 180) 
Prostata cancer ND (181, 182) 
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continuation of Table I-5: Platelet-derived vesicles in several diseases 
Diseases Changes in the level of PL-EVs References 
Infectious diseases 
 
Sepsis ↑↓ (82, 183, 184) 
Prion disease ↑ (185) 
Autoimmune diseases 
 
Systemic lupus erythematodes ↑ (186, 187) 
Antiphospholipid syndrome ↑ (188) 
Systemic sclerosis ↑ (189, 190) 
Rheumatoid arthritis ↑ (187, 191, 192) 
Acute vasculitis ↑ (193) 
Type 1 diabetes mellitus ↑ (194) 
Multiple sclerosis ↑ (195) 
Sjögren syndrome ↑ (187) 
Other 
 
Type 2 diabetes mellitus ↑ (196-199) 
Metabolic syndrome, central 
obesity 
↑ (200, 201) 
Obstructive sleep apnea ↑ (202) 
Uremia ↑ (203) 
Cerebral malaria ND (204) 
Decompression sickness ↑ (205) 
Preeclampsia ↑↓ (206-208) 
Spontaneous abortion ↑ (209) 
Alzheimer disease - (210, 211) 
Raynaud´s phenomenon ↑ (212) 
(Table adapted and supplemented by (213)) 
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Further interest in PL-EVs is directed towards their content in blood concentrates, especially in 
plateletpheresis products. Important investigations are currently performed concerning the level 
of PL-EVs in PCs in comparison to platelets and the surrounding donor plasma (15) and their 
potential application to quality control measurements of PCs. 
1.4.2. Distribution of PL-EVs 
In bloodstream of healthy individuals, platelet-derived vesicles are believed to represent the 
major circulating microparticle fraction amounting to 75-90% of all circulating microparticles (15, 
142). They were found at concentrations of 6 to 300 x 10
9
/ L, based on the results of the 
measurements carried out by the new generation of flow cytometry (FCM) instruments (214). In 
healthy individuals, the concentration of PL-EVs of circulating platelets under resting conditions 
constitute approximately 3% (172), whereas after stimulation with collagen the concentration 
increases to approximately 32%. Upon treatment with TRAP-6 (SFLLRN), the PL-EV 
concentration reaches 53%. 
Megakaryocytes may also serve as a source of PL-EV because they express platelet-specific 
glycoprotein (GP)IIb-IIIa (82, 86, 215). Based on the results of the group of Flaumenhaft, there 
is no evidence of PL-EV release from resting platelets. Circulating PL-EVs in healthy individuals 
are likely to originate from activated platelets or from megakaryocytes, however, the latter ones 
are currently less in the focus of investigations (11). Yet, the obtained results of the 
differentiation of these two groups of PL-EVs have to be confirmed. Megakaryocyte (MK) -
derived EVs may serve other functions than PL-EVs derived from activated platelets which are 
involved in cardiovascular diseases. In patients subjected to autologous or allogeneic 
hematopoietic stem cell transplantation, MK-EVs should be analyzed in blood samples ex vivo. 
In patients after total body irradiation, MK-EVs disappeared much faster in comparison to PL-
EVs and platelets (216). In order to remain consistent with the term of “platelet-derived 
vesicles”, the present work focused only on the release of vesicles from platelets, not from 
megakaryocytes. 
PL-EV levels underlay gender-specific differences (female > male) in platelet-poor plasma 
(PPP) and platelet-free plasma (PFP) of healthy individuals (217, 218) and increase with age 
(156), during pregnancy (219) and after exercise with increased hemostatic potential (220, 221). 
Lowered levels are described in postmenopausal women with decreased estradiol levels, 
hormone replacement therapy reverses this effect, though (222, 223). 
Beside the fact that PL-EVs in the circulation are of diagnostic interest, it is also important to 
gather the information on the presence, concentration and composition of PL-EVs in platelets. 
An observation that high concentration of PL-EVs in PCs strongly correlates to PS-exposure 
and correlates to the use of different apheresis systems was already published in 2000 (224). 
The enrichment of PL-EVs in PCs is up to 4-fold higher in comparison to the plasma of healthy 
donors because of EV-formation in either rested platelets or activated platelets. However, the 
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majority of EV-subpopulations in PCs stem from resting platelets. Over the storage time, the 
production of PL-EVs in resting platelets remains low in comparison to the increased level of 
CD62P-and CD63-positive PL-EVs from activated platelets. Rank also reported a decreased 
amount of cumulative annexin V- and CD61-positive EVs over the storage time of 5 days (15). 
In addition to PC-specific, namely platelet-derived vesicles, EVs may also originate from other 
cell types, i.e. red blood cells or endothelial cells (15). The results of this study confirm the 
presence of EVs of red blood cell origin.  
1.4.3. Characteristics of PL-EVs 
PL-EVs are released from activated or senescent platelets in the form of nano- or microvesicles, 
budded from the platelet membrane and in the form of exosomes originating from MVEs and α-
granules (54). As mentioned in chapter 1.4.2, the present study does not focus on 
megakaryocyte-derived vesicles due to their low concentration.  
Despite the fact that PS-exposure on activated platelets rather comes from PS of the inner 
leaflet of platelet membranes than from PS on granules (225), it is not completely clear whether 
the absence of PS-negative PL-EVs corresponds to rapid clearance or to the low in vitro 
generation of PL-EVs and megakaryocyte-derived vesicles. Heijnen and colleagues reported 
that PS-exposure with binding of annexin-V was found mainly on larger PL-MVs with a larger 
diameter and surface, but not on small PL-EXs (54). Exosomes could partially contribute to the 
procoagulability of microvesicles.  
Common detection markers for PL-EVs are listed in Table I-6. PL-EVs contain numerous 
platelet-specific molecules, such as adhesion proteins (e.g. CD42a, CD31, fibrinogen, 
thrombospondin, vWf) or proteins involved in coagulation (e.g. FVa, FVIII, TF), growths factors 
(e.g. VEGF, PDGF, TGF-β1). Additionally, detected complement proteins (e.g. CD55, CD59, 
C5b-9, C3b, C1q, C1-INH), lipids (e.g. PS, arachidonic acid, LPA, TXA2), immune response 
molecules (CD40L) and others (e.g. CD63 especially on PL-EXs, lactadherin) classified EVs as 
platelet-derived compounds (140). 
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Table I-6: This overview shows common and variable glycoprotein (GP) receptors or activation 
markers of platelet-derived and megakaryocyte-derived extracellular vesicles (EVs) 
 
Platelet-   
derived EVs 
Megakaryocyte-
derived EVs 
References 
CD41, CD61 (fibrinogen receptor 
GPIIb-IIIa, integrin αIIbβ3) 
+ + (9, 226) 
CD42b (von Willebrand factor 
receptor GPIb) 
+ + (9, 226) 
Phosphatidylserine (PS) + + (226) 
CD63 (GP55) + + (9, 227, 228) 
CD62P (p-selectin) after 
stimulation  
+* - (226) 
CD107a (LAMP-1) after stimulation  +* - (226) 
Full length filamin A after 
stimulation 
- + (226) 
Cleaved filamin A +* - (226) 
* PL-EVs are released from activated platelets that exhibit activation marker at detectable 
levels. 
 
1.4.4. Specific features of PL-EV formation 
Current knowledge of PL-EV formation at the molecular level is still incomplete. The present 
understanding encompasses the formation of PL-EV during the process of platelet activation, 
platelet senescence, destruction, thrombus degradation and during megakaryocytosis (9). The 
assumed constitutional production of platelets and smaller cell-derived vesicles from 
megakaryocytes were discussed earlier (see 1.4.3). 
In vitro activated platelets of a normal size up to 2 µm release two clearly distinguishable 
populations of PL-EVs. The first population is constituted of small vesicles (<100 nm) which 
originate from MVEs and α-granules and express tetraspanin CD63 assigned to exosomes 
(EXs). The second population is composed of larger vesicles (100 nm - 1 µm) as microvesicles 
(MVs; formerly microparticles, MPs) of a typical immunophenotype of platelets and 
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megakaryocytes (47, 54, 227). An overlap of both subtypes is apparent and it depends on the 
non-uniform isolation protocols and detection techniques of PL-EVs in existing studies and on 
the fluent transition of membrane reticulation.  
Vesiculation follows activation of platelets by physiological agonists such as thrombin and 
collagen. Compounds such as Ca
2+
 ionophore [A23187, ionomycin], phorbol esters (9), 
complement protein C5b-9 (69, 229) as well as high shear stress (230-233), contact with 
surfaces (234) and low temperatures (235) also are factors activating platelets. The non-
physiological agonists directly affect second messenger levels (9). The essential step of 
activation, which translates to the increase of intracellular calcium levels, affects intracellular 
enzymes (e.g. calpain which degrades actin-binding protein, talin and myosin) and protein 
kinase C (PKC) (9). The activation of several isoforms of PKC follows the [Ca
2+
]i increase and 
phosphorylation of intracellular proteins involved in signal transduction and structure. The 
calcium increase is also caused by platelet activation by ADP or thrombin. Complement 
activation is a mechanism involved in PL-EV release which remains unaffected by activated 
enzymes (i.e. calpain). Another stadium of elevated PL-EV concentration is accompanied by 
fibrin association (236) and disintegration of platelets during and after thrombus formation (237) 
and implicates that the presence of PL-EVs in blood may reflect degradation of thrombus (9).  
PL-EV formation also occurred in stored platelets undergoing senescence (14) or upon 
induction of apoptosis (118, 238). Although programmed cell death involves DNA fragmentation, 
a process which does not happen in anucleated cells, platelets contain apoptosis-associated 
proteins (9). The intrinsic pathway of apoptosis triggers caspase 3 formation and cleavage of 
structural proteins, such as ROCK I.  
ROCK I participates in the phosphorylation of myosin light chain and induction of membrane 
contraction (78, 120).  
However, there is another process leading to a vesicle production in damaged platelets, i.e. in 
platelets with a shorter life span. Higher levels of PL-EVs were found in patients with acquired 
clonal disorder of abnormal hematopoietic stem cells with deficiency in glycosyl-phospatidyl-
inositol (GPI)-anchored proteins (paroxysmal nocturnal hemoglobinuria, PNH). Lack of these 
GPI-anchored proteins results in a deletion of the complement inhibitors CD55 and CD59 and 
implicates an increased risk of thrombosis development (89, 169).  
1.4.5. Clearance of PL-EVs 
In animals, upon introduction into blood circulation, PL-EV clearance takes only a few minutes, 
e.g. 30 min in mice, 10 min in rabbits (11, 239). PL-EV clearance in thrombocytopenic patients 
after transfusion of platelet concentrates happened with a half-life of 5.3 to 5.8 hours, depending 
on the subgroups of PL-EVs (228) and was much faster than the clearance of platelets from 
PCs.  
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Several potential clearance pathways relate to enhanced EV-clearance. The consumption “by 
hemostatic events such as bleeding, thrombosis and clot formation” (1) is one of the clearance 
mechanisms. Moreover, the generally accepted mechanism involves PS exposure on PL-EVs 
(240). Beside “find-me” messages, PS exposure serves as the most common “eat-me” signal for 
phagocytic cells of the reticuloendothelial system (RES), as a sign of altered or pathologic cells 
and cell fragments (241). It is assumed, that there are multiple distinct PS receptors on 
phagocytic cells which are able to bind directly or indirectly to PS exposed on cells or cell 
fragments prior to being subjected to engulfment (240). PS-binding protein lactadherin (also 
known as milk fat globule-epidermal growth factor-8, MFG-E8), a macrophage-derived indirectly 
binding opsonin, is supposed to be involved in clearance of PL-EVs (242). Lactadherin-deficient 
mice have higher plasma levels of PL-EVs and the opsonization may occur in splenic 
macrophages from these mice. Patients with immune thrombocytopenic purpura (ITP) showed a 
higher PL-EV level after splenectomy than non-splenectomized ITP patients. However, 
significantly different results were only obtained for the elevated levels of red blood cell-derived 
and leukocyte-derived EVs in the splenectomized group (243). This research refers to an 
alternative pathway of PL-EV-clearance employing the binding of C3b complement on PL-EVs 
via complement receptor 1 (CR1, CD35) on erythrocytes in order to deliver PL-EVs to 
macrophages in liver and spleen (11). 
Altogether, a different origin of PL-EVs, from resting and activated platelets or megakaryocytes, 
and rapid clearance mechanisms of PL-EVs let assume that PL-EV production is balanced 
under physiological and pathological conditions (226). 
1.4.6. Detection techniques 
Because of an increasing interest in the detection of extracellular vesicles, especially of the 
small exosome fraction, many new techniques have been developed. The classic and most 
widely used method in the detection of extracellular vesicles is conventional or standard flow 
cytometry (sd-FCM) (9, 218, 244), with its ability to detect distinct EVs and their origin from 
mother cells using specific fluorescent labeled monoclonal antibodies (moAbs). A survey of the 
International Society of Thrombosis and Hemostasis (ISTH) indicated the use of FCM in 75% of 
the reports (245). Beside this method, new techniques are applicable to PL-EV measurement 
and two of them were used in this study, e.g. high-sensitivity flow cytometry (hs-FCM) (see page 
59, chapter 4.6.3.3) and Nanoparticle Tracking Analysis (NTA; see page 60, chapter 4.7). 
However, it is worth notifying that the evaluation of an absolute particle count is still the greatest 
challenge (56). Three used techniques in this study with variable possibilities and limitations, 
which may be complementary, were used to quantify and to characterize PL-EVs from PCs. As 
mentioned earlier, PL-EVs include larger microvesicles and smaller exosomes; therefore, two 
new techniques were necessary for the analysis of EVs and EXs beyond conventional FCM. 
There are detection limits within these three techniques, as well as advantages and 
disadvantages of their application, as listed in Table I-7.  
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Compared with sd-FCM, the hs-FCM indicated enhanced forward scatter (FS) resolution, a 
lower background noise and a 9-fold increase of the PL-EV count in PFP from the patient’s 
plasma (246). 
 
Table I-7: Pros and cons of detection techniques for measurement of extracellular vesicles 
 
sd-FCM  
(i.e. Navios™) 
hs-FCM  
(i.e. A-50 Micro FCM) 
NTA  
(i.e. NS500) 
Lower detection 
limit of beads    
500 nm*  
(polystyrene) 
100 nm*  
(polystyrene) 
50 nm  
Lower detection 
limit for EVs  
(bead-eq**) 
≥ 300 nm  ~ 180 nm ≥ 50 nm 
Specificity    
(cellular origin) 
+++ 
(moAbs) 
+++ 
(moAbs) 
(+) 
Advantages established method; 
widely used; 
small sample volume 
volumetric sample 
system gives absolute 
count; 
small sample volume 
fluorescence is 
adjustable 
Disadvantages quantification only by 
count beads;  
no detection of EXs 
underestimation of 
smaller MVs 
long capture time 
during analysis; 
photobleaching of 
fluorophores; high 
sample volume 
Practicability +++ +++ ++ 
References (246, 247); 
 by experience 
(214, 246) 
Manufacturer; personal 
correspondence  with O. 
Kenyon; by experience 
(9, 248, 249); 
by experience 
*  on the basis of size detection using FSC; **bead-eq: bead equivalent  
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In 2008, Robert et al. introduced a standardized protocol of PL-EV counting with the help of a 
newer FCM (FC500, Beckmann-Coulter) using fluorescent size-calibrated, polystyrene 
microspheres in order to apply the protocol to metacentric studies (218). However, the trial did 
not succeed because the data of PL-EV analysis by FCM are hardly comparable with one 
another as they are produced by different instruments within one investigation center. 
Additionally, FCM protocols and the pre-analytical preparation of samples within one center 
differ from one another. In the literature, many data on PL-EV concentrations in plasma samples 
from healthy individuals were reported, as seen in Table I-8. Comparable data on PL-EV 
concentrations in PC samples are listed in Table I-9. A standard protocol for measurement of 
PL-EVs needs defined standard criteria for both, PL-EVs in blood samples and PL-EVs in PCs.  
The following criteria of PL-EV analysis in blood samples by FCM were described: (i) 
Standardization of pre-analytical variables is necessary. This includes venipuncture (20- or 21- 
gauge needle; antecubital vein; first 2 - 3 ml should be discarded), collection tube (sodium 
citrate is most common), transportation (horizontal position), time to/ and differential 
centrifugation (stable within 2h in citrated or CTAD tubes; cell-free plasma with 1,500 - 2,500xg 
for 15 - 20 min followed by 13,000 g for 2 min) (250, 251). (ii) The commonly used expression 
analysis of specific antigens such as GPIIb/IIIa or GPIb with or without PS-expression needs to 
be defined (252). (iii) The definition of EV size from 0.1 to 1 µm is necessary (218). (iv) 
Implementation of adequate calibration beads and the use of bead-equivalent size range 
according to physical differences between biological vesicles and latex or silica spheres would 
be of importance (214, 246), as shown in Table I-10.  
In this context, depending on investigations of the real size distribution of biological vesicles by 
FCM using the Mie-theory and Rayleigh scattering, it has to be accepted that cell-derived 
vesicles correspond to the size of beads with an equivalent size and not to the measured bead 
size. “In theory, a 1.0 µm sized platelet microparticle would scatter as much light as a 
polystyrene microsphere of about 0.5 - 0.6 µm in diameter.” “Our data indicate that a size gate 
based on 0.5 - 0.9 µm polystyrene microspheres detects cellular particles of approx. 1 - 2 µm of 
diameter on Apogee A40” (214). Chandler reported, thereby, the approx. 10-fold lower efficacy 
in light scattering of biological vesicles due to the lower refractive index which means, that the 
smallest biological vesicle must be larger than ~ 500 nm in order to be detected by FCM (49). 
In the view of the fact that the application of hs-FCM facilitates discrimination of different vesicle 
populations in size, new biological information may become more accessible (246). 
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Table I-8: Designation of PL-EV concentrations from plasma samples of healthy individuals by 
flow cytometry as reported in the literature 
Flow cytometer EV region set on beads Materials:  
PPP, PFP, ND 
References 
FC500 (BC) >0.5 µm, <0.9 µm 
(polystyrene) 
407 - 3039/ µL 
 
(218) 
Apogee A40 <0.4 µm 
(polystyrene) 
≤1 µm (cellular origin) 
6 - 300 x10
9
/ L (214) 
FACSAria (BD) 0.3 µm,  <1 µm  
(polymethyl-methacrylate) 
220/ µL *, 420/ µL** (80) 
FACSCalibur (BD) unknown;  
count beads: 3 µm (latex) 
147 ± 238 x10
3
/ mL (193) 
EPICS XL-MCL (BC) 0.1 µm - 6.0 µm  
(polystyrene) 
5,3 x10
3
/ mL  
of whole blood† 
(253) 
Δ ND ≤1000/ µL  
=1 PL-EV per ~200 
PLT 
(254) 
Δ ND 100 - 4000/ µL (245) 
PPP: platelet poor plasma; PFP: platelet free plasma ; *after ionophore; ** after TRAP-6; 
†only annexin V+ PL -EVs; in ital ic letter: sd-FCM; ND: not determined;  Δ: not mentioned 
 
 
Interestingly, Rank at al. reported that the PL-EV count (MPs positive for CD61-labeling) from 
PCs reached approximately 10000 x10
6
/ L on the first day. The level of PL-EVs decreased 
during storage and amounted to approximately 7500 x10
6
/ L on the fifth day. These results 
referred to measurement of all cell-derived vesicles by FACScan (Becton Dickinson) according 
to Berckmans (86) formula which is as follows: 
 number/ L = multiplication of several dilution steps x used sample volume and the analyzed 
volume (15).  
However, it is not only a challenge to measure size but also to measure concentration of 
vesicles. EV analysis has still to be improved. This necessity is supported by the “iceberg 
theory” (49) and theory of the “swarm detection” (255) which imply that the FCM technique 
significantly reduces the values of EVs due to not only limited detection technique of commonly 
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used FCM but also due to the unexpected detection of large numbers of smaller vesicles, the 
“swarm”. 
 
Table I-9: PL-EV concentration of platelet concentrate samples measured by flow cytometry as 
reported in literature 
Materials:  
PRP, PPP, PFP 
Machines Concentration References 
Buffy coat-derived 
platelet concentrates; 
PFP 
A-50 (Apogee) 24,2 x10
3
/ µL 
≡ 24200 x10
6
/ L 
CD42b (+streptavidin-AF 
647nm-R-PE) 
(256) 
Plateletpheresis 
concentrates; 
PPP 
ND 1264 x10
6
/ L 
CD42b+  
(1% paraformaldehyd          
in PBS) 
(257) 
Plateletpheresis 
concentrates; 
after freeze: PFP  
(on day 1) 
FACScan (BD) 10000 x10
6
/ L 
CD61+ 
(15) 
Buffy coat-derived PCs; 
Ionophore-stimulated 
PRP (on day 1) 
FACScalibur (BD) PL-EV ratio: 
approx.  5% 
(258) 
PRP: platelet rich plasma; PPP: platelet poor plasma; PFP: platelet free plasma; ND: not 
determined; in ital ic letter: sd-FCM 
 
 
Using NTA, Harrison et al. and Dragovic et al. suggested that 90% of EVs in PFP are below  
200 nm of a concentration of 1 to 5 x 10
10
/ mL (lipoproteins excluded) (248, 255). In this aspect, 
measured PL-EV concentrations by FCM become rather estimated values. In addition, the 
recent literature provides numerous comments on the NTA system. As seen in Table I-10, the 
material of calibration beads is the most important variable in size-detection by NTA and FCM. 
FCM is not the only method, which is based on the refractive index of vesicles scattering light. 
Therefore, more suitable material for standardization of EV measurement, such as silica beads, 
was preferred (214, 259).  
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Table I-10: Bead and vesicle characteristics for detection by light scatter 
 
Polystyrene 
beads 
 
Silica beads 
 
 
Organic vesicles 
(membrane and 
lipid vesicle) 
Refractive index  
(RI; ɳ) 
1.59 1.43 - 1.46 1.39 
    
Measured amount of scattered 
light by NTA (in ratio) 
2.57 1.5 1 
RI applying the Rayleigh 
approximation 
- - 1.41 
Predicted scattering ratio by the 
Rayleigh approximation 
3.16 1.5 1 
(Data from (259)) 
 
Using the Rayleigh approximation, consistent values of the same refractive indices of 
polystyrene spheres, silica spheres and EVs were achieved together with comparable values of 
both EVs and silica beads. Although, silica beads and EVs scatter similar amount of light, EVs 
may be undervalued as compared to silica beads (259). Gardiner et al. obtained accurate 
measurements of 60 nm silica microspheres and provided a very important advice, that the 
“minimum track length has no effect on concentration measurement but determines the 
proportion of events used to build a size distribution”. In the course of measurement of Cell 
Mask-labeled EVs from plasma, the fluorescent measurement was consistent to the light 
scattering size distribution of cell derived vesicles (259). Nonetheless, the phenomenon of 
photobleaching of fluorophores, the most commonly used to identify cell lineage specificity of 
EVs, constitutes a serious problem for fluorescence measurement by NTA. Indeed, body fluids 
or samples from blood concentrates are polydisperse for vesicles and not user-friendly. 
Gardiner et al. also attended care of overestimating larger particles due to the change of size 
distribution with different camera levels, especially in samples with very low EV numbers. The 
problem of analyzing polydisperse samples by NTA deals with different requirement for light 
intensity of the beam for particles of different sizes to scatter the same light. In order to detect 
smaller vesicles, usually higher camera levels are needed as compared to larger vesicles. 
Either one sample has to be measured under three distinct settings (low dilution and low 
camera level for large EVs; medium dilution and middle camera level for microvesicles; high 
dilution and high camera level for exosomes) or the larger vesicle has to be diluted so that only 
small EVs are analyzed (259).  
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Additionally, the high amount of the EV-typical sized lipoprotein particles (over 98%) in platelet-
free plasma (PFP) of healthy individuals was demonstrated. At least, the pellet of ultra-
centrifuged PFP contained 0.5 - 5.0 x10
10
 EV/ mL of an average size of 70-120 nm. 
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II Aims of the study 
During storage of plateletpheresis concentrates (PC) under blood banking conditions for up to 4 
days, platelets develop so-called platelet storage lesion (PLS), which is a major limitation of in 
vitro platelet storage. Previous investigations have shown that platelet-derived extracellular 
vesicles (PL-EVs) are a part of PLS. The current approaches to quality control (QC) of PCs from 
platelet hemapheresis now include the analysis of PL-EVs performed at the University Hospital 
of Regensburg, as presented in Figure II-1. 
The primary aim of this dissertation was to investigate how the amount of PL-EVs from PCs 
may contribute to the quality-defining process within QC program. The study includes the 
determination of a correlation between the measurement of PL-EVs in fresh PCs and PCs over 
time and the measurement of well-established platelet function tests, i.e. expression of CD62P 
on platelets´ surface after activation with thrombin receptor activating peptide 6 (TRAP-6).  
The first goal was to validate the method of PL-EV analysis by standard flow cytometry (sd-
FCM). The two new analytical methods, the high-sensitivity flow cytometry (hs-FCM) and 
nanoparticle tracking analysis (NTA) were compared to sd-FCM (Inter-assay validation). 
Further, it was aimed to show, that aggregometry with PC-samples is not the method of choice 
for QC, since aggregometry required the whole PC and it does not allow a separate analysis of 
individual PC components (i.e. platelets, PL-EVs and surrounding plasma). Not only 
coagulability, number and amount of PL-EVs was detected, it was also questionable, if several 
conditions of PCs, such as preparation, sampling, storage or activation may affect the 
attendance of platelet vesiculation, as described in chapter V 5.1 of results. 
The correlation among donor-specific parameters and laboratory parameters and quality-
defining parameters of PCs was investigated, because donor-specific parameters (i.e. body 
mass index, etc.), collection-specific parameters (i.e. time of apheresis) and storage-associated 
parameters (i.e. shear stress) may also influence the quality of PCs, as seen in chapter V 5.2.  
Three methods of PL-EV analysis, i.e. sd-FCM, hs-FCM and NTA were correlated to the 
standard platelet function test (CD62P expression). Changes of PL-EV amount over time during 
storage was determined, which may correlate with standard quality-defining laboratory tests as 
well as with extra conditions, i.e. irradiation, as described in chapter V 5.3. 
Investigations was necessary in order to evaluate the amount of EVs originating from other cells 
than from platelets within PCs (as described in chapter V 5.4), because that amount may affect 
the total number, size and function of cell-derived vesicles in blood components, in this case 
PCs. 
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Figure II-1: Investigation of quality in plateletpheresis concentrates in vitro involves the analysis of separate concentrate components, i.e. plasma, 
platelets and platelet-derived extracellular vesicles (PL-EVs) 
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III Materials 
3.1 Technical equipment 
Machine  Manufacturer 
A50-Micro Flow Cytometer Apogee Flow Systems Ltd., UK 
ABL 90 FLEX Radiometer GmbH, Willich 
Amicus Crescendo Cell separator Fenwal Inc., Lake Zürich, IL, USA 
Apact 4S Plus Rolf Greiner Biochemica, Flacht 
BCS® System Siemens Healthcare Diagnostics 
BD FACS Canto™ II Becton Dickinson  (BD-Bioscience), 
Heidelberg 
Blood bank refrigerator BL-520 Philipp Kirsch GmbH, Offenburg, Germany 
BN ProSpec Siemens Healthcare Diagnostics 
Cobas Integra Roche Diagnostics, Germany 
Donor Tube Stripper Fenwal Inc., Lake Zürich, IL, USA 
Fridge, 261844 (2°C - 8°C) Liebherr, Germany 
Hematron™ 3 Fenwal Inc., Lake Zürich, IL, USA 
Heraeus Megafuge 1,0 R  DJB Labcare Ltd, UK 
Immulite 2000 XPi Siemens Healthcare Diagnostics 
Irradiation device Type IBL-437 Isotopen Diagnostik CIS GmbH, Dreieich 
Lamina Air Flow  Thermo Electron Company  
Multiplate® Analyzer Dynabyte GmbH, Munich, Germany 
NanoSight NS500 NanoSight Ltd., Amesbury, UK 
Navios™, AN 41158 Beckman Coulter GmbH, Krefeld 
Platelet Agitator PF96i Helmer Laboratories, Noblesville, USA 
Platelet Agitator PFS84 Helmer Laboratories, Noblesville, USA 
Platelet Incubator PC3200h Helmer, Laboratories, Noblesville, USA 
Pro BP 3400  Welch Allyn Inc., NY 
Reference Pipette 0,5-10 µL, 500 µL,           
50-200  µL, 1000 µL, 20 µL, 50 µL 
Eppendorf, Germany 
Research Pipette 10-100 µL, 100-1000 µL Eppendorf, Germany 
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continuation of table of technical equipment  
 
Machine  Manufacturer 
Scale VC 3 K1M Gottl/ Kern & Sohn GmbH, Germany 
Sunrise™ Tecan Photometer Tecan Deutschland GmbH, Crailsheim 
ThermoScan Braun Welch Allyn Kaz Europe SA 
Trima-Accel® Cellseperator Terumo BCT Inc., USA 
TSCD-II Terumo  Terumo, Germany 
Ultracentrifuge SW-41TI rotor Beckman, Fullerton, CA 
Vista Dimension® 1500 Siemens Healthcare Diagnostics 
Vortex-Genie 2 USA Scientific Inc., USA  
XE-5000 hematology analyzer Sysmex, Norderstedt, Germany 
 
3.2 Consumables 
Product Manufacturer 
Blood Gas Monovette® Sarstedt, Germany 
Capillary tubes Sysmex GmbH, Germany 
Falcon tubes, 5ml Sarstedt, Germany 
Multiplate-disposable-Measuring cell Dynabyte GmbH, Münich, Germany 
Pipette tip „epTIPS“ 0,1 - 2500 μL Eppendorf, Germany 
Platelet Apheresis Kit Terumo BCT, Europe n.V. Belgium 
Platelet Apheresis Kit Fenwal Inc., Lake Zürich, IL, USA 
Polypropylene round bottom tubes  
5 mL, 2mL 
Sarstedt, Germany 
Polystyrene round bottom tubes, 5mL Falcon/BD, Eremdodegem, Belgium 
Rad-Sure Blood irradiation indicator LMB Technologie GmbH, Schwaig 
Safety-Multifly-Set, 20G, 0,9 x 19mm Sarstedt, Germany 
S-Monovette®, Clotting activator Sarstedt, Germany 
S-Monovette®, EDTA K3 Sarstedt, Germany 
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continuation of table of consumables 
 
Product  Manufacturer 
S-Monovette®, Sodium-Citrat Sarstedt, Germany 
Spiking Mandrel R4R1401 Fenwal Inc., Lake Zürich, IL, USA 
Syringe without Luer Look 20mL, 50mL Falcon/BD, Eremdodegem, Belgium 
Transfer-needle, 27G Sarstedt, Germany 
 
3.3 Reagents 
Substance Manufacturers 
ACD-A, RDB8652 Fenwal Inc., Lake Zürich, IL, USA 
ADP (adenosine diphosphate), 5 µM Rolf Greiner Biochemica 
Apolipoprotein A-I Flex® reagent cartridge Siemens Healthcare Diagnostics 
Apolipoprotein B Flex® reagent cartridge Siemens Healthcare Diagnostics 
Apolipoprotein CI Human ELISA Kit Abcam plc., Cambridge, UK 
Apolipoprotein J Human ELISA Kit BioVendor GmbH, Heidelberg 
Aqua  dest. B. Braun, Melsungen 
Arachidonic acid Rolf Greiner Biochemica 
BC-Thrombin-Reagent Siemens Healthcare Diagnostics 
Berichrom-PAI 1 Kit Siemens Healthcare Diagnostics 
C3-Complement Flex® reagent cartridge Siemens Healthcare Diagnostics 
CaCl2 Solution Siemens Healthcare Diagnostics 
Calcium Flex® reagent cartridge Siemens Healthcare Diagnostics 
Calibration BeadMix #1493 Apogee Flow Systems Ltd, UK 
Calibration beads, 100nm NanoSight Ltd., Amesbury, UK 
Calibration beads, 100nm, green fluorescent NanoSight Ltd., Amesbury, UK 
Calibration beads, 200nm NanoSight Ltd., Amesbury, UK 
Calibration beads, 50nm NanoSight Ltd., Amesbury, UK 
CD41-PE, Clone P2, Type IgG1 IOTest®/ Beckman Coulter 
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continuation of table of reagents 
 
Substance Manufacturer 
CD61-PC7, Clone SZ21, Type IgG1 IOTest®/ Beckman Coulter 
CD61-PerCP, Clone RUU-PL 7F12, Type 
IgG1-Kappa 
BD- Biosciences 
CD62P-FITC, Clon CLB-Throm/6, Type IgG1 IOTest®/ Beckman Coulter 
Cellpack (PK-30L, 20 L) Sysmex GmbH, Germany 
Cholesterol Flex® reagent cartridge Siemens Healthcare Diagnostics 
Collagen Rolf Greiner Biochemica 
C-reactive Protein Flex® reagent cartridge Siemens Healthcare Diagnostics 
ELISA Kit Human Apo-B48 Tecan Deutschland GmbH 
Fibrinogen N Antiserum Siemens Healthcare Diagnostics 
Glucose Flex® reagent cartridge Siemens Healthcare Diagnostics 
Hemoglobin A1c Kit Roche Diagnostics 
High-Density-Lipoprotein-Cholesterol Flex® 
reagent cartridge 
Siemens Healthcare Diagnostics 
Human-Apolipoprotein E Antiserum Siemens Healthcare Diagnostics 
IgG1-PC7, Clone 679.1Mc7, isotypic control IOTest®/ Beckman Coulter 
Immulite IGF-BP-3 Test Siemens Healthcare Diagnostics 
Immulite IGF-1 Test Siemens Healthcare Diagnostics 
Kalium Flex® reagent cartridge Siemens Healthcare Diagnostics 
Low-Density-Lipoprotein-Cholesterol Flex® 
reagent cartridge 
Siemens Healthcare Diagnostics 
MegaMix BioCytex, Marseille, France 
Multifibren U Siemens Healthcare Diagnostics 
NaCl (0.9%), HAGE1324 Baxter, Germany 
NaCl, 0.9% B. Braun Melsungen AG, Germany 
N-Latex Lp(a) Siemens Healthcare Diagnostics 
N-Lp(a) Control SY Siemens Healthcare Diagnostics 
N-Lp(a) Standard Siemens Healthcare Diagnostics 
Optiprep Density Gradient Medium Sigma-Aldrich, Steinheim, Germany 
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continuation of table of reagents 
 
Substance Manufacturer 
PBS-Dulbecco, w/o Ca
2+
/Mg
2+
 Buffer Biochrom AG, Berlin 
Ristocetin Rolf Greiner Biochemica 
TRAP-6 (Thrombin-Receptor-Activating-
Peptide, SFLLRN), 1µM 
Bachem Biochemica, Heidelberg 
Triglyceride Flex® reagent cartridge Siemens Healthcare Diagnostics 
Tyrodes buffer All components are acquired from Sigma-
Aldrich, Steinheim, Germany 
 
3.4 Analytical Software 
Software  Manufacturer 
Amicus Crescendo Software V 3.2 Fenwal Inc., Lake Zürich, IL, USA 
Apogee Histogram Software, V3-1 Apogee Flow Systems Ltd, UK 
FACSDiva Software, Version 6.1.3 Becton Dickinson  (BD-Bioscience), 
Heidelberg 
Multiplate Software Version V 2.02.11 Dynabyte medical, Munich 
NanoSight NTA 2.3 Analytical Software NanoSight Ltd., Amesbury, UK 
Navios Software, Version 1.0 Beckman Coulter GmbH, Krefeld 
Office 2012 Office suite Microsoft, Unterschleißheim 
Reference Manager Thomson Reuters, San Francisco, USA 
SigmaPlot 12 Systat Software GmbH, Erkrath 
SPSS 20 statistical software package IBM, Ehningen 
swisslab, Release 2011_03 Roche Deutschland Holding GmbH 
Trima-Accel®, Software 5.1 Terumo BCT Inc., USA 
XLSTAT MS Excel Microsoft, Unterschleißheim 
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3.5 Preparation of solutions 
3.5.1 TRAP-6 
TRAP-6 (Thrombin-Receptor-Activating-Peptide, SFLLRN) stock solution, 3 µM: 
 5 mg TRAP-6 dissolved in 2225 µL Aqua dest. (3 mM stock solution 1) 
 100 µL stock solution 1 diluted in 9,9 mL PBS-Dulbecco (30 µM stock solution) 
 Aliquots á 20 µL stored in cups with screw-cap (Eppendorf) at -15°C or at lower 
temperatures are stable for one year according to the manufacturers recommendation 
 Before utilization, aliquots have to be thawed at room temperature for a few minutes 
(min)   
3.5.2 Tyrode buffer 
Calcium-free Tyrode-Hepes buffer or modified Typrode-Hepes buffer (Tyrode-N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic
 
acid), pH 7.4, sterile-filtrated 
138 
3 
12 
(0.4 
1 
5 
10 
10 
mM 
mM 
mM 
mM 
mM 
mM 
mM 
mM 
NaCl 
KCl 
NaHCO3 
NaH2PO4) 
MgCl2 
glucose 
Hepes 
EDTA 
MW: 58.442 
MW: 74.56 
MW: 84.01 
MW: 137.99 
MW: 203.3 
MW: 180.2 
MW: 238.306 
MW: 372.2 
8.065 g/ L 
0.224 g/ L 
1.008 g/ L 
0.055 g/ L 
0.203 g/ L 
0.901 g/ L 
2.383 g/ L 
3.722 g/ L 
 
3.6 Plateletpheresis concentrates  
Hemapheresis donations for platelet concentrates (PCs) were obtained according to the 
German regulations of Bundesärztekammer (33) for blood donation from healthy volunteer 
platelet apheresis donors. All donors gave informed consent. For a single-donor apheresis cell 
separators Trima Accel® (Terumo BCT, with the single-needle-System) and Amicus (Fenwal 
Inc., with the double-needle-System) were used under standard procedures of blood donation 
centers. As specified in the manufacturing authorization (PEI.H.03019.01.1, “Human-
Thrombozytapherese-konzentrat UKR, leukozytendepletiert, bestrahlt”; PEI.H.02563.01.1, 
“Human-Thrombozyten-Apheresekonzentrat UKR, leukozytendepletiert”), PCs included human 
platelets from a single donation in amount varying from 2.0 to 4.0x10
11
 platelets/ unit in a total 
volume varying from 200 mL to 300 mL, whereas leukocyte content was lower than 1x10
6
/ unit 
and erythrocyte content lower than 3x10
9
/ unit.  
Further components are autologous plasma (0.74 - 0.85 mL/ mL) and Anticoagulant Citrat 
Dextrose Solution Formula A (ACD-A; Fenwal Inc.; 0.15 - 0.26 mL/ mL).  
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Gamma irradiation with 25 Gy (Irradiation device Type IBL-437, Isotopen Diagnostik CIS GmbH, 
Dreieich) of PCs was conducted in our laboratory on the day of platelet collection (day 0). 
Irradiation was successful when the ‘NOT’ in the window of Rad-Sure indicator darkened after 
irradiation and the indicator: ‘IRRADIATED’ was displayed. Platelet concentrates were stored 
for up to 7 days at 22°C ± 2°C under constant agitation at 60 cycles/ min (Platelet Agitator 
PF96i, Helmer Laboratories, Noblesville, USA). 
 
3.7 Red blood cell units 
For analysis of vesicles in red blood cell (RBC) units, five expired and non-irradiated units were 
used. They were labeled as “Human-Erythrozytenkonzentrat CPD-SAGM L BSD/BRK” of the 
blood donation center “Bayerisches Rotes Kreuz, GmbH München” and stored under standard 
blood banking conditions at 4°C ± 2°C (Blood bank refrigerator BL-520 according to DIN 58371, 
Philipp Kirsch GmbH, Offenburg, Germany). The number of days exceeding the expiry date of 
RBC units varied from one to three days, i.e. red blood cells reached the age from 43 days up to 
45 days. According to the manufacturer information, the standard RBC unit of a volume of 280 
up to 380 mL comprises erythrocytes of a hematocrit level ranging from 0.5 to 0.7 and a 
stabilizing solution CPD (sodium citrate, citric acid, monohydric glucose, sodium-hydrogen 
phosphates di-hydrates). Additionally, RBC units contain an additive solution SAG-M (sodium 
chloride, adenine, glucose monohydrate, and mannitol) and donor plasma with residual 
leukocytes amounting to less than1 x 10
6
 per standard container. 
 
3.8 Blood samples of healthy donors  
Peripheral venous blood samples were collected on day 0 directly before apheresis. Test tubes 
were filled with ethylenediaminetetraacetic acid (1.6 mg EDTA/ 1 mL blood; S-Monovette®, 
EDTA K3, Sarstedt), or citrate (pre-dosed as a 0.106 molar solution, equivalent to 3.2% 
trisodium citrate; S-Monovette®, Sodium-Citrat, Sarstedt) in a mixed ratio of 1:10 (1 part citrate 
+ 9 parts blood) or with beads coated with a clotting activator (silicate; S-Monovette®, clotting 
activator, Sarstedt). Serum was obtained by centrifugation of blood samples at 2500 g for 15 
min. To quantify apolipoprotein C-I, clusterin, apolipoprotein B48, insulin-like growth factor 1 
(IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), samples were immediately stored 
at 2°-8°C until measurements were carried out. All analytical techniques, except vesicle 
analysis, were implemented in the routine workflow at the Institute for Laboratory and 
Transfusion Medicine, University of Regensburg, Germany. 
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IV Methods  
4.1 Background 
Altogether, 106 platelet concentrates have been investigated. Donor specific parameters (BMI, 
post-prandial status, blood pressure, etc.) were determined directly before platelet 
hemapheresis. Plasma parameters were determined by photometry, nephelometry, ELISA, 
CLIA, coagulometry or chromogenic method on clinical chemistry analyzers according to 
standard procedures of manufacturer. 
PCs were exposed to effects of agonists of platelet activation and aggregometry of PCs was 
measured with the help of an impedance aggregometer (Multiplate®) and light transmission 
aggregometer (Born) according to the instructions of the manufacturer. 
Analysis of platelet-derived extracellular vesicles (PL-EVs) was carried out by standard flow 
cytometry in volume-defined PC samples using a size calibrator micro bead cocktail 
(Megamix®). Additionally, PL-EVs were measured with a micro flow cytometer and partially 
fluorescent beads smaller sized as the MegaMix beads (Apogee bead mix #1493). 
Concentration and allover particle size distribution of all plasmatic vesicles without 
immunostaining were analyzed by nanoparticle tracking analysis (NTA, NanoSight, UK). Platelet 
function tests were performed with an agonist of platelet activation by standard flow cytometry 
and platelet specific immunostaining. 
For comparison, erythrocyte- and leukocyte-derived vesicles from PCs were also measured by 
flow cytometry. 
 
 
 
Methods            46 
 
  
4.2 Flow chart of plateletpheresis and sampling for quality control 
 
Figure IV-1: Workflow diagram for manufacturing and sampling of platelet concentrates (PC) on 
several days after apheresis  
*Citrate values were measured merely on day 0 of PCs. 
 
 
Figure IV-2: Flowchart of sample count (n=) from plateletpheresis concentrates  
Overall, 106 PCs were analyzed. The first group included 42 PCs analyzed on day 0 and 
subsequently on day 5. In the second group, 40 PC tube samples were analyzed exclusively on 
the day of hemapheresis (day 0) and in the third group 24 PCs after expiry date. 
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4.3 Sampling of platelet concentrates 
Tests for platelet (PLT) count of PCs, PLT function, pH-value, PL-EV amount and citrate values 
were performed on samples taken on day 0 and/ or day 5, at day 6, or day 7 after donation. 
Sampling of PCs on day 0 was performed before agitation and incubation at room temperature, 
sampling on day 5, 6 and 7 was carried out at room temperature after constant agitation of PCs 
incubated at 22°C ± 2°C according to standard blood banking conditions.  
Two different sample types of PCs after apheresis were used. At first, samples were drawn from 
the content of PC bags by sterile docking of spiking mandrel after thorough mixing of the bags. 
Next, samples were drawn from the flexible, concentrate-filled, tube system of the closed 
apheresis set after stripping the tube twice. Sampling by sterile docking is favorable in aspect of 
an arbitrary sample volume for tests of PC quality whereas the tube volume of the apheresis 
sets is limited. The PLT count in both different sample types was equal and amounted 
approximately 1,000,000,000 PLT/ mL. 
 
While sampling, the PC bag concentrates were placed under a laminar flow hood and were 
connected with a spiking mandrel (R4R1401, Fenwal) by sterile docking immediately after 
opening the PC bag on injection port. The mandrel was tapped with a needle (Safety-Multifly-
Set, 20 G, and 0.9 x 19 mm, Sarstedt, Germany) to transport the content of the bag into the 
previously prepared test tubes. 
In case of laminar flow hood conditions were not available, sampling from PC bags was 
performed by using a container closed to the apheresis set. The container was filled with PC 
content (the container was gently squeezed with two fingers) and welded with a heat sealer 
(TSCD-II Terumo, Germany) before the content was conveyed in the prepared tests tubes. 
PC sample from a concentrate-filled, flexible tube connected with apheresis set was 
disconnected with a sterile heat sealer (TSCD-II Terumo, Germany). Perforation of the tube with 
a needle (Safety-Multifly-Set, 20 G, 0.9 x 19 mm, Sarstedt, Germany) under laminar airflow 
hood was performed to transfer the content of the tube into a prepared test tube. Flexible tubes 
of a length up to 28 cm and a radius of 0.15 cm gave a sample volume of max. 1.979 mL, as 
determined with the help of the formula: V=h x π x r
2
 (V=28 cm x 3.1416 x (0.15 cm)
2
 =1.979 
cm
3
 =1.979 mL). Therefore, a tube of 1 cm
3 
volume corresponds to a sample of 1 mL and tubes 
with a length up to 1 cm bring about a sample volume of max 0.0707 mL (V=1 cm x 3.1416 x 
(0.15 cm)
 2
 =0.0707 cm
3
 =0.0707 ml). The average platelet count in tubes of 1 cm length is 
70.678.571 PLTs and in tubes of 28 cm length amounted to 1.979.000.000 PLTs. 
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Figure IV-3: Disconnection of the tube of plateletpheresis set after donation 
 
 
 
Figure IV-4: Flexible tube filled with plateletpheresis product after disconnection from the 
apheresis set from a double donation 
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Table IV-1: Summary of count (n=) from plateletpheresis concentrate (PC) samples and tube samples for analysis on day 0 and day 5 (red numbers 
belong to the irradiated samples) 
 
 
Count of samples for specimen analysis (n=) 
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PC 
day 0 
27/15 26/15 27/15 15/15 27/15 15/15 15/15 15/15 15/15 15/15 - - - - - - - - - 
PC 
day 5 
45/21 10/15 27/15 - 44/18 32/18 32/18 45/21 0/15 0/15 19/11 15/0 25/6 1/0 12/6 3/1 12/1 7/1 3/16 
Tube  
day 0 
40/0 - - - 39/0 39/0 38/0 40/0 - - 29 2 36 - 24 - - 2 27 
Tube  
day 5 
- - - - - - - - - - - - - - - - - - - 
All n  
day 0 
82 41 42 30 81 69 68 70 15 15 29 2 36 - 24 - - 2 27 
All n 
day 5 
66 25 42 - 62 50 50 66 15 15 30 15 31 1 35 0/1 0/1 8 19 
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4.4 Sample preparation of platelet concentrates for measurement of platelet-derived 
and red blood cell-derived extracellular vesicles 
4.4.1 Dilution of PC samples 
Analysis of plasmatic and platelet-derived extracellular vesicles of PCs was performed on 
samples diluted with PBS-Dulbecco (DPBS), w/o Ca
2+
/Mg
2+
 Buffer (Biochrom AG, Berlin). For 
measurement of PL-EVs by flow cytometry with Navios™ (Beckman Coulter GmbH, Krefeld ), 
PC samples was diluted first at 1:500 ratio and analyzed in a final dilution of 1:2500. PC 
samples for measurement with A50-Micro Flow Cytometer (Apogee Flow Systems Ltd., UK) 
were diluted first at 1:100 and used in a final dilution of 1:500.  
Analysis of plasmatic EVs by nanoparticle tracking analysis (NTA) with NanoSight NS500 
(NanoSight Ltd, Amesbury, UK) was performed on PC samples diluted at a ratio of 1:500. 
4.4.2 Platelet- and EV-containing plasma preparation  
Aggregometry was carried out in centrifuged PC samples at 336 x g for 10 min at room 
temperature to remove erythrocytes, leukocytes and most platelets and to obtain platelet rich 
plasma (PRP). Additionally, PRP was centrifuged anew at 1500 x g for 10 min at room 
temperature to produce platelet poor plasma (PPP). 
4.4.3 Preparative isolation of EVs from plateletpheresis concentrates 
EVs from PCs were isolated on day 0 and day 5 by differential centrifugation. Platelets were 
eliminated by centrifugation twice at 1.500 x g for 15 min, followed by filtration of the 
supernatant through 1 µm diameter pore filter. To pellet EVs, the filtrate was centrifuged at 
30.000 x g for 45 min and the pellet was washed twice with 40 mL Tyrode-Hepes buffer and 
stored at -80°C until analysis was carried out. The aforementioned protocol was used to isolate 
EVs from thrombocyte concentrate (200 mL) for preparative purposes (lipidomics, 
transcriptomics and proteomics) and is a refinement of the protocol published in Pienimaeki-
Roemer et al. Transfusion July 2012. 
 
4.5 Sample preparation of red blood cell units for measurement of platelet-derived and 
red blood cell-derived extracellular vesicles 
EVs from red blood cell units were isolated by differential centrifugation. At first, one sample of 
RBC unit (25ml) was diluted with 25ml PBS-Dulbecco, w/o Ca
2+
/Mg
2+
 Buffer (Biochrom AG, 
Berlin) and subjected to centrifugation for 20 min twice at 1850 x g in order to eliminate red 
blood cells. Subsequently, the obtained supernatant was centrifuged for 20 min at 3200 x g.  
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In addition, the supernatant was centrifuged by ultracentrifugation once at 120.000 x g for 90 
min, followed by wash steps with PBS, three times at 120.000 x g for 90 min. Next, the pellet (P) 
was resuspended in 2 ml PBS, supplemented with an enzyme inhibitor (1 to 2 µL) and the 
mixture was stored at 5°C until the analysis was performed (2 to 3 days). All vesicles were 
divided in subfractions (fraction I, II, III) by density gradient centrifugation with OptiPrep Density 
Gradient Medium in diverse solutions (10%, 15%, 20%, 25%, and 30%) at 40.000 x g for 3h. 
Subfractions were captured with a 27G needle, aliquoted and stored at -80°C. 
 
Table IV-2: Preparation of red blood cell units for analysis of extracellular vesicles by 
ultracentrifugation and density gradient centrifugation 
 
 
4.6 Flow cytometry 
4.6.1 Principles and parameters 
Flow cytometry is a routine laboratory method for the analysis of single living cells of a size 
ranging from 400 nm to 40 µm. Conventional flow cytometers are also used for the analysis of 
single extracellular vesicles within the range of approximately 300 nm up to 1 µm. Because of 
the limitations in resolution of conventional flow cytometry and the small size of extracellular 
Preparation step Procedure 
1  undiluted RBC unit 
2  dilution with PBS 1:1 
3  20 min, 1850 x g  
4  20 min, 1850 x g  
5  20 min, 3200 x g 
6  90 min, 120.000 x g 
 pellet 1 (P1) 
 pellet 2 (P2) 
 pellet 3 (P3) 
 
7  first wash step 90 min 120.000 x g  
8  second wash step 90 min 120.000 x g  
9  third wash step 90 min 120.000 x g  
10   pellet (P4) 
11  fraction I 
 density gradient centrifugation 12  fraction II 
13  fraction III 
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vesicles, numerous techniques were developed for quantitative and qualitative analysis of 
vesicle populations of smaller diameters then 70 nm (260). The instruments used for the 
experiments in this thesis were standard flow cytometers as Navios™ (Beckman Coulter GmbH, 
Krefeld), Canto™ II (Becton Dickinson, Heidelberg) and a high-resolution flow cytometer, the 
A50-Micro Flow Cytometer (Apogee Flow Systems Ltd, UK). All further descriptions and 
technical data refer to these instruments. 
Prior to the analysis, cells were pushed from the sample tube through an injection tube. Then, 
sheath fluid pushed the cells through the flow chamber and positioned them in the middle of the 
laser beam by means of hydrodynamic focusing. 
Two light scattering parameters are measured directly without further light filtering. Forward 
scatter (FSC) is a morphological parameter which is dependent on the relative size of the cell, 
whereas side scatter (SSC) is measured parallel to the laser beam and depends on the relative 
granularity or on homogeneity of the analyzed cell. Additional fluorescence channels can be 
used to investigate surface markers. For this purpose, optical filters are positioned in the light 
path to separate the signals emitted from the different fluorochromes. These fluorochromes 
absorb the laser light from the argon laser at 488 nm and emit at a specific longer wavelength. 
The signal is quantified with photomultipliers and further analyzed with the help of appropriate 
software. 
4.6.2 Platelet function test 
Externalization of platelet p-selectin (CD62P) in response to thrombin receptor activating 
peptide-6 (TRAP-6) as a measure of platelet activation marker was assessed on day 0 (day of 
production) and day 5 (after expiry date). The evaluation was carried out by flow cytometry 
according to standard protocols with evaluation of the expression of the major platelet 
membrane glycoproteins which support platelet adhesion and aggregation (GPIIb/GPIIIα). The 
fluorescence of platelets was analyzed (FACSDiva Software, Version 6.1.3, Becton Dickinson, 
Heidelberg) and given in the mean fluorescent intensity (MFI) of positively stained platelets. 
This was related to the basal expression of p-selectin, granulophysin and the formed 
glycoproteins. 
PC samples after resting storage on day 0 and agitated storage on day 5 were diluted with 
PBS-Dulbecco, w/o Ca
2+
/Mg
2+
 Buffer (Biochrom AG, Berlin) to a final concentration of platelets 
of ≤ 20 000/ µL. Diluted PC samples (20 µL) were incubated with 10 µL TRAP-6 in molar mass 
of 10 M for 10 minutes (min) versus control with 10 µL PBS-Dulbecco, w/o Ca
2+
/Mg
2+
 Buffer at 
room temperature in darkness. Immunostaining was performed with the monoclonal antibodies 
CD62P-FITC, CD41-PE and CD61-PerCP according to the standard protocols of manufacturer. 
 
 
Methods                                     53 
 
  
 
Table IV-3: Scheme of immunostaining for analyzing PLT function test  
20 µL of diluted PC sample was incubated with fluorescence labeled antibodies after activation 
of platelets in vitro by thrombin receptor activating peptide-6 (TRAP-6, Bachem Biochemica, 
Heidelberg). Standard labeling was performed with three platelet specific antibodies. All 
antibodies were used for elaborated analysis of platelet function 
CD41-PE CD61-PerCP CD62P-FITC 
20 µL 20 µL 20 µL 
. 
 
 
Flow cytometry measurements were performed with the standard 3-colour instrument setting 
(FACS Canto™ II, BD). For each sample, data were collected until the 10,000-event stop 
criterion was met. The whole platelet population was gated on forward and side scatter with 
adjusted gains. Gating strategy was applied to forward scatter (FSC) and to side scatter (SSC) 
according to CD41 and/ or CD61 positively stained platelet population; subsequently, 
percentage of CD62P positive platelets was gated. 
 
Figure IV-5: Gating strategy by flow cytometry with Canto™ II 
a) Gating of CD61 (not shown) labeled platelets on FSC to SSC (P1). b) Gate of P1 
corresponds to platelet populations labeled with CD62P to SSC (P2). Events of lower intensity 
are the equivalent of platelet debris and were not considered as a correct population. 
 
Methods                                     54 
 
  
 
Figure IV-6: Absolute values of platelet events and Mean Fluorescence Intensity by analytical 
FACSDiva Software 
The CD62P Mean Fluorescence Intensity (MFI, without dimension) of a) activated platelets 
(incubated with TRAP-6) was calculated in percent to basal CD62P MFI of b) platelets without 
activation (incubated with PBS-Dulbecco) in vitro set up to 100%. 
 
Figure IV-7: Changes of externalization of CD62P after activation with TRAP-6 by flow 
cytometry 
a) Gated platelets (P3) with basal activatability (MFI = 100%) and b) activated after stimulation 
with TRAP-6 (MFI = x %). Platelet population shifts to the right of the x-axis (→) which indicates 
higher intensity of CD62P externalization. As expected, PC stimulated with CD62P with 
sufficient quality characteristics amounts at least to 200% on day 0 and at least to 140-150% on 
day 5. 
 
 
4.6.3 Platelet-derived extracellular vesicles 
4.6.3.1 Navios™ 
The flow cytometer (Navios™, Beckman Coulter, Krefeld, Germany) scatter size was calibrated 
by fluorescent polystyrene beads with a refractive index (RI) of 1.61 (Megamix beads; BioCytex, 
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Marseille, France) to discriminate platelets (approx. 0.9 - 3.0 µm) from platelet-derived 
extracellular vesicles (PL-EVs; approx. 0.5 - 0.9 µm) as described earlier (261). Staining of 100 
µL of 1:500 diluted platelet rich plasma (PRP in phosphate buffered saline, PBS-Dulbecco w/o 
Ca
2+
/Mg
2+
) was performed by incubation with saturating amount (2.5 µL) of R Phycoerythrin-
Cyanine (PC)7-labeled mouse IgG1 against CD61 glycoprotein GPIIIa (IOT®, Beckman Coulter) 
at room temperature for 10 min in darkness. After addition of 500 µL PBS (final dilution of 
1:2500), samples were analysed immediately as described. Each sample run produced data of 
500,000 events occurring within 180 seconds in a defined volume of samples. The relative PL-
EV and platelet counts were used to calculate the count of released PL-EVs/ platelet (as ratio in 
%). IgG1-PC7 (IOT®, Beckman Coulter) was used as isotypic control to detect unspecific 
binding. 
 
 
Figure IV-8: Calibration of instrument settings for EV-analysis with Navios™
 
a) EV gate (pictured as red box) excludes 0.5 µm bead population (green circled). b) Gates in 
FITC/SS INT LOG belongs to bead populations: 0.5 µm, 0.9 µm, 3.0 µm, the green bulk 
corresponds to the instrument noise. c) FS INT LOG for 0.5 µm bead rate is measured up to 
50%. 
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Figure IV-9: Gating strategy for EV analysis by flow cytometry with Navios™ 
Gating of PL-EVs (light blue) smaller than 500 nm corresponds to the gating strategies of bead 
gating. 
 
 
Figure IV-10: Scatter plots of events for platelets and platelet-derived EVs by flow cytometry 
with Navios™ 
a) CD61-PC7 positive labeled PL-EVs according to the size calibration with 500 nm beads. b) 
Platelets labeled with CD61-PC7 distinguishable from PL-EVs. The box below presents the 
legend with data of the occurred events. The PL-EV and platelet counts were used to calculate 
the count of released PL-EVs per platelets (in %). For representative results, semi quantitative 
determination of PL-EVs on day 0 was 3.12%. PL-EVs of PC amount to 5-10% on day 0 and at 
least to 10% on day 5. 
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4.6.3.2 FACS Canto™ II 
The flow cytometer FACS Canto™ II (Becton Dickinson, Heidelberg) scatter size was calibrated 
by a bead mix (Apogee Flow Systems Ltd, UK) with eight subpopulations of beads which differ 
in size and refractive index (RI). The bead mix contains silica spheres of the following 
diameters: 180 nm, 240 nm, 300 nm, 590 nm, 880 nm and 1300 nm with a refractive index of 
ɳ=1.42, and 110 nm and 500 nm green fluorescent beads with a refractive index of ɳ=1.59 
(latex). Staining of 100 µL 1:500-diluted platelet rich plasma (PRP in phosphate buffered saline, 
PBS-Dulbecco w/o Ca
2+
/Mg
2+
) was performed by incubation with saturating amount (2.5 µL) of 
R Phycoerythrin-Cyanine (PC)7-labeled mouse IgG1 against CD61 glycoprotein GPIIIa (IOT®, 
Beckman Coulter) at room temperature for 10 min in darkness. After addition of 500 µL PBS, 
samples were immediately analysed. For each sample run, data were acquired for up to 15,000 
events of the longest time of 3 min, in a defined volume of sample. The relative PL-EV and 
platelet counts were used to calculate the count of released PL-EVs/ platelets (in %). 
 
 
Figure IV-11: Calibration of the instrument settings for EV-analysis with Canto™ II 
Fluorescent bead populations (110 nm, 500 nm) and non-flourescent bead populations (240 
nm, 300 nm, 590 nm, 800 nm, 1300 nm) of the bead mix are presented. 180nm beads are not 
distinguishable from 240 nm beads and are included in this bead population. 
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Figure IV-12: Gating strategies for EV-analysis by flow cytometry with Canto™ II 
Two fluorescent bead populations of the bead mix (110 nm, 500 nm) are presented in the upper 
right histogram. Instrument noise overlapped with the 110 nm bead population and was 
excluded from the analysis of events 240 nm. 
 
 
Figure IV-13: Platelet-derived EV analysis by flow cytometry with Canto™ II 
The same >240 nm gate of the calibration setting with beads was applied for the measurement 
of EVs from PC samples. Top left: discrimination of platelet population and PL-EVs in SSC. 
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4.6.3.3 Apogee 
4.6.3.3.1 Background 
In contrast to a conventional flow cytometer, the Apogee A50-Micro model offers a resolution of 
a much higher light scatter sensitivity and absolute count ability for EV subpopulations without 
the use of count beads. According to manufacturer’s information, the Small Angle Light Scatter 
(SALS: identical to Forward Scatter or FSC) sensitivity is higher than that of 110 nm silica beads 
(NanoSight, 100 nm beads) and the Large Angle Light Scatter (LALS: identical to Side Scatter 
or SSC) sensitivity is higher than that of 110 nm silica beads. 
4.6.3.3.2 Practical details 
The flow cytometer Apogee A-50 Micro (Apogee Flow Systems Ltd, UK), fitted with 2 light 
scatters (LS), 4 fluorescent filter blocks (FL) and a blue laser (488 nm, 50 mW), was used to 
analyse PL-EVs from PC samples on day 0 and day 5. The scatter size was calibrated by a 
bead mix (Apogee Flow Systems Ltd, UK) containing silica spheres with the following 
diameters: 180 nm, 240 nm, 300 nm, 590 nm, 880 nm and 1300 nm diameter with a refractive 
index of ɳ=1.42, and 110 nm and 500 nm green fluorescent beads with a refractive index of 
ɳ=1.59 (latex). The beads were used to set up the EV gate in FSC and SSC with a voltage of 
250 V for FSC and a voltage of 270 V for SSC. The threshold was set at 8 (or 65535) units for 
FSC and 8 (or 65535) units for SSC to discriminate the smallest beads (110 nm) from 
instrument noise (determinate with PBS). 
 
 
Figure IV-14: Histogram of calibration of the instrument settings of Apogee A-50 Micro 
The bead mix (Apogee) includes bead populations with diameters 110 nm, 180 nm, 240 nm, 
300 nm, 500 nm, 590 nm, 880 nm and 1300 nm and are presented as blue peaks under the 
gates (black horizontal lines). 
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Staining of 100 µL 1:100-diluted PRP (in phosphate buffered saline, PBS) was performed by 
incubation with saturating amount of R Phycoerythrin-Cyanine (PC)7-labeled mouse IgG1 
against CD61 glycoprotein GPIIIa (IOTest®/ Beckman Coulter) at room temperature for 10 min 
in darkness. After addition of 500 µL PBS, samples were analysed immediately for CD61-
positive events in the far red zone by gating for platelets (2 - 3 µm) and PL-EVs in the range of 
values lower than 180 nm (size: S), 180 - 300 nm (size: M) and 300 - 590 nm (size: L). Flow rate 
was standardized to 1.39 µL/ min and a sample run of 130 µL to maintain the number of events/ 
sec amounting to approximately 2,000-5,000. Samples was acquired within at least 90 seconds. 
The concentration of PLT/ µL, EVs/ µL was calculated from the flow rate and the measurement 
time. Data were compared by analysing events/ µL. IgG1-PC7 (IOT®, Beckman Coulter) was 
used as isotypic control to detect unspecific binding. 
 
4.7 Nanoparticle Tracking Analysis 
4.7.1 Background 
Nanoparticle tracking analysis (NTA) is based on light scattering, which illuminates particles in 
suspension. Light is induced by a laser beam, therefore, rapidly moving particles are visualized 
by an optical microscope equipped with a conventional video camera (CCD: Charge-coupled 
Device) to capture them and produce a movie. Vesicles are present as small spheres of light 
(262). Software program dynamically analyses the paths the particles take under Brownian 
motion over a defined period of time captured by the camera. Speed of motion or diffusion 
coefficient (Dt) is related to the size of each particle. The software selects trajectories whose 
lifetime is sufficiently long to ensure statistically accurate results and it measures the average 
distance, which the particle covers per frame. The NTA software calculates the particle size with 
the particle movement velocity by tracking individual particles and their positional changes in 
two dimensions. This calculation is based on the Stokes-Einstein equation:  
   
   
 𝜋   
 
In the equation Dt is the diffusion coefficient (the mean squared displacement in two 
dimensions, <x, y>
2
), KB stands for the Boltzmann´s constant, T is the temperature of solvent in 
Kelvin, η means solvent viscosity and rh corresponds to the hydrodynamic radius. The 
measured Dt of a particle by NTA belongs to a spherical particle, as assessed by Strokes-
Einstein equation, and is further ascribed to the correlating diameter of the particle. 
The estimated concentration of particles is based on the assumed scattering volume calculated 
from the dimensions of the vision’s field. The sample chamber is approximately 500 nm deep 
and the depth of laser beam is around 20 µm at the time of analysis. The average concentration 
per scattering volume is estimated by counting the number of tracked particles. 
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4.7.2 Practical details 
For NTA the NanoSight NS500 system (NanoSight, Amesbury, UK) was used, equipped with a 
green laser (Excitation 532 nm, Emission 565 nm long pass) and an EMCCD-Camera (EMCCD 
high sensitivity camera) with 20 x objective magnification applied as a standard. Calibration of 
instrument settings was carried out with 1:500 diluted (PBS-Dulbecco w/o Ca
2+
/Mg
2+
 Buffer, 
Biochrom AG, Berlin) monodispers solutions of polystyrene beads in diameter of 50 nm, 100 
nm, 200 nm and 400 nm (Nanosight, Amesbury, UK). 
All measurements of native PC samples without additives (diluted 1:500 with DPBS) were 
performed under the same conditions as following: temperature of 22°C, camera level at 9, high 
threshold at 9882 ± 50 and tracking period time of 120 sec, during which the videos 
corresponding to the settings for high polydispersity and high reproducibility of the values are 
made. The PC samples were diluted in a total volume of 1000 mL to achieve the recommended 
particle concentration ranging between 10
8
/ mL and 10
9
/ mL for optimum determination of 
particle concentration, shown as 40 particles per image (PPI) in the movie. The pre-processing 
settings were used in the auto-capture mode. 
Staining of PL-EVs was not implemented; hence the analyzed particle population includes not 
only PL-EVs, but also immunocomplexes and lipid vesicles. 
 
4.8 Aggregometry 
4.8.1 Impedance aggregometry 
Platelet aggregability of PCs on day 5 was analysed by impedance aggregometry on the 
Multiplate® platelet function analyser (Multiplate Analyzer, Software Version 2.02.11, Dynabyte 
GmbH, Munich, Germany) using various platelet agonists to induce in vitro activation and 
platelet-to-platelet adhesion. Immediately after sample collection, platelet rich plasma (PRP) 
was centrifuged at 1500 g for 10 min at room temperature to generate platelet poor plasma 
(PPP). PRP was diluted in PPP to a concentration of 400 platelets/ nL. 
For analysis using Multiplate®, 300 µL of the plasma sample was diluted in a ratio of 1:1 with 
NaCl (for ASPItest) or with NaCL-CaCl2 (for COLtest, ADPtest and TRAPtest) and stimulated 
with agonists yielding the following final concentrations at 37°C: ADP (6.5 µmol/ L), collagen 
(3.2 µg/ mL), arachidonic acid (AA, 0.5 mmol/ L), Thrombin-Receptor-Activating-Peptide 
(TRAP)-6 (32 µmol/ L). Multiplate assay measures changes in electrical resistance given as 
aggregation units over time (AU*min). 
4.8.2 Light transmission aggregometry 
Platelet aggregation analysis of PCs after 5 days of storage was carried out by Born 
aggregometry on the APACT 4 S Plus (Rolf Greiner BioChemica GmbH, Flacht Germany) using 
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various platelet agonists to induce in vitro activation and platelet-to-platelet adhesion. 
Immediately after sample collection, platelet rich plasma (PRP) was centrifuged at 1500 g for 10 
min at room temperature to generate platelet poor plasma (PPP). PRP was diluted in PPP to a 
concentration of 400 platelets/ nL. For Born aggregometry, 200 µL diluted plasma sample were 
stimulated by agonists yielding the following final concentrations at 37°C: ADP (20 µmol), 
collagen (10 µg/ mL), ristocetin (1.5 mg/ mL), arachidonic acid (AA, 0.5 mg/ mL), thrombin-
receptor-activating-peptide (TRAP)-6 (0.1 mM). Maximal aggregation of platelets was registered 
as a change of transmission of light within at least 8 min as percentage of aggregation (0-100%) 
and was compared to that for PPP alone. 
 
4.9 Total blood count and platelet count analysis  
Blood counts of donors were measured on the XE-5000 hematology analyzer (Sysmex, 
Norderstedt) with impedance measurement by using hydrodynamic focusing technologies and 
flow cytometry according to the standard procedures using ethylenediamine tetra-acetic acid 
(EDTA) blood samples on day 0. Platelet count and immature platelet factor (IPF) of donor and 
PC samples were measured by the fluorescent optical method and impedance measurement 
was conducted by hydrodynamic focusing technologies and flow cytometry. Analysis of PCs is 
based on the internally defined standard procedures for blood concentrates (validated method) 
with diluted PC samples (50 µL) in capillary tubes (Sysmex, Germany) with 200 µL Cellpack-
buffer (Sysmex, Germany) in a mixed ratio of 1:5. 
 
4.10 Photometry 
Serum parameters of glucose and lipid metabolism were determined by bichromatic and 
polychromatic endpoint measurement on the clinical chemistry analyzer Dimension Vista® 1500 
(Siemens Healthcare Diagnostics) according to standard procedures of manufacturer. Tests 
included the measurement of cholesterol (540 nm, 452 nm, 700 nm), LDL-cholesterol (540 nm, 
700 nm), HDL-cholesterol (600 nm, 700 nm), triglyceride (510 nm, 700 nm) and calcium blood 
as well as non-fasting serum glucose (340 nm, 383 nm) of donor blood samples with clot 
activator (day 0). 
 
4.11 Nephelometry 
Serum parameters of lipid metabolism and the initial point of complement cascade in donor 
blood samples with clot activator (day 0) including apolipoprotein A-I, apolipoprotein B100 and 
complement C3 and C reactive protein (CRP) were determined by nephelometry on the clinical 
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chemistry analyzer Dimension Vista® 1500 (Siemens Healthcare Diagnostics) according to 
standard procedures. 
In addition, lipoprotein (a) and apolipoprotein E were determined by nephelometry on the clinical 
chemistry analyzer BN ProSpec (Siemens Healthcare Diagnostics) according to standard 
procedures. 
 
4.12 Enzym-Linked Immunosorbent Assay (ELISA) 
Serum parameters of lipid metabolism in donor blood samples with clot activator (day 0), i.e. 
apolipoprotein B48, apolipoprotein C-I, and clusterin (apo J), were determined by a Sunrise™ 
Tecan Photometer at 450 nm. Tests conformed to the standard procedures of a quantitative 
sandwich enzyme immunoassay technique with polyclonal and biotinylated polyclonal 
antibodies specific for human apolipoproteins which were recognized by a streptavidin-
peroxidase conjugate. The intensity of color was measured. 
 
4.13 Chemiluminescence immunoassay (CLIA) 
Serum insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 
(IGFPB3) were determined in blood samples with clot activator from donors on day 0 using an 
automated CLIA analyzer Immulite 2000 XPi (Siemens Healthcare Diagnostics) according to 
manufacturer’s protocols. 
 
4.14 Coagulometry 
Multifibren U reagent (Siemens Healthcare Diagnostics) is a bovine thrombin reagent and was 
used in the modified Clauss determination of fibrinogen in citrate blood samples from donors on 
day 0 by coagulometry in the BCS® System (Siemens Healthcare Diagnostics) according to 
standard protocols of manufacturer. 
 
4.15 Chromogenic method 
The Berichrom Antithrombin III (A) Kit (Siemens Healthcare Diagnostics) is a chromogenic 
activity assay and was used in the BCS® System (Siemens Healthcare Diagnostics) to measure 
antithrombin III (ATIII) in citrate blood samples from donors on day 0 before apheresis. The 
Berichrom PAI Kit (Siemens Healthcare Diagnostics) is a chromogenic test system and was 
used in the BCS® System (Siemens Healthcare Diagnostics) to analyze plasminogen activator 
inhibitor -1 (PAI-1) in blood samples according to the standard protocols of manufacturer. 
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4.16 Immunturbidometry 
HbA1c measurements were performed in ethylenediamine tetra-acetic acid (EDTA) blood 
samples from donors on day 0 with the help of the Hemoglobin A1c Kit (Roche Diagnostics, 
Germany) by immunturbidimetric method on the Cobas Integra (Roche Diagnostics, Germany) 
according to the standard protocol of manufacturer. 
 
4.17 Potentiometric method 
The measurement of pH-values was performed in PC samples (Blood Gas Monovette®, 
Sarstedt, Germany) on day 0 and day 5 at 22°C ± 2°C by potentiometric method on ABL 90 
FLEX (Radiometer GmbH, Willich) according to the standard protocols of manufacturer and to 
the intern validated method for pH-analysis of platelet concentrates. 
 
4.18 Statistical analysis 
Data were collected and organized in Microsoft Excel spreadsheets. Summary files containing 
means of all experimental data were assembled to facilitate graphic and statistical evaluation of 
the data. For statistical computing, the corresponding data were imported and analyzed using 
the statistics package SPSS 20 (IBM). In all experiments, statistically significant differences or 
correlation were considered when p values were less than <0.05 (*), <0.01 (**) and <0.001 (***). 
Graphical presentations were carried out by using SigmaPlot 8.0 and SPSS 19.0 softwares. 
Graphs were created in Excel 2010 (Microsoft), SPSS 20 (IBM) or in Sigmaplot 8.0 (Systat 
Software). The applied tests and the resulting p-values are mentioned in the figure legends. 
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V Results 
5.1 Results of methodological issues 
5.1.1 Validation of PL-EV measurement with standard flow cytometry 
First, a validation of the semiquatitative analysis of PL-EVs in PCs was performed. The aim was 
to define the sensitivity of the method (see Figure V-1, A). The saturating amount of the 
monoclonal antibody (moAb) CD61 (PE-Cy7) was titrated in three PC samples on day 0. 
Maximal saturation of 1 µL moAb solution was required to saturate CD61 epitopes in 100,000 
platelets absolute count according to the manufacturer’s protocols. Absolute platelet count in PC 
samples was about 197,400 platelets per assay. Saturation of moAb was detectable already at 
the level of 0.5 µL of moAb, for both PLTs and PL-EVs. 
In order to define accuracy of the method (see Figure V-1, B), a single, three-day stored PC was 
analyzed in triplicate. Platelet poor plasma (PPP) of this PC was aliquoted and subjected to 
analysis. The same standard configurations were applied to all samples.   
A minor deviation of the PL-EV values and a recovery rate of 97.85% to 99.44% in samples with 
PPP could be assigned, indicative that the accuracy of method is acceptable.  
Proof of linearity was limited, possibly due to the fact that the presented method cannot be 
applied to the absolute quantification of PL-EVs. Three PC samples on day 3 were analyzed as 
controls and compared to the same samples, but spiked with autologous PPP (see Figure V-1, 
C). As a result, a linear increase of PL-EVs was observed. However, statistical analysis of the 
data is not achievable since bead-based calibrators with the same refractive index and density 
as PL-EVs are currently not available. Therefore, the amount of PL-EVs [in %] in PC samples 
without spiking was outlined as 100% and was related to PL-EVs [in %] of spiked samples (+1 
µL PPP, +2 µL PPP, +3 µL PPP, +4 µL PPP). Data of PL-EVs from PCs show a linear 
coherence between increased volume of spikes and amount of PL-EVs (dashed line in Figure 
V-1, C depicts PL-EVs from PPP). Increase of PL-EVs reached 81.1% (mean) per addition of 1 
µL PPP (SD=2.3). 
In order to obtain reliable results of intra-assay variation (see Figure V-1, D), 5 samples of 3 
PCs on day 2 (PC1, PC2, PC3) were analyzed under the same standard immunolabeling and 
flow cytometer settings, as described in 4.6.3.1. First, a measurement was performed without 
mixing of sample. The following measurements were performed with PC samples which were 
gently manually mixed. Coefficients of variation were determined for all PCs and amounted to 
3.1%, 3.1% and 2.3%, respectively. Analysis of stability of the method (see Figure V-1, E) was 
performed with 3 PC samples on day 2 (PC1, PC2, PC3) after 0-30 minutes, 1h, 2h, 4h and 24h 
after plateletpheresis. All samples were diluted in PBS-Dulbecco medium at a ratio of 1:500 and 
incubated with moAb CD61-PerCP at room temperature for 10 minutes. Each sample of a total 
volume of 500 µL was measured within 180 seconds by flow cytometry (Navios™, Beckmann 
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Coulter). The analyzer was previously calibrated with a standard calibration bead mix (Megamix 
Beads (0.5µm, 0.9µm, 3.0µm Polystyrene-Beads, RI=1.6). Coefficients of variation of the 
method stability within 24 hours were determined for PC1, PC2 PC3 at 3.0%, 4.9% and 7.3%, 
respectively. 
 
 
Figure V-1: Validation of PL-EV measurement by standard flow cytometry 
A: Titration curve of saturating amount of moAb against CD61 as a sensitivity assay (PE-
Cy7=PC7). For the detection of the CD61 positive events of platelets and platelet-derived 
extracellular vesicles (PL-EV) [Mean fluorescent intensity = MFI, without dimension] varying 
volumes of moAb CD61-PECy7 were added. B: Accuracy of the method for the analysis of PL-
EVs (n=3) was proven by measurements in triplicate. C: Linearity assay of PL-EV analysis. 
Increase of PL-EV in PCs (continuous line) after addition of platelet poor plasma (PPP) of 
different volumes (1 µL, 2 µL, 3 µL, 4 µL). PL-EV amount in PPP (dashed lines). D: Intra assay 
precision examination of the method for PL-EV analysis (n=3). E: 24h-stability of the 
measurement of PL-EVs (n=3). Values of A, B, D, E are presented as mean ± SD. 
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5.1.2 Validation of nanoparticle tracking analysis 
In order to prove linearity of quantification of vesicles in a solution, an analysis of diluted 
samples was performed by nanoparticle tracking analysis (NTA, NS500; NanoSight, UK) with 
monodispers 100nm diameter bead solution and different dilutions of PC samples. The solution 
of polystyrene beads was diluted with PBS-Dulbecco medium at a ratio of 1:20 to 1:10000 and 
measured with the same instrument settings. As pictured in Figure V-2, the curve depicting a 
dilution factor below 1:1000 runs parallel to the curve of the computed values of the bead 
concentrations per mL. To confirm the data, the analysis was repeated with other sizes of 
monodispers bead solutions (50 nm, 200 nm) and similar results of linearity were obtained. 
When a bead solution is intensively mixed, NTA discriminates different bead populations 
according to their size and to their bead concentration in different dilutions. Subsequently, the 
obtained results were compared to the computed values. This procedure was successfully 
repeated in human vesicle preparations from plateletpheresis concentrates in order to test 
performance of linearity of concentrations and precision with triplet measurements in highly 
polydisperse samples. 
 
 
Figure V-2: Linearity of the method for nanoparticle tracking analysis (NTA) with beads 
Concentrations of several diluted samples (1 to 20 down to 1 to 10000) of monodispers 
polystyrene bead spheres of size of 100 nm are shown as black bars and approximate linearity 
was proven for dilutions up to 1:1000. 
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Figure V-3: Linearity and accuracy of plasma vesicle size analysis (A) and recovery and 
accuracy of plasma vesicle concentration (B) by NTA 
Measurement in triplicate was performed with one fresh PCs of different dilutions with PBS-
Dulbecco. In order to confirm accuracy of the method, coefficients of variation of size analysis 
were computed for the following dilution factors: 50, 100, 250, 500, 1000 and 10000 (20.3%, 
11%, 7.3%, 5.6%, 7% and 19.4%) corresponding to particle concentration (10.3%, 11.6%, 
31.7%, 11.8%, 9.8%, 28.3%). 
      
Figure V-4: Cumulative graph represents proof of size recovery for NTA with monodispers bead 
solutions  
The red curve shows 50 nm sized beads, whereas the brown curve corresponds to 100 nm 
sized beads, the green one to the fluorescent beads (100 nm) and the blue curve depicts the 
200 nm sized beads. 
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Figure V-5: Accuracy of size measurements with mixed up polystyrene bead solutions 
Solutions of beads of size of 100 nm, 200 nm and 400 nm were mixed and diluted with PBS to 
achieve 1:100 dilution for analysis by NTA. The intensity of scattered light of each bead and its 
corresponding size is figured in panel A. Red circles surround population of the same size. The 
diagram in panel B represents concentration x10
6
/ mL versus the size of bead populations in 
nm. 
 
 
5.1.3 Analysis of plasma-vesicle-measurement by different flow cytometers and 
nanoparticle tracking system 
In order to analyze EV four different analytical systems, two standard flow cytometers, one high 
sensitivity flow cytometer and one nanoparticle tracking system (NTA), were tested as tools to 
validate inter- and intra-assay performance. Both methods, flow cytometry and NTA, are not 
directly comparable with each other. The three flow cytometric methods remained in focus of the 
quantitative comparison of the results, while NTA system provides information related to 
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changes of size distribution of blood products over storage time. Nonetheless, size distribution 
of all plasma vesicles, lipoproteins or plasma proteins and their complexes need to be 
discriminated by the NTA system to identify changes of blood products over storage time. With 
the purpose of inter-assay validation tests the same PC samples were examined by all 
instruments in parallel. Comparable results of size and concentration of plasma vesicles in PCs 
were obtained (see Table V-1 and Figure V-6) and NTA can be assumed as a reliable method 
of vesicle quantification and vesicle size distribution. Plasma vesicles including PL-EVs were 
identified between 40 and 530 nm with a main peak at approximately 100 nm. 
 
Table V-1: Vesicle quantification of plateletpheresis concentrates (PCs) by NTA 
Immunolabeling was not required, when analyzing vesicle count and size. Dilution factor of the 
correct analysis of NTA software depends on the cumulative amount of vesicles in concentrates 
(n=6, on day 4 and 7). Particle size values are reported as the absolute value of the most 
abundant subpopulation of vesicles. 
  Particles/ ml Range of size [nm] Peak of size [nm] 
PC 1 (1:500) 4.03 x 10
8
 40-380 100>172>340 
PC 2 (1:1000) 4.77 x 10
8
 40-420 77>141>217 
PC 3 (1:500) 3.69 x 10
8
 40-380 97>322 
PC 4 (1:500) 3.78 x 10
8
 40-480 110>206 
PC 5 (1:500) 2.25 x 10
8
 50-530 130>195 
PC 6 (1:500) 2.27 x 10
8
 40-480 170>260>370 
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Figure V-6: Line chart of plasma vesicle size of plateletpheresis concentrates 
PC samples on day 4 (n=3) and day 7 (n=4) were analyzed with the NTA-system NS500 
(NanoSight, UK) at dilutions of 1:500. 
 
The analysis was carried out by flow cytometry with immunolabeling of platelets and platelet-
derived vesicles showing PL-EV values which are comparable to other systems (CV=6.2%) on 
day 4 only. Differences in PL-EV levels were due to the discrimination of smaller vesicles in the 
micro flow system. Nevertheless, for the purpose of a routine analysis, the amount of PL-EVs 
within PCs on day 4 can be estimated by both flow cytometers Navios™ and Apogee. 
 
 
Figure V-7: Inter-assay coefficients of variability 
Grey bar demonstrates the results of the PL-EV analysis on day 4, blue bar corresponds to the 
analysis on day 7. Navios™
 
(Beckman Coulter), Canto™ II (Becton Dickinson) and A50-Micro 
Flow Cytometer (Apogee Flow Systems Ltd., UK) were applied for the examination. 
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5.1.4 PL-EV-boost after TRAP-6 activation 
TRAP-6 activation of fresh platelets from PCs results in elevated levels of CD61 positive PL-
EVs. The increase reaches up to 26.4% as compared to control. Detection of PL-EVs revealed 
the presence of PL-EVs in a size corresponding to smaller than 500 nm beads measured by 
standard flow cytometry (sd-FCM) with Navios™ (Beckman Coulter). Incubation with PBS-
Dulbecco, w/o Ca
2+
/Mg
2+
 Buffer shows no vesiculation effect of platelets. Increase of PL-EV 
correlates with the p-selectin surface exposure on platelets as an activation marker after 
stimulation.  
One of the PCs showed more vesiculation as the other two PCs, because of the physiological 
inter-individual differences among blood donors. The mean of initial values of PL-EVs was 
10.2% (the values were ranging from 7.6 - 11.8% in control). However, stimulated platelets 
show PL-EV values ranging from 10.2% to 13.8% (mean 13.3%). Interestingly, the PC with the 
lowest PL-EV level before activation was most prone to activation among all PCs resulting in the 
highest PL-EV level after stimulation. 
 
 
Figure V-8: Release of PL-EVs in response to TRAP-6 in fresh PCs on day 0 
PL-EVs are depicted as grey box plots, marked with moAb CD61-PC7, in correlation to the 
activation with TRAP-6 versus control groups without stimulation. Control groups reflect native 
values of PL-EV production from platelets in fresh PCs. PBS-Dulbecco does not induce release 
of PL-EVs. Mean increase of PL-EV after TRAP-6 stimulation against the control group reached 
26.4% (ranging from 16.3 to 32.8%). No statistically significant differences between control and 
TRAP-6–stimulated group (Wilcoxon, p=0.1) were found. 
 
 
Results  73 
 
  
5.1.5 Rebound phenomenon, dependent on type of sampling and shear-stress 
Subsequently, it was investigated whether the initiation of platelet vesiculation and CD62P 
expression are reversible after resting of platelets at room temperature in sample tubes (shown 
in Figure V-9 and Figure V-10).  
This study employed samples subjected to minimal shear stress (titled ‘without shear stress’) 
and samples subjected to strong shear stress (titled ‘with shear stress’) during sampling. 
Differences of altered vesiculation and CD62P externalization in the two sample types were 
investigated.  
PL-EV values of both sample types reached their maxima four hours after sampling and then 
decreased (Figure V-9, A). Statistically significant changes over time were only computed for 
PL-EVs from samples subjected to shear stress. Statistical significant differences of PL-EVs 
between the two groups are rejectable.  
24 hours after sampling the lowest CD62P values were observed for both groups, which, 
however, gradually elevated after 144 hours (Figure V-9, B). It is supposed that platelets 
subjected or not subjected to shear stress are capable of reestablishing their functionality.  
Further, no statistically significant differences after 144 hours were found between the two 
groups, indicative that all platelets are able to sediment after hours and regain their functionality, 
despite no standard storage conditions were given.  
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Figure V-9: Rebound effect of platelet vesiculation and platelet function over time 
A: PL-EV level in PCs after activation by shear stress versus control (without shear stress). 
Significant differences in PL-EV amount over time were observed only among samples 
subjected to shear stress (Wilcoxon; p<0.05 *). B: CD62P expression on platelets after 
activation by shear stress versus control. In both groups, no statistically significant differences 
among samples over time were computed. No statistically significant differences between the 
two groups, neither for PL-EV nor for CD62P were determined (Mann-Whitney-U-test; p >0.05). 
 
 
When correlating PL-EV-ratio and CD62P, differences within each group and differences 
between both groups over time occurred, that are shown in Figure V-10.  
A strong negative coherence between PL-EVs and CD62P is assumable, but only significant for 
samples exposed to stress at 4 hours after sampling.  
The amount of PL-EVs translates to the ability of platelets to undergo activation. During the 
course of time the negative correlation between the presence of more PL-EVs and lower 
externalization of p-selectin upon stimulation may reflect a low quality of PCs with stressed 
platelets. 
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Figure V-10: Differences in rebound phenomenon depending on shear stress 
In the line chart, the correlation coefficients (cc) between PL-EVs and CD62P of PC samples at 
various times after sampling are given, computed by Pearson’s correlation (two-way-tailed, with 
assumed significance of 0.05*). The grey line and grey dots are related to samples without 
shear stress, the blue line and blue dots represent samples of the same PCs with shear stress. 
All samples were collected manually by different type of sampling. Positive cc (data above the 
zero line) let assume that the more PL-EVs are measurable, the more CD62P, as a marker of 
activation of platelets, is expressed. Under sampling conditions without shear stress, PL-EVs 
are formed in a physiological way. For samples with shear stress negative cc (data below the 
zero line) was computed (4 – 144h). PL-EVs formed under shear stress correlate with loss of 
platelet function. 
 
For platelets without shear stress, a positive correlation between platelet activation (CD62P) 
and PL-EV level at the time of sampling (0h) and after 4 – 144 hours was found. The effects of 
exhaustion of platelets, that means maximal secretion of α-granules and expression of CD62P, 
was reached at 2 hours after sampling and disappeared and base line values of activation 
response was found after 4 to 144 h. 
Opposite results were analyzed in samples subjected to shear stress. At base line, the depletion 
of platelet granules, shown as a negative correlation between PL-EVs and CD62P expression, 
was followed by a short resting after 2 hours. PC sampling under shear stress condition 
revealed negative correlation between PL-EVs and CD62P after 4 to 144 hours, without 
reaching base line values.  
The increase of PL-EVs significantly correlate to lowered CD62P response on platelets (4h, 
cc=0.99*, p=0.024). Shear stress as a platelet activator affected PL-EV response by up to 9.8% 
(mean; SD: 1.3%) as compared to PL-EV level from platelets, not subjected to shear stress, 
which reached level of 5.1% (mean; SD: 0.6%). 
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5.1.6 Aggregometry 
To demonstrate the effect of PL-EVs on coagulation, platelet free plasma (PFP) and platelet-
derived exosomes were analyzed for platelet aggregation as AUC upon TRAP-6 activation 
using the Multiplate® platelet function analyser. The results show a significant aggregation 
difference between control (PL-EV free plasma) and PFP. Isolated exosomes (the smallest EV 
fraction) from PCs were added and a considerable elevation of aggregation of platelets could be 
detected, see Figure V-11. It is suggested, that spiked PL-EV stimulated platelet aggregation. 
Therefore, this batch method is not appropriate to analyze platelet aggregation in PCs 
resembling a mixture of platelets and procoagulant PL-EVs that cannot be discriminate. 
 
 
Figure V-11: Effects of PL-EVs on platelet aggregation  
Both figures show the results of platelet aggregation analysis of PC-samples by TRAP-6 test 
using Multiplate® platelet function analyzer. A: PC-samples were prepared as EV-free plasma 
as control (left) versus EV-containing platelet free plasma (PFP, right). B: Analysis was also 
performed with PBS as control (left) versus isolated PL-exosomes (PL-EXs, right). Aggregation 
results, shown as area under the curve (AUC in %) were influenced due to the fact, that PL-EVs 
and PL-EXs have coagulant properties. Altogether, 21 fresh PCs were used for this test. 
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5.2 Donor and apheresis specific values 
The intake of medication by donors before apheresis was excluded. All donors were healthy and 
no interrupts of donation were recorded. Table V-2 summarizes donor characteristics. Results of 
blood count (see Table V-3) and serum parameters (see Table V-4) from donors show no 
deviation from reference levels. All healthy volunteers classified to the study were normal 
weight, with normal blood pressure and with age ranging from 20 to 62 years. Due to the 
premenopausal fluctuation of blood count, i.e. alteration in hemoglobin and hematocrit values in 
women, mostly male donors were selected. No gender-related differences in the amount of PL-
EVs from PCs were found, not for PL-EVs measured by sd-FCM or by hs-FCM and not for 
determination of size/ concentration measured by NTA (Mann-Whitney-U test, p>0.05). 
It is important to mention, that in the group of healthy volunteers 17% of donors showed 
elevated Lp(a) level exceeding 30 mg/ dL (up to 78.3 mg/ dL), yet without any influence on the 
quality-defining parameters of PCs.  
Oral substitution of calcium (on average 633.3 mg, n=15) during apheresis may negatively 
affect the amount of PL-EVs on the day of apheresis before irradiation (cc= -0.5) and after 
irradiation (cc= -0.5). Citrate consumption during donation (on average of 419.8 ml, n=15) did 
not affect the level of substituted calcium (cc=0.4, n=15), but may affect the PL-EVs from freshly 
irradiated PCs (cc= -0.5, n=15) and irradiated PCs on day 5 (cc= -0.59, n=15). 
 
Table V-2: Characteristics of donors and of the apheresis process 
106 healthy donors with normal anamnesis volunteered for the study. Donor specific variables, 
conceived before plateletpheresis (b. p.) and after plateletpheresis (a. p.) are displayed. All 
data, accepted sex and apheresis system (*), are reported as the mean ± SD (range). 
Variable Value 
Sex* 27 females/ 79 males 
Age (years) 34 ± 10.6 (20 - 62) 
BMI 24.47 ± 2.7 (18.6 - 31.9) 
RR systolic, b. p. 126 ± 13.1 (97 - 160) 
RR diastolic, a. p. 78 ± 8.5 (61 - 107) 
RR systolic, b. p. 116 ± 10.9 (94 - 145) 
RR diastolic, a. p. 74 ± 6.9 (60 - 93) 
Pulse (per minute), b. p. 68 ± 10.8 (47 - 105) 
Pulse (per minute), a. p. 71 ± 10.0 (43 - 101) 
Duration of apheresis 59.3 ± 10.9 (40 - 95) 
Processed blood volume 3397.3 ± 545.0 (2263 - 4814) 
Apheresis system by Amicus (double-needle system)* 68 
Apheresis system  by Trima (single-needle system)* 38 
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Table V-3: Blood count parameter of platelet donors 
Automated hematological analysis of specimens from 106 healthy donors, obtained within 4 
hours after drawing blood samples by XE5000 (Sysmex). HGB: hemoglobin, HCT: hematocrit, 
RBC: red blood cells, RDW-SD: red cell distribution width as standard deviation from the mean 
red cell size, RDW-CV: red cell distribution width as a coefficient of variation from the mean red 
cell size. PLT: platelets, PDW: platelet distribution width, MPV: mean platelet volume, IPF: 
immature platelet factor. All values are reported as the mean ± SD (range). 
Variable Value Reference level 
HGB [g/ dL] 14.4 ± 0.9 (12.3 - 17.1) 11.2 - 15.7 
HCT [%] 42.2 ± 2.5 (36.9 - 48.2) 34.1 - 44.9 
RBC [10
6
/ µL] 4.8 ± 0.4 (3.9 - 5.8) 3.93 - 5.22 
RDW-SD [fL] 42.1 ± 2.6 (36.9 - 50.9) 36.4 - 46.3 
RDW-CV [%] 13.1 ± 0.7 (11.9 - 15.6) 11.7 - 14.4 
PLT [10
3
/ µL] 264.6 ± 38.4 (186 - 373) 182 - 369 
PDW [fL] 11.7 ± 1.5 (8.5 - 18) 9.8 - 16.2 
MPV [fL] 10.2 ± 0.7 (8.6 - 12.8) 9.4 - 12.5 
IPF [%] 2.6 ± 1.3 (0.6 - 9.6) 1.1 - 6.1 
IPF [nL] 6.8 ± 3.4 (1.4 - 19.3) - 
 
 
Table V-4: Serum characteristics of donors 
Analysis of serum blood samples of donors was carried out with automated laboratory analyzer 
by photometry, nephelometry, immunturbidometry, ELISA, CLIA, coagulometry, chromogenic 
method. Modified number of samples is displayed in the last slot (n). CHOL: total cholesterol, 
LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, TRIG: 
triacylglycerol, Lp(a): lipoprotein (a), VLDL-C: very low density lipoprotein cholesterol, Apo E: 
apolipoprotein E, ApoB100: apolipoprotein B100, ApoB48: apolipoprotein B48, Apo A-I: 
apolipoprotein A-I, Apo C-I: apolipoprotein C-I, Apo-J: apolipoprotein J (also known as 
clusterin), GLC: blood glucose, HBA1c: hemoglobin A1-c, IGF-1: insulin-like growth factor 1, 
IGFPB3: insulin-like growth factor binding protein 3, CRP: c-reactive protein, C3c: complement 
factor c3, ATIII: antithrombin 3, PAI-1: plasminogen activating inhibitor 1. All values are reported 
as the mean ± SD (range). 
Variable Value Reference level n 
CHOL [mg/ dL] 186.4 ± 33.4 (113-280) <200 81 
LDL-C [mg/ dL] 109.6 ± 29.6 (55-186) <100 81 
HDL-C [mg/ dL] 54.6 ± 13.4 (29-88) 40.0-60.0 81 
TRIG [mg/ dL] 133.0 ± 57.8 (47-346) <150 81 
Lp(a) [mg/ dL] 19.9 ± 18.5 (5.0-78.3) <30 80 
VLDL-C [mg/ dL] 21.2 ± 8.5 (9.0-52.0) 0.0-40.0 35 
Apo E [md/ dL] 3.4 ± 1.0 (1.83-8.44) 2.2-6.3 46 
Apo B100 [mg/ dL] 84.1 ± 20.4 (50.3-140.0) 55.0-125.0 35 
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continuation of Table V-4: Serum characteristics of donors  
Variable Value Reference level n 
Apo B48 [µg/ mL] 17.1 ± 14.6 (4.1 - 91.6) 3.53 - 7.29 35 
Apo A-I [mg/ dL] 156.9 ± 21.0 (124.0 - 212.0) 125.0 - 215.0 47 
Apo C-I [µg/ dL] 4.4 ± 0.9 (3.02 - 6.51) 4.0 - 7.0 35 
Apo J [µg/ mL] 53.8 ± 10.3 (37.3 - 78.5)  80.5 - 165.0 35 
GLC [mg/ dL] 78.3 ± 29.9 (12.0 - 165.0) 74.0 - 106.0 48 
HBA1c [NGSP] 5.2 ± 0.2 (4.8 - 5.7) 4.8 - 5.9 35 
HBA1c [IFCC] 33.6 ± 2.4 (29.0 - 39.5) 29.0 - 42.0 35 
IGF-1 [ng/ mL] 174.2 ± 47.7 (95 - 330) 93.5 - 251.9 35 
IGFBP3 [µg/ mL] 4.6 ± 0.7 (3.3 - 6.3) 3.4 - 6.7 35 
CRP [mg/ L] 2.9 ± 0.1 (2.9 - 3.8) - 62 
C3c [mg/ dL] 105.4 ± 17.2 (72.7 - 154.0) 90.0 - 180.0 47 
Fibrinogen [mg/ dL] 262.4 ± 35.9 (194.1 - 347.3) 210.0 - 400.0 35 
ATIII [%] 99.3 ± 9.0 (82.9 - 115.1) 75.0 - 125.0 35 
PAI-1 [U/ mL] 1.1 ± 1.1 (0.0 - 3.9) 2.0 - 7.0 35 
 
 
Table V-5 presents several relevant donor parameters, which were selected in order to compare 
them with the quality determining parameters of PCs. The age of donors did not significantly 
correlate to the expression of CD62P in fresh platelets. A positive correlation between BMI and 
CD62P is likely to occur both on day 0 and on day 5. A negative correlation of BMI to the 
amount of PL-EVs on day 5 was observed. This allows assumption, that the higher the BMI 
level, the lower PL-EV levels are detectable on day 5. Duration of apheresis expectedly affects 
the platelet count in PCs and further the expression of CD62P on platelets and the amount of 
PL-EVs on day 0. Two correlations were found to be the most essential: the first one relates to 
the application of single-needle against double-needle system in correlation to CD62P 
expression (Figure V-12). The second one relates to different apheresis instruments correlating 
to PL-EV levels (Figure V-13). It is worth notifying that the single-needle system requires less 
time in combination with higher flow rates and higher levels of citrate, which in turn lowers the 
pH, thus affecting the activation of platelets. This induced considerable differences in 
vesiculation of fresh platelets obtained with the use of different apheresis instruments. It was 
also observed that the higher levels of immature platelet fraction (IFP) of donors, obtained 
before apheresis, revealed lower PL-EV levels detected on day 0 and higher levels on day 5.  
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Table V-5: Relevant correlation of donor-specific, clinical or laboratory parameters to PC quality 
Parameter of 
donors (n=42) 
Quality parameter of plateletpheresis concentrates (n=42) 
Correlation coefficient (bold) and significance (Pearson, two-way analysis) 
day 0 day 5 
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single-needle/ 
double-needle 
system 
-0.575** 
0.000 
- - 0.412* 
0.024 
-0.327* 
0.035 
-0.412** 
0.007 
0.360* 
0.019 
- 
Age [years] 0.315* 
0.042 
- - - - - - - 
BMI 0.352* 
0.022 
- - - - 0.423** 
0.005 
- -0.316* 
0.041 
Apheresis 
instrument 
0.366* 
0.017 
- -0.456* 
0.011 
- - 0.326* 
0.035 
0.335* 
0.03 
-0.369* 
0.016 
Duration of 
apheresis 
0.230* 
0.039 
0.406** 
0.008 
0.417* 
0.022 
- - - - - 
IPF [/ nL] -  -0.429* 
0.018 
- - - 0.308* 
0.048 
0.422** 
0.005 
Cholesterol 
[mg/ dL] 
0.346* 
0.025 
- - - - - - - 
LDL cholesterol 
[mg/ dL] 
0.394** 
0.01 
- - - - - - - 
 
 
Cholesterol level, especially LDL-Cholesterol, showed a weak but positive correlation to 
activation sensitivity (CD62P) of platelets on day 0. Other donor- or apheresis-related 
parameters show no significant association with the quality determining parameters of PCs. 
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Figure V-12: Effect of single-needle versus double-needle apheresis system on CD62P 
Box plots represent CD62P expression on fresh platelets obtained by two different apheresis 
systems. The correlation of CD62P expression to apheresis systems is significantly negative for 
the benefit of the single-needle system (Pearson two-way analysis, p= -0.575**). 
 
 
   
Figure V-13: Effect of apheresis instruments on PL-EV levels in PCs 
Differences in the values of PL-EVs on day 0 before irradiation among the treatment groups 
(apheresis instruments) are greater than expected. There is a statistically significant difference 
between the results obtained with the help of the first instrument (A62266) and the results 
originating from the other instruments (p=0,026; Kruskal-Wallis one-way analysis of variance on 
ranks).The instruments were applied with the same frequency. 
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BMI and age of the donors (Table V-5) correlate significantly positive to evaluated serum lipids, 
such as triglycerides (TRIG) and HDL-cholesterol (HDL-C, for BMI only), cholesterol (CHOL) 
and LDL-cholesterol (LDL-C, both for age only) and complement protein C3c (for BMI only).  
Age of the donors correlated equally significant to apolipoprotein (Apo) B-100 and to the level of 
HbA1c (according to NGSP or IFCC).  
As shown in Table V-6, a considerable correlations were found between TRIG and Apo E levels, 
constituents of remnants of chylomicrons and VLDL; and between HDL-C and Apo A-I, 
components of HDL particles. CHOL and LDL-C negatively correlated to glucose levels before 
apheresis, reflecting differences of the fasting or postprandial state of donors early in the 
morning.  
Associations were found among red blood cells (RBC), hemoglobin (HGB) and hematocrit 
(HCT) on the one hand and among HDL-C, C3c (HGB and HCT only) and Apo A-I (RBC only) 
on the other hand. The RBC count and Apo A-I levels inversely correlated to higher 
concentration of RBC, which in turn corresponds to lower Apo A-I levels. In contrast, HDL-C 
levels positively correlated to RBC count. Positive correlation between RBC and HCT on one 
side and HDL-C on the other side was observed. However, HGB negatively correlated to HDL-
C. Complement proteins, in this case C3c, are known to bind to RBC under several conditions. 
According to results obtained in the current study, no positive correlation between C3c and RBC 
was found, but C3c correlated positively to HGB and HCT. 
Evaluated donor-related serum parameters (not shown in the table) did not match any quality 
control defining parameters for PCs.  
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Table V-6: Relevant donor specific parameters in correlation to one another 
Parameter of 
donors (n=42) 
Parameter of donors (n=42) 
Correlation coefficient (bold) and significance (Pearson, two-way analysis) 
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Triglycerides 
[mg/ dL] 
- - - - 0.332** 
0.002 
- - 0.745** 
0.009 
Cholesterol 
[mg/ dL] 
- - - -0.723** 
0.008 
- 0.486** 
0.001 
- - 
LDL-C 
[mg/ dL] 
- - - -0.816** 
0.001 
- 0.530** 
0.000 
- - 
HDL-C 
[mg/ dL] 
0.631** 
0.000 
-0.531** 
0.000 
0.584** 
0.000 
- 0.473** 
0-002 
 
- 
0.84** 
0.001 
- 
Apo A-I -0.624* 
0.03 
- - - - - - - 
ApoB100 - - - - - 0.520** 
0.001 
- - 
C3c - 0.755** 
0.005 
0.648* 
0.023 
- 0.408** 
0.004 
- - - 
HbA1c 
(NGSP) 
- - - - - 0.519** 
0.001 
- - 
HbA1c 
(IFCC) 
- - - - - 0.520** 
0.001 
- - 
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5.3 Platelet concentrate specific values 
5.3.1 Characteristics of PCs over time 
In this study, the platelet count, immature platelet factor (IPF), citrate concentration in PCs, pH 
values and typical expression markers on the surface of platelets were evaluated, as well as the 
measurement of platelet-derived extracellular vesicles (PL-EVs) and plasma vesicles. The 
values obtained on day 0 and day 5, together with the number of cases, are reported in Table 
V-7 and Table V-8. 
The effects of sampling, irradiation and storage on the parameters are presented in the 
following chapters. The coherence of PL-EVs and plasma vesicles to the expression of p-
selectin, used here as a main characteristic of platelet viability, are presented separately (5.3.6 
et seqq.). 
 
Table V-7: Characteristic laboratory analysis of PCs over time  
All values are reported as the mean ± SD (range). Reference levels pertain to the standard test 
and acceptance certificates in plateletpheresis manufacturing († only on day 0; ‡ only on day 5; 
PC: samples from the whole PC; Tube: samples from tubing system). 
Variable day 0 n day 5 n Reference 
level 
PLT  
[10
3
/ µL] 
1180.2 ± 324.6 (9 - 1639) 
1268.5 ± 142.5 (946 - 1639) PC 
1087.6 ± 424.7 (9 - 1533) Tube 
82 
42 
40 
1284.3 ± 180.2 (849 -1780)
 
66 800 - 1600‡ 
IPF [%] 1.8 ± 0.9 (0.4 - 3.8) 41 3.4 ± 1.6 (1.0 - 7.3) 25 - 
Citrate  
[mg/ L] 
3213.5 ± 412.9 (2554 - 4230) 30 - - - 
pH 7.2 ± 0.02 (7.14 - 7.27) 42 7.35 ± 0.08 (7.0 - 7.5) 42 6.4 - 7.8† 
CD61-
PerCP [%] 
 
141.7 ± 19.3 (98 - 182) 
146.5 ± 18.6 (98 - 177) PC 
138.0 ± 19.3 (104 - 182) Tube 
69 
30 
39 
142.1 ± 35.3 (25 - 221) 50 - 
CD41-    
PE [%] 
188.9 ± 40.6 (104 - 349) 
194.9 ± 42.3 (104 - 349) PC 
184.2 ± 39.1 (114 - 275) Tube 
68 
30 
38 
187.9 ± 97.3 (73 - 802) 50 - 
CD62P-
FITC [%] 
1094.7 ± 767.0 (121 - 4232) 
1328.3 ± 775.4 (288 - 4232) PC 
843.1 ± 681.6 (121 - 2737) Tube 
81 
42 
39 
547.3 ± 294.8 (103 -1613)
 
62 - 
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5.3.2 Platelet-derived extracellular vesicles and storage 
The values of PL-EV ratio obtained by sd-FCM and hs-FCM on day 0 and day 5 as well as non-
irradiated versus irradiated PCs are listed in Table V-8.  
The table summarizes PL-EV events per µL both for all PL-EVs and for individual 
subpopulations (small, medium, large), discriminated by hs-FCM, in addition to platelet count, 
plasma vesicle concentration and plasma vesicle size distribution by NTA.  
Plasma vesicles measured by NTA in fresh, non-irradiated PCs occurred in a concentration of 
5.9687 x10
8
/ mL (mean), whereas irradiated fresh PCs reached the concentration of 6.2753 
x10
8
/ mL (mean). In irradiated PCs after expiry, the plasma vesicle concentration was evaluated 
at 6.06 x10
8
/ mL as measured by NTA.  
The medium sized PL-EVs (180 nm to 300 nm) represented the major subfraction of all PL-EVs 
regardless of the duration of analysis constituting 57-58% of the population. 
Flow cytometric quantification with the Apogee A-50 Micro showed that PL-EVs occurred in 
fresh, non-irradiated PCs at a concentration of 1633.75/ µL (mean) and decreased after 
irradiation to a concentration of 1359.03/ µL (mean). PL-EV events per mL from irradiated PCs 
after expiry appeared at a mean concentration of 2754.3/ µL. 
The platelet count determined by Apogee A-50 Micro was sufficiently comparable to the platelet 
count measured by Sysmex automated hematology analyzer on day 0 (1241.9 x10
3
/ µL; 1180 
x10
3
/ µL) and on day 5 (1408.1 x10
3
/ µL; 1284.3 x10
3
/ µL). 
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Table V-8: PL-EV and plasma vesicle values in PCs analyzed by flow cytometry and NTA  
The semiquatitative PL-EV-ratio [%] was measured by the Navios™ system (°) with samples in 
a final dilution of 1:2500. The PL-EV-ratio [%] and, further, the quantitative PL-EV analysis were 
performed with A-50 Micro (†) and plasma vesicle analysis by NTA with NS-500 (*) with the 
same samples in a final dilution of 1:500 [non-irrad.: non-irradiated; irrad.: irradiated; PC: 
samples from the whole PC; Tubes: samples from the PC tubing system]. 
Variable  day 0 n day 5 n 
PL-EVs by FCM   
PL-EV ° non-irrad.  
[%
] 
6.1 ± 3.7 (2.4 - 17.4) PC 
6.69 ± 5.13 (2.4 - 29.4) PC 
8.8 ± 10.4 (2.78 - 61.7) Tubes 
15 
30 
40 
7.1 ± 3.1 (3.1 - 18.7) 
PC 
- 
- 
27 
- 
- 
PL-EV ° irrad.  6.8 ± 5.6 (3.3 - 26.7) PC 15 11.8 ± 5.8 (4.4 - 24.3) 
PC 
22 
PL-EV † non-irrad. 67.0 ± 65 (12 - 236) 15 - - 
PL-EV † irrad. 54.0 ± 61 (8 - 235) 15 97.0 ± 63 (19 - 213) 15 
Small PL-EV † non-irrad.  
[E
v
e
n
ts
/ 
µ
L
] 
 
55.08 ± 53.77 (10 - 212) 15 - - 
Small PL-EV † irrad. 29.11 ± 15.26 (12 - 63) 15 164.4 ± 222 (18.5 - 
886.0) 
15 
Medium PL-EV † non-irrad. 951.27 ± 1020.38 (113 - 3687) 15 - - 
Medium PL-EV † irrad. 794.53 ± 951.33 (61 - 3580) 15 1574.2 ± 1169.2 (160   
3459) 
15 
Large PL-EV † non-irrad. 627.4 ± 664.25 (162 - 2760) 15 - - 
Large PL-EV † irrad. 535.4 ± 618.13 (116 - 2557) 15 1015.7 ± 749.3 (33 - 
2944) 
15 
Platelet count † non-irrad. 2483.8 ± 345.4 (1568 - 2864) 15 - - 
Platelet count † irrad. 2658.33 ± 351.63 (1956 - 3281) 15 2816.2 ± 673.1 (1699 - 
3920) 
15 
All PL-EV † non-irrad. 1633.75 ± 1688.62 (324 - 6589) 15 - - 
All PL-EV † irrad. 1359.03 ± 1555.15 (233 - 6161) 15 2754.3 ± 1958.3 (508.5 
- 7246) 
- 
Plasma vesicles by NTA   
  
Concentration * non-irrad.  
[E
8
/ 
m
L
] 
 
5.9687 ± 2.99 (2.28 - 11.96) 15 - - 
Concentration * irrad.  6.2753 ± 3.27 (2.48 - 13.02) 15 6.06 ± 2.49 (2.75-
11.08) 
15 
Size distribution * non-irrad. 
[n
m
] 150.2667 ± 16.45 (124 - 175) 15 - - 
Size distribution * irrad.  150.4667 ± 19.39 (129 - 201) 15 157.53 ± 19.65 (129-
194) 
15 
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5.3.3 Comparability of sample types (PC samples and tube samples) 
Considering the fact that there may be alternative sampling methods for quality control analysis 
using residual samples from the tubes of the apheresis system on day 0, we tested whether 
samples from the tubing system are comparable with samples from the whole PCs. The 
equivalence for platelet count was rejected, because of the high variance of platelet count, 
especially for the lower platelet count in samples from the tubing system, see Figure V-14. 
 
 
 
Figure V-14: Box plots for platelet count values of two sample types of plateletpheresis quality 
control analysis  
PC samples (n=42) and tube samples (n=40) were compared; both groups were non-irradiated. 
Dark horizontal lines represent the mean within the boxes corresponding to the 25
th
 and 75
th
 
percentiles and the whiskers depict the 5
th
 and 95
th 
percentiles (outliers represented by circles). 
Statistical analysis was performed with Mann-Whitney-U-test, p=0.284. In addition, the two 
groups were statistically analyzed for assumed equality of platelet count with an equivalence-
test (TOST: two-one-sided-test, XLSTAT Excel) based on supposition that the groups are 
normally distributed. 90% confidence interval of the mean (α=0.05, confidence interval (1-2 x 
0,05) x100=90%) was used to explore the difference and to compare it to the defined TOST 
interval of upper bound and lower bound with 255 PLT/ nL, according to 20% of PLT/ nL value 
in standard samples (PC samples from the whole PC content). It is noticeable that at the total 
*p-value of 0.803 (p is not 0.005 for equality), the equivalence is rejected. 
 
 
 
 
 
Results  88 
 
  
In addition, the equivalence of both sampling methods has to be rejected since the expression 
of p-selectin (CD62P) on platelets (Figure V-15) is differentially distributed between PCs and 
tubes which show significant lower expression of p-selectin. 
 
 
 
Figure V-15: Box plots for CD62P expression on platelets from PCs of two sample types 
Samples of whole plateletpheresis concentrates (n=42) versus samples of PC-filled tubes 
(n=39), were compared for the analysis of immunolabeled platelets after stimulation with TRAP-
6. The values were calculated as percentage of mean fluorescent intensity (MFI) from samples 
without stimulation (PBS-Dulbecco), which represent 100%. Outliers are represented by circles. 
Statistical analysis was performed with Mann-Whitney-U-test, p=0.04 (*p<0.05). In addition, the 
two groups were statistically analyzed for assumed equality of CD62P expression with an 
equivalence-test (XLSTAT Excel) on supposition that the groups are normally distributed. 90% 
confidence interval of the mean (α=0.05, confidence interval (1-2*0,05)*100=90%) was used to 
explore the difference and compare it to the defined TOST interval of upper bound and lower 
bound with 260%, according to 20% of CD62P expression value in standard samples (PC 
samples from the whole PC content). It is obvious, that at the total **p-value of 0.881 (p is not 
0.005 for equality), the comparability is not sufficient. 
 
 
In QC analysis, the values referring to PL-EV amount from tubes of PCs were inconsistently 
distributed as compared to the values of PL-EVs of the whole PCs (see Figure V-16). 
The analysis of samples taken from the tubing system of PCs did not produce equivalent results 
for platelet count, p-selectin expression on platelets and the amount of PL-EVs as compared to 
the samples from the whole PC. Therefore, the use of tube samples for quality control is not 
recommended. 
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Figure V-16: Box plots of the interquartile range (IQR) for PL-EV raw data of different sample 
types 
PC samples (n=30, non-irradiated) and tube samples (n=40, non-irradiated) were compared. 
The boxes signify the upper and lower quartiles and dark horizontal lines within the boxes 
represent the mean (outliers represented by circles, extreme outliers by stars). PL-EV levels in 
PC samples varied from 2.4 to 26.7% and in tube samples from 2.8 to 61.7%. There are more 
extreme outliers of the tube samples than in PC samples, because of the inhomogeneity of the 
sample und platelet aggregates (for example, falsely determined ratio of PLT/ PL-EVs 
contributable to less platelet events measured by flow cytometry). Statistical analysis was 
performed with Mann-Whitney-U-test, p=0.148. In addition, the two groups were statistically 
analyzed for assumed equality of PL-EVs with an equivalence-test (XLSTAT Excel) on 
supposition that the groups are normally distributed. 90% confidence interval of the mean was 
used (α=0.05, confidence interval (1-2*0,05)*100=90%) to generate the difference and to 
compare it to the defined TOST interval of upper bound and lower bound with 1,28%, according 
to 20% of PL-EV mean values in standard samples (PC samples from the whole PC content). 
With a total *p-value of 0.659 (p is not 0.005 for equality), the equivalence is not sufficient. 
 
 
 
5.3.4 Effects of irradiation (Differences between non-irradiated versus irradiated PCs) 
Counts of platelets on day 0 significantly differ (p=0.035) between the two groups of non-
irradiated PCs and irradiated PCs, but platelet count elevates during the gamma irradiation 
process (Figure V-17). Elevation of platelet count after irradiation analyzed by hs-FCM confirms 
this assumption (Figure V-20). No significant difference was observed for platelet count on day 
5 between the two groups (p=1.06). 
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Figure V-17: Box plots illustrating the effect of irradiation on platelet count 
Platelet count of plateletpheresis concentrates (n=42; 27 non-irradiated, 15 irradiated) on day 0 
were analyzed with XE-1500 (Sysmex). Statistical analysis with Mann-Whitney-tests supposes a 
statistically significant difference between both groups, p=0.035**. No significant difference was 
found in platelet count values for both groups on day 5 (p=0.106). 
 
The PL-EV ratio measured by sd-FCM (Navios™) showed strong deviations between the two 
groups on day 5 (p=0.002), whereas no statistically significant PL-EV elevation measured by sd-
FCM on day 0 (p=0.56) was found. The PL-EV ratio visibly increased in irradiated PCs during 
storage; see Figure V-18. 
 
Figure V-18: Box plots illustrating the effect of irradiation on PL-EV levels measured by sd-FCM 
The dissimilar shedding of platelet-derived extracellular vesicles not exposed (grey box) or 
exposed to irradiation (red box) is shown using PL-EV values on day 5 (Navios™, Beckman 
Coulter). Platelet concentrates (n=42; 27 non-irradiated, 15 irradiated) were stored under 
standard blood banking conditions. Statistically significant differences within PL-EVs, measured 
by the Mann-Whitney test, p=0.002**, were solely found on day 5. 
 
Results  91 
 
  
These results were not confirmed by the analysis with hs-FCM (Apogee). Statistically significant 
differences of the PL-EV ratio on day 0 showed decreased PL-EV ratios after irradiation (Figure 
V-19 and Figure V-20) in contrast to the nonsignificant increase of the ratio after irradiation as 
determined by sd-FCM.  
The PL-EV ratio depends on the platelet count in FCM. This count was evaluated by numbers of 
events per µL for platelets, which increased after irradiation. However, the PL-EV/ PLT ratio 
may decrease false positively because of the inappropriate counting of large platelets by an 
instrument that is configured for small particles (hs-FCM). 
 
 
 
 
 
Figure V-19: Effect of irradiation on the PL-EV/ PLT ratio in fresh PCs measured by hs-FCM 
The analysis was performed by hs-FCM with A50-Micro flow cytometer (Apogee Flow Systems 
Ltd., UK) on 15 samples of the same PCs before and after irradiation with 25 Gy. Statistically 
significant differences can be assumed (Wilcoxon test, p=0.001). 
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Figure V-20: Effect of irradiation on PL-EV and PLT count in PCs measured by hs-FCM 
The analysis was performed with the same non-irradiated and subsequently irradiated PCs 
(n=15) on day 0 by flow cytometry with A50-Micro flow cytometer (Apogee Flow Systems Ltd., 
UK). Statistically significant differences can be assumed among the samples of the same PCs 
before and after irradiation (Wilcoxon test, two-tailed; PLT p=0.027*; PL-EV p=0.02*; small PL-
EVs p=0.031*; medium PL-EVs p=0.001***; large PL-EVs p=0.005**). 
 
In contrast, the values of all plasma vesicles, i.e. vesicle concentration and size distribution, 
evaluated by NTA did not differ between the two groups of PCs on day 0 as shown in Figure 
V-21 and Figure V-22. 
 
There are no statistically significant differences between the two groups with non-irradiated or 
irradiated PCs (n=42, in 15 cases irradiated) in the values of p-selectin expression on fresh 
platelets (day 0) found with Mann-Whitney-test: p=0.265 and Kruskal-Wallis-test, p=0.265. 
Further, p-selectin externalization did not exhibit any changes on day 5 (Mann-Whitney-test: 
p=0.59 and Kruskal-Wallis-test, p=0.590). 
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Figure V-21: Effect of irradiation on the vesicle concentration in PCs measured by NTA 
The analysis was performed on 15 samples of the same PCs before and after irradiation with 25 
Gy by NTA (NS500, NanoSight). No statistically significant difference can be assumed 
(Wilcoxon test, p=0.233). There are more extreme upper outliers after irradiation, figured as red 
circles above the red box plot. 
 
 
 
Figure V-22: Effect of irradiation on size distribution of vesicles in PCs measured by NTA 
The EV analysis of PC samples before and after irradiation (n=15) was performed on day 0 by 
NTA with NS500 (NanoSight). Statistically significant differences cannot be assumed (Wilcoxon, 
p=0.706). 
 
 
 
Results  94 
 
  
5.3.5 Alteration of PCs during storage 
The platelet count of 42 PCs during 5 days of storage under standard blood banking conditions 
showed no statistically significant differences (p=0.573; Figure V-23). Statistical analysis by 
Wilcoxon-test revealed comparable results for subgroups of non-irradiated PCs between day 0 
and 5 (p=0.517, n=27) and irradiated PCs over time (p=0.82, n=15; not figured as box plots).  
The expression of p-selectin on platelets upon stimulation differed between PCs on day 0 and 
PCs on day 5 (p=0.000, n=42) as shown in Figure V-24, likewise in subgroups of non-irradiated 
versus irradiated PCs. 
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Figure V-23: Box plots demonstrating changes of platelet count over time  
After analysis of PLT count (XE-1500, Sysmex) in 42 PCs on day 0 (27 non-irradiated, 15 
irradiated) and continued analysis of the same PC samples on day 5, the figure corresponding 
to the obtained results presents no statistically significant differences between platelet count on 
the day of apheresis and on the day after date of expiry (statistical analysis was performed with 
the Wilcoxon test, p=0.573). 
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Figure V-24: Box plots of different CD62P externalization on platelets of PCs over time (A) and 
after irradiation (B) 
A: P-selectin after stimulation with TRAP-6 (platelet function test with Canto™ II, BC) on day 0 
and on day 5 of the same plateletpheresis concentrates (PCs, n=42; 27 non-irradiated, 15 
irradiated) was evaluated. Statistical analysis was performed with the Wilcoxon test, p=0.000** 
and statistically significant differences are acceptable. B: Results of platelet function test on day 
0 and day 5 showed no statistically significant inter-group differences between non-irradiated 
and irradiated PCs on day 0 (1 and 2) or on day 5 (3 and 4). Therefore, the results of intra-group 
comparison showed differences within non-irradiated PCs (1 and 3, day 0 and day 5, p=0.000**) 
and irradiated PCs (2 and 4, day 0 and day 5, p=0.001**). 
 
 
The PL-EV ratio measured by sd-FCM significantly differ between the group of PCs on day 0 
[7.8 ± 8.4 (2.4 - 61.7)] and PCs on day 5 [8.6 ± 4.7 (3.1 - 24.3)] (p=0.000) as shown in Figure 
V-25. The PL-EVs increase during the storage of PCs did not depend on irradiation on day 0. 
Both subgroups, non-irradiated (p=0.009) and irradiated PCs (p=0.002), exhibited increased 
levels of PL-EVs in comparison to the unaltered platelet count over time (Figure V-26). 
When comparing PL-EVs from fresh PCs and PL-EVs from expired PCs, significant differences 
were observed. It is suggested that the higher PL-EV values on day 0 is accompanied by a 
higher PL-EV concentration on day 5. (cc=0.725; Figure V-27). The more PL-EVs were 
determined in fresh PCs, the more PL-EVs in PCs over time were measurable. 
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Figure V-25: Box plots of shedded PL-EVs in PCs over time measured by sd-FCM 
PCs (n=30, 15 non-irradiated) on day 0 and on day 5 were analyzed by standard flow cytometry 
(sd-FCM) with Navios™ (Beckman Coulter). Statistical analysis was performed with the 
Wilcoxon test, p=0.000**. 
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Figure V-26: Box plots of differences in PL-EVs depending on irradiation measured by sd-FCM 
First group included 15 non-irradiated PCs (1 and 3) over time; second group included 15 
irradiated PCs (2 and 4) on day 0 versus day 5. Analysis was performed by sd-FCM with the 
Navios™ (Beckman Coulter). Statistical analysis was performed with the Wilcoxon test and 
significant differences in both, the first group (p=0.009**) and the second group (p=0.002**) are 
acceptable. 
** 
** 
** 
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Figure V-27: Scatter plot of the correlation between PL-EVs of fresh versus expired PCs 
measured by sd-FCM 
15 non-irradiated and 15 irradiated PL-EVs, originating from the same PCs (n=30) were 
analyzed on day 0 and on day 5 and an important correlation between the PL-EV amount on 
day 0 and day 5 was noticed.  Statistical analysis was performed by Pearson’s correlation 
(cc=0.725**, p=0.000). 
 
 
The increase of the PL-EV ratio over time, determined by sd-FCM, was confirmed by the 
evaluation of PL-EV ratio by hs-FCM, in samples originating from 15 irradiated PCs (P=0.006), 
see Figure V-28.  
Plasma vesicle concentration did not change in the investigated irradiated PCs over time as 
measured by NTA (shown in Figure V-29). 
Immature platelet fraction, figured in Figure V-30, also grew over time during storage (p=0.000). 
The values of pH statistically significantly rose between day 0 [7.2 ± 0.02 (7.14-7.27)] and day 
5 [7.35 ± 0.08 (7.0-7.5)] in both non-irradiated (p=0.000) and irradiated groups (p=0.003), 
shown in Figure V-31. 
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Figure V-28: Box plots of PL-EV ratio of irradiated PCs over time measured by hs-FCM 
PL-EVs were analyzed with the Apogee A-50 Micro as CD61-PerCP positive immunolabeled 
events on day 0 and day 5 in samples of irradiated plateletpheresis concentrates (n=15). 
Statistically significant difference on day 0 versus day 5 was acceptable (p=0.006** with 
Wilcoxon-test). 
      
1 2
V
e
s
ic
le
 c
o
n
c
e
n
tr
a
ti
o
n
 [
E
8
/m
L
],
 N
T
A
0
2
4
6
8
10
12
14
1: irradiated, day 0
2: irradiated, day 5
 
Figure V-29: Box plots of plasma vesicles concentration of irradiated PCs over time measured 
by NTA 
PCs on day 0 and day 5 were analyzed by NTA with NS500 (NanoSight, UK). The irradiated 
PCs were stored during these days under standard blood banking conditions. No statistically 
significant difference was observed (Wilcoxon-test, p=0.570). 
** 
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Figure V-30: Box plots of IPF of fresh and stored PCs measured by automated hematology 
analyzer  
Immature platelet fraction (IPF) was measured with XE-1500 (Sysmex) on day 0 (n=41) and day 
5 (n=30) of PCs (15 irradiated PCs were included). Statistical analysis was performed with the 
Wilcoxon test, p=0.000**. 
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Figure V-31: Box plots of pH values of PCs over time and the effects of irradiation 
PCs were analyzed on day 0 and day 5 (n=42; 27 PC were non-irradiated, 15 PC were 
irradiated) with ABL 90 FLEX (Willich). Statistical analysis was performed with Wilcoxon-test 
and significant differences within the two groups (non-irradiated, p=0.000**; irradiated, 
p=0.003**) after five-day storage under standard conditions are acceptable. The pH values play 
a crucial role in the quality specifications referring to PCs on day 0 and on day 5. 
** 
** 
** 
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5.3.6 Linear regression analysis of platelet CD62P expression and PL-EV levels (sd-
FCM) 
PL-EVs from fresh, non-irradiated PCs significantly negative correlated to the expression of 
CD62P on platelets (cc= -0.43*, p=0.018, Figure V-32). The negative correlation between PL-
EVs from fresh irradiated PCs and CD62P was not statistically significant (cc= -0.43, p=0.11). 
 Vice versa, no significant correlation between PL-EVs and CD62P in non-irradiated PCs after 
expiry was found (cc= -0.122, p=0.545), in contrast to irradiated PCs after expiry (cc= -0.686**, 
p=0.005).  
To explore the dependency of PL-EVs to CD62P, linear regression was used to determine the 
potential decrease of CD62P caused by vesiculation of fresh platelets. In non-irradiated fresh 
PCs, one percent of increased PL-EV ratio importantly affected the loss of CD62P expression 
up to 51.544 percent, p=0.018 (with a variability of 18.5 percentage due to the PL-EV ratio from 
PCs). A negative effect of vesiculation on the p-selectin (CD62P) expression in fresh, non-
irradiated platelets from PCs was suggested.  
In irradiated PCs, one percent of the increased PL-EV/ PLT ratio affected the loss of CD62P 
expression by approximately 47.7%, p=0.11 (with a variability of 18.5% due to the PL-EV ratio 
from PCs), but not statistically significant. There was no evidence given for a negative effect of 
platelet vesiculation on the p-selectin expression in fresh, irradiated platelets in PCs. 
By contrast, in expired PCs, the CD62P expression was inversely correlated to PL-EVs in non-
irradiated and irradiated PCs. In non-irradiated PCs on day 5, the effect of one percent increase 
of the PL-EV ratio lowered the CD62P expression by approximately10.4%, p=0.545 (with a 
variability of 12.2%). However, in irradiated PCs on day 5 for the CD62P expression significant 
dependency was found with lower levels about -16.9%, p=0.005 by one percent of a higher PL-
EV ratio (variability of this effects due to the PL-EVs was found at 47%). Thereby, the 
significantly negative effect of platelet vesiculation on platelet p-selectin (CD62P) expression 
from PCs after expiry was found only in irradiated PCs (shown in Figure V-32). 
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Figure V-32: Scatter plot distribution of PL-EVs in correlation/ linear regression to CD62P 
externalization 
All PC samples were analyzed in order to assess the externalization of p-selectin (CD62P-FITC 
in [%] of PBS-incubated platelets (as control) after stimulation with TRAP-6 in vitro. In all 
samples a negative correlation of PL-EV to CD62 expression was found. As figured in scatter 
plot A-D, a coherence of PL-EV was found with one more unit of PL-EV [%], that decreased the 
CD62P externalization of platelets (outlined as coefficient of regression, B in %). R
2
, as figured 
above, is the value of variability of CD62P due to the presence of PL-EVs in the concentrate. P-
values were estimated using a linear ANOVA model and additionally linear regression was used 
for CD62P as a dependent variable and PL-EVs as independent variable (T). To correlate both 
parameters, coefficient of correlation (cc, according to Pearson’s correlation) was estimated and 
significance (p) of coherence was determined. A: For non-irradiated PCs (n=30) on day 0 with 
observed data (as follows: B= -51.544, R
2
=18.5%, p=0.018*, T= -2.521, cc= -0.43*, p=0.018) a 
significant coherence was assumable. B: In samples drawn from non-irradiated PCs on day 5 
(B= -10.4, R
2
=1.5%, p=0.545, T= -0.613), coefficient of correlation was estimated with cc= -
0.122, p=0.545 and no significant correlation was found. C: Irradiated fresh PCs (n=15) on day 
0 (B= -47.7, R
2
=18.5 %, p=0.11, T= -1.716) showed no significant relation (cc= -0.43, p=0.055) 
between PL-EVs and CD62P. D: In samples drawn from irradiated PCs (n=15) on day 5 (B= -
16.89, R
2
=47%, p=0.005**, T= -3.397) a significant correlation was observed (cc= -0.686**, 
p=0.005). 
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5.3.7 Correlation between standard PL-EV analysis (sd-FCM) and the new systems (hs-
FCM and NTA) 
The aim of the work was to compare a standardized EV analysis to two new methods, i.e. hs-
FCM (Figure V-34, A) and NTA (Figure V-35 A, B, C).  
At first, the methods of PL-EVs analysis, sd-FCM and hs-FCM, applied to fresh non-irradiated 
PCs were compared to each other (cc=0.72**, p=0.002, n=15), and the results are displayed in 
Figure V-33 and Table V-9. Additionally, a positive correlation between sd-FCM and hs-FCM 
measurements on day 0 with irradiated PCs (n=15), estimated by Pearson, two-way-tail 
(cc=0.80**, p=0.000) was shown.  
PL-EVs from irradiated PCs after expiry revealed no statistically significant correlation between 
both sd-FCM and hs-FCM (cc=0.491, p=0.063, n=15). Over time, positive correlations were 
found between PL-EVs of irradiated PCs measured by sd-FCM and the PL-EV concentration for 
all PL-EVs and, particularly for medium-sized PL-EVs (180-300 nm) and for the large-sized PL-
EVs (300-500 nm). No significant correlation between the amount of smallest PL-EV (<180 nm, 
measured by hs-FCM) and the amount of large PL-EV (>500 nm, measured by sd-FCM) 
populations were found. Both groups of PL-EVs, the medium and the large, from fresh non-
irradiated PCs, showed a significant positive correlation. 
 
 
Figure V-33: Comparison of sd-FCM and hs-FCM PL-EV analysis on day 0 
Pearson’s correlation indicated a positive correlation between sd-FCM (y-axis) and hs-FCM (x-
axis) for both non-irradiated PCs on day 0 (cc=0.72**, p=0.002, n=15) and irradiated PCs on 
day 0 (cc=0.8**, p=0.000, n=15) with statistical significance. 
 
Results  103 
 
  
Secondly, the concentration of plasma vesicles, measured by NTA, from fresh non-irradiated 
PCs (cc=0.014, p=0.962, n=15 with Pearson analysis) and fresh irradiated PCs (cc= -0.068, 
p=0.811, n=15 with Pearson analysis) were correlated to PL-EVs analyzed by sd-FCM (not 
figured). No statistically significant correlation was found. After expiry (data not shown), PL-EVs 
from irradiated PCs evaluated by sd-FCM did not significantly correlate to the concentration of 
plasma vesicles evaluated by NTA (cc=0.228, p=0.415, n=15 by Pearson’s correlation). 
 
 
Figure V-34: PL-EV analysis by hs-FCM (A) and sd-FCM (B) 
A: PL-EVs representative for fresh, non-irradiated PCs were determined by high sensitive flow 
cytometry (hs-FCM) [CD61-positive events/ µL=1037, PL-EV ratio=47%]. B: Analysis 
representative for fresh, non-irradiated PCs was carried out by standard flow cytometry (sd-
FCM) [CD61-positive events/ 500 µL diluted sample=1050, PL-EV ratio=4.8%]. 
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Figure V-35: Evaluation of plasma vesicles from PCs by NTA 
A: Black Graph represents concentration (x10
8
/ mL) of plasma vesicles representative for fresh, 
non-irradiated PC in correlation to vesicle size (nm). B: Size of vesicles versus intensity of 
scattered light is shown and green boxes represent every single vesicle measured. C: Freeze 
image of a video representative for tracked vesicles (white dots) is shown. 
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Table V-9: PL-EV analysis by sd-FCM versus hs-FCM or NTA 
   
PL-EV [%] (sd-FCM) 
day 0  
non-irradiated 
day 0  
irradiated 
day 5  
irradiated 
h
s
-F
C
M
 
Small 
PL-EVs 
[Events/ µL] 
day 0, non-irradiated 0.493   
day 0, irradiated  -0.025  
day 5, irradiated   0.474 
Medium 
PL-EVs 
[Events/ µL] 
day 0, non-irradiated 0.753
**
   
day 0, irradiated  0.801**  
day 5, irradiated   0.479 
Large 
PL-EVs 
[Events/ µL] 
day 0, non-irradiated 0.897
**
   
day 0, irradiated  0.902**  
day 5, irradiated   0.864** 
PLT count 
[Events/ µL] 
day 0, non-irradiated 0.243   
day 0, irradiated  0.025  
day 5, irradiated   0.467 
All 
PL-EVs 
[Events/ µL] 
day 0, non-irradiated 0.824
**
   
day 0, irradiated  0.848**  
day 5, irradiated   0.671** 
PL-EV Ratio 
[%] 
day 0, non-irradiated 0.72**   
day 0, irradiated  0.8**  
day 5, irradiated   0.491 
N
T
A
 
Plasma EV 
concentration 
[x10
8
/ mL] 
day 0, non-irradiated 0.014   
day 0, irradiated  -0.068  
day 5, irradiated   0.109 
Size 
distribution 
[nm] 
day 0, non-irradiated -0.139   
day 0, irradiated  0.034  
day 5, irradiated   0.228 
Correlation is assumed as significant at p≤0.01** and p≤0.05*  wi th two-tailed Pearson 
analysis .  (hs-FCM denotes high sensitivity f low cytometry; sd -FCM denotes standard flow 
cytometry). 
 
 
 
5.3.8 Correlation between platelets CD62P and PL-EV analyses by hs-FCM and NTA 
Although a significant correlation between hs-FM and sd-FM analyses of PL-EVs has been 
found, it was also investigated whether there is a relation between PL-EV ratio determined by 
hs-FM and platelet p-selectin expression upon TRAP-6 stimulation.  A significant negative 
correlation was found among all measured samples from non-irradiated and irradiated PCs on 
day 0 and from irradiated PCs on day 5 (cc= -0.736** (p=0.002); cc= -0,646** (p=0,005);        
cc= -0.660** (p=0.007) respectively). A strong negative correlation is shown in Figure V-36 and 
data are presented in Table V-10. 
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Figure V-36: Correlation between CD62P expression and the PL-EV-ratio by hs-FCM 
Non-irradiated PCs and irradiated PCs on day 0 and day 5 were analyzed (n=15). A strong 
negative relation between the PL-EV ratio (x-axis) and activatability of platelets (y-axis) was 
found (determined with the correlation coefficient, two-way-tailed). Values of CD61-positive PL-
EV events were correlated to CD61-positive platelets events and graphically presented as dots. 
Subsequently, the ratio of PL-EVs to platelets was calculated. Values of CD62P expression are 
shown as the mean in percent to basal CD62P expression. Correlation was assumed as 
significant at p≤0.01** and p≤0.05*. 
 
 
 
A statistically significant correlation between the plasma vesicle concentration measured by 
NTA and platelet CD62P expressed after TRAP-6 stimulation was not detectable. Neither in 15 
fresh non-irradiated (cc=0.264, p=0.343)/ irradiated PCs (cc=0.351, p=0.2), or 15 irradiated 
expired PCs (cc=0.118, p=0.676) any statistically significant correlation between vesicles and 
CD62P expression has been found (not figured, analyzed by Pearson´s test of correlation 
coefficient, one-way-tailed). Similar results showing no important correlation between CD62P 
after TRAP-6 stimulation and the size of plasma vesicles, measured by NTA, were obtained 
(data reported in Table V-10). 
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Table V-10: Correlation between platelet CD62P expression after TRAP-6 determined by hs-
FCM and by NTA 
Correlation is assumed as significant at p≤0.01** and p≤0.05* (two-tailed by Pearson’ 
correlation). 
   
CD62P after TRAP-6 
day 0  
non-irradiated 
day 0  
irradiated 
day 5  
irradiated 
h
s
-F
C
M
 
Small 
PL-EVs 
[Events/ µL] 
day 0, non-irradiated -0.336   
day 0, irradiated  -0.229  
day 5, irradiated   -0.297 
Medium 
PL-EVs 
[Events/ µL] 
day 0, non-irradiated -0.765**   
day 0, irradiated  -0.722**  
day 5, irradiated   -0.617* 
Large 
PL-EVs 
[Events/ µL] 
day 0, non-irradiated -0.649**   
day 0, irradiated  -0.610*  
day 5, irradiated   -0.625* 
PLT count 
[Events/ µL] 
day 0, non-irradiated 0.215   
day 0, irradiated  0.399  
day 5, irradiated   -0.180 
All 
PL-EVs 
[Events/ µL] 
day 0, non-irradiated -0.728**   
day 0, irradiated  -0.687**  
day 5, irradiated   -0.641** 
PL-EV Ratio 
[%] 
day 0, non-irradiated -0.736**   
day 0, irradiated  -0.689**  
day 5, irradiated   -0.660** 
N
T
A
 
Plasma EV 
concentration 
[x10
8
/ mL] 
day 0, non-irradiated 0.264   
day 0, irradiated  0.351  
day 5, irradiated   0.118 
Size 
distribution 
[nm] 
day 0, non-irradiated 0.066   
day 0, irradiated  0.092  
day 5, irradiated   -0.272 
 
 
The method of NTA turned out to be unhelpful in answering the main question whether hs-FCM 
or NTA are useful as a quality control approach. However, with hs-FCM it was possible to show 
additional significant correlation between the CD62P expression after TRAP-6 stimulation and 
single subpopulations of PL-EVs and between the CD62P expression and all PL-EVs . Not only 
was the PL-EV ratio visibly negative in correlation to the responsiveness of platelets, but the 
concentration of PL-EVs was recorded as CD61-positive events per µL. 
 
The population of all PL-EVs included PL-EVs smaller than 180 nm, medium-sized PL-EV with a 
size range of 180 - 300 nm and large PL-EVs with diameters ranging from 300 to 500 nm. The 
smallest PL-EVs as a minor part of the whole fraction negatively correlated to platelet CD62P 
expression, but did not reach the level of significance. In contrast, the medium and large PL-
EVs showed significance for negative correlation to platelet CD62P expression after TRAP-6 
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and to the PL-EV ratio analyzed by hs-FCM. Correlation between values of PL-EVs, especially 
of the medium-sized PL-EVs, and the expression of CD62P was more significant than the 
correlation between semiquantitative analysis of PL-EVs and CD62P analysis (for both non-
irradiated and irradiated PCs). 
To visualize this correlation, three dot plots were created for 15 PCs, analyzed on day 0 (shown 
in Figure V-37, then investigated upon irradiation (Figure V-38) and finally after five-day storage 
(Figure V-39). 
 
 
 
Figure V-37: Correlation between CD62P (after stimulation with TRAP-6) and PL-EV 
subpopulations in fresh non-irradiated PCs measured by hs-FCM 
Non-irradiated PCs on day 0 (n=15) were analyzed. A strong negative relation between PL-EVs 
(x-axis) and activatability of platelets (y-axis) was found, determined with the correlation 
coefficient (two-way-tailed). Levels of the CD61-positive PL-EVs are pictured as the mean 
[Events/ µL], values of CD62P expression are shown as the mean in percent to basal CD62P 
expression. Correlation was assumed as significant at p≤0.01** and p≤0.05*. 
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Figure V-38: Correlation between CD62P (after TRAP-6 stimulation) and PL-EV subpopulations 
in fresh irradiated PCs measured by hs-FCM 
Irradiated PCs on day 0 (n=15) were analyzed. A strong negative relation between PL-EVs (x-
axis) and activatability of platelets (y-axis) was found, analyzed with the correlation coefficient 
(two-way-tailed). Levels of the CD61-positive PL-EVs are pictured as the mean [Events/ µL], 
values of CD62P expression are shown as the mean in percent to basal CD62P expression. 
Correlation was assumed as significant at p≤0.01** and p≤0.05*. 
 
 
 
Figure V-39: Correlation between CD62P (after stimulation with TRAP-6) and PL-EV 
subpopulations in senescent irradiated PCs measured by hs-FCM  
Irradiated PCs on day 5 (n=15) were analyzed. A strong negative relation between PL-EVs (x-
axis) and activatability of platelets (y-axis) was found, analyzed with the correlation coefficient 
(two-way-tailed). Levels of the CD61-positive PL-EVs are pictured as the mean [Events/ µL], the 
values of CD62P expression are shown as the mean in percent to basal CD62P expression. 
Correlation was assumed as significant at p≤0.01** and p≤0.05*. 
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In contrast to the sd-FCM analysis, the hs-FCM measured quantitative PL-EV levels. The 
correlation between platelet CD62P expression and absolute PL-EV values analyzed by hs-
FCM was more significant, suggesting that there is a relevant relation of vesiculation and 
platelet function in PCs at any time. A negative correlation between CD62P expression and PL-
EVs in samples of fresh non-irradiated PCs, fresh irradiated PCs as well as of irradiated PCs 
after expiry was observed. To use PL-EVs as a parameter in a quality control of PCs, the new 
system, i.e. hs-FCM method, is favored over sd-FCM in PL-EV analysis. With hs-FCM, PL-EVs 
analysis provides a plausibility check which enables estimating platelet functionality. 
 
5.4 Extracellular vesicle composition in plateletpheresis concentrates and red blood 
cell units 
Due to shear stress during plateletpheresis, artificial extracellular vesicle released from other 
blood cells such as red blood cells (RBCs) or leukocytes might appear and vesicles may be 
stored in PCs. Therefore, we tested, whether PCs contain cell-derived EVs originating from red 
blood cells (RBC-EVs) or leukocytes (L-EVs).The analysis was performed under the same 
conditions as described for PL-EVs. In PCs, independent of the time of analysis (day 0, day2 
and day 5), the ratio of RBC-EVs in PCs as measured by sd-FCM was less than 2% and L-EVs 
were not measurable, shown in Figure V-40. PL-EV analysis by hs-FCM showed similar results, 
that means, no relevant ratios of RBC-EVs were found (data not shown). The composition of 
cell-derived vesicles was constituted mostly of CD61-positive PL-EVs (98-99%) of all measured 
events. In flow cytometric analysis, vesicles were labeled with moABs against CD45 as a pan-
leukocyte marker, CD61 as a platelet marker as well as against CD235 as a marker for RBCs. 
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Figure V-40: Composition of cell-derived vesicles in PCs 
Vesicles of a size of approx. 300 - 500 nm were labeled with monospecific fluorescent 
antibodies against erythrocytes (red), platelets (yellow) and leukocytes (green, no events 
measurable) and analyzed by sd-FCM (Navios™). The main fraction of vesicles in PCs 
originated from platelets, whereas vesicles from leukocytes were not measurable (A-F). 
Vesicles from erythrocytes represented a ratio less than 2% on day 0 (B), on day 2 (C) and on 
day 5 (D). For samples in different dilutions, one of 1:100 (E) and of 1:500 (F) no significant 
changes in composition were found. 
 
 
According to the method of preparation of platelet-derived exosomes (PL-EXs) from PCs, RBC-
derived EVs were prepared by ultra-centrifugation from RBC units. Different pellets were 
obtained and analyzed. The pellet after four centrifugation steps with 120.000 g was named P4 
(see Figure V-41, B). The cell-derived vesicles (P4) of RBC units did not originate from the main 
cell component - the RBCs. In contrast, undiluted samples of RBC units comprise of RBC-EVs 
amounting to 80% of all cell-derived vesicles (see Figure V-41, A). Values of RBC-EVs, PL-EVs 
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and L-EVs from the EV-pellets (P4), which included exosomes more concentrated than the 
supernatant of RBC units, let assume, that, especially in the third fraction after density gradient 
centrifugation (Figure V-41, C-E), only PL-EVs were obtained. 
 
 
Figure V-41: Pie chart of the cell-derived EV percentage in red blood cell units 
EV analysis of RBC units (n=3) was performed by sd-FCM with Navios™. The main fraction of 
undiluted concentrates (A) of vesicles originated from erythrocytes, whereas the vesicle pellet 
(P4, B) in a tenth part of one unit included predominantly platelet-derived vesicles. These results 
were confirmed by EV-analysis from single fractions of this pellet, i.e. the fraction I (C), fraction 
II (D) and fraction III (E) collected after density gradient centrifugation. Vesicles from leukocytes 
were not found. 
 
 
In earlier centrifugation steps during preparation of pellet 4 (P4), as described in Table IV-2, 
three pellets were obtained after wash steps (90 min, 120.000 g) and they were quantitatively 
analyzed by hs-FCM.  
Exemplarily, the PL-EV event count per µL was measured in one quarter of pellet 3 comprising 
of vesicles of a size ranging from 30 to 500 nm (Figure V-42). Interestingly, in this vesicle pellet 
of RBC units, PL-EV concentration was found at the level of 2056*/ µL. However, the RBC-EV 
concentration from the same pellet was determined at the level of 967*/ µL (* shown in Figure 
V-42). With the help of the semiquantitative EV analysis performed by sd-FCM, it was possible 
to demonstrated that in 500 µL of pellet 3 there were 13538 CD61-positive events (PL-EVs) and 
20070 CD235a-positive events (RBC-EVs) (data not shown). 
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Figure V-42: Platelet-derived EVs and erythrocyte-derived EVs from red blood cell units 
EV analysis of red blood cell units (n=2) was performed by hs-FCM with A50-Micro Flow 
Cytometer (Apogee Flow Systems Ltd., UK). For each single preparation step (1, 5 - 9, see 
Table IV-2) and pellets 1 - 3 (P1 - P3), vesicle quantification was reported for small (≤180 nm), 
medium (180 – 300 nm) and large (≥300 nm) vesicles. Values are reported as mean and written 
in italic for CD235a-positive labeled vesicles or normal written for CD61-positive labeled 
vesicles. Marked values (*), exemplarily, represent unequal distribution between PL-EVs and 
RBC-EVs in a pellet of a RBC unit. 
 
 
A size diagram of all cell-derived and plasma containing vesicles stemming from RBC units and 
a diagram of vesicle concentration are depicted in a form of line charts representing one single 
pellet fraction (see Figure V-43).  
Particle size in the first pellet (Pellet 1, Figure V-43) was determined with median particle size of 
228 nm, to the second pellet (Pellet 2, Figure V-43) with median particle size of 232 nm and to 
the last pellet (Pellet 3, Figure V-43), including the exosome fraction, with particle size of 143 
nm. Pellet 1 and 2 contained larger vesicles at a lower concentration, whereas pellet 3 
contained higher concentrated, but smaller vesicles. 
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Figure V-43: Plasma and cell-derived vesicles from red blood cell units measured by NTA 
After isolation of EVs and EXs from RBC units (n=3), vesicle concentration at a final dilution of 
1:500 (first diagram) and vesicle particle size (second diagram) were measured with NS500 
(NanoSight, UK). Values are reported as mean. Black bars represent the medium (mean size of 
228 nm) and large vesicles (mean size of 232 nm) at a lower concentration (8.4 - 9.0 x 10
8
/ µL). 
The pellet 3 included smaller vesicles (size ranging from 65 to 192nm, mean size of 143 nm) at 
a higher concentration of 16.0 x 10
8
/ µL, shown as grey bars. Freeze image of a video 
representative for tracked vesicles (white dots) is shown on the right. 
 
 
In this study, the vesicle composition of PCs and RBC units was investigated by sd-FCM, hs-
FCM and NTA. The results obtained from both flow cytometers, i.e. hs-FCM and sd-FCM, 
showed that PL-EVs constituted the main vesicle part of PCs, whereas RBC-EV concentration 
did not exceed the level of 2% during 5 days of the analysis. The L-EV amount measured in 
PCs turned out to be negligible.  
Interestingly, with the help of flow cytometry, it was found that PL-EVs acted as a main vesicle 
part of RBC units. After preparation of RBC units, the vesicle quantification applied to vesicles 
from several pellets confirmed this thesis. Analysis by NTA allowed estimation of the size of 
prepared vesicles, but no immunolabeling was performed in order to determine the cell 
specificity. It remained unclear, whether PL-EVs were found in RBC units as a major 
subpopulation among all vesicles because of their resistant membranes, or due to the fact, that 
platelet vesiculation was more pronounced in comparison to vesiculation of RBCs during 
manufacturing of RBC units. 
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VI Discussion 
Red blood cell units, fresh frozen plasma and platelet concentrates are the most commonly 
administered blood concentrates. This study focused on platelet concentrates, obtained from 
apheresis donation, in order to improve their in vitro quality measurements. 
Application of plateletpheresis concentrates (PCs) is an essential and life-saving treatment of 
patients undergoing a surgery, suffering from bleeding disorders or bone marrow failure 
syndromes. Platelets play a fundamental role in preventing vascular disintegration. In Germany, 
a consistent annual increment of PC preparation was investigated (263). More than 580,000 
whole blood and apheresis platelet products were manufactured in the year 2012 (264). 
Compared with other blood concentrates, PCs have a relatively short half life and their durability 
was restricted to 5 days, including the day of apheresis. This fact results in the alterations of 
platelet function in vitro, namely, leads to the so-called platelet storage lesion (PSL) (17), which 
is characterized by reduced platelet recovery and survival in vivo (265). According to the best 
suitable description, PSL is a sum of all changes in platelet activity, its morphology, metabolic 
activity, signaling and functional features such as adhesion and coagulation in vitro. Weakened 
recovery and survival of platelets is frequently accompanied by bacterial contamination, which 
has an additional impact on the storage of platelets (266). Therefore, because of these 
obstacles, the production and consumption of PC products have to be balanced in order to 
guarantee a proper treatment of all patients.   
In relation to the whole amount of manufactured PCs all over Germany, more than 490,000 
concentrates were used in the treatment of thrombocytopenic recipients (264), therefrom 5588 
at the University Hospital Regensburg. In order to prevent the application of low quality, non-
sterile PCs or those of a non-fairly consistent dose, the preparation and storage of PCs 
underlay rigorous guidelines for approval and delivery according to the standard test and 
acceptance certificates in plateletpheresis manufacturing. Standard test are embedded in strict 
quality control (QC) programs with commonly accepted standards worldwide, allowing, however, 
minor deviations from manufacturer to manufacturer.  
In order to improve the quality-defining analysis of QC in the view of current requirements 
referring to the influence of extracellular vesicles (EVs) on health and disease, this study 
implemented the investigation on platelet-derived extracellular vesicles (PL-EVs) from PCs as a 
quality control approach. Relevant fragments of results obtained in this study deal with 
emerging donor-related, preparation-related and storage-related differences within PL-EVs from 
PCs.  
Vast knowledge on coagulatory and anticoagulatory functions of PL-EVs (9, 47, 140) could be 
beneficial in evaluation of not only the physiological distribution of vesicles in blood circulation, 
but also of their distribution after application of PCs. However, until today, this aspect has 
attracted only a little attention (5, 15, 228). It must be considered, that a certain amount of PL-
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EVs underlies changes within PSL and it is not obvious, whether and how the viability and 
activatability of platelets in stored PCs in vitro are affected by the vesiculation of platelets. It has 
also to be established how the coagulatory and anticoagulatory forces of PL-EVs in vivo after 
application of PCs are manifested. The assumed effects of PL-EVs on the changes in platelets 
during storage are transferable to other cell-derived vesicles within PCs (i.e. vesicles derived 
from red blood cells) and to other blood components and their storage lesions, for example red 
blood cell units. This aspect was considered as the last part of this study. 
The most critical question in evaluating PL-EVs originating from PCs relates to the 
methodological issues dealing with detection of small particles by standard or new technologies. 
In order to facilitate the answer, the conventional flow cytometry (FCM) was validated as a gold 
standard. When detecting PL-EVs derived from fresh and altered PCs, the method, defined as a 
standard method (sd-FCM) by Navios™ (Beckman Coulter), proved to be reliable, stable and 
precise. In comparison to the scientifically present state of the art, the analysis of cell-derived 
EVs from several body fluids by sd-FCM has proved to be a qualified and satisfactory method 
(245). Further, sd-FCM analysis of PL-EVs originating from PCs was described as an 
assumably reliable method (15).  
This knowledge provides the basis for consideration of the aspects of PL-EV analysis, the 
measurement of absolute vesicle concentration and the determination of vesicle size. It is 
beyond a doubt that vesicles can be determined in a reliable way, but it has not yet been clear if 
detected vesicles possess the expected size. The size of membrane-derived vesicles depends 
on the resolution of the flow cytometer and the calibration of the machine by beads with the 
physically distinct characteristics in scattering of light. The polystyrene beads used to calibrate 
sd-FCM by setting the vesicle gate, differ to membrane vesicles in a higher refractive index and, 
thereby, lower intensity of light is necessary to scatter light in the same way like cell-derived 
vesicles do.  
It has been reported that due to the differences between refractive features of vesicles and 
beads, the captured cell-derived vesicles reveal a size which varies from this of polystyrene 
beads. In case, 0.5 µm polystyrene beads are applied to the calibration of vesicle-gates, the 
cell-derived vesicle size corresponds to the size of 1.0 µm (49).  
The PL-EV analysis by sd-FCM with limited size detection and calibration with polystyrene 
beads, employed in this study, let assume that only PL-EVs and no larger platelets (PLTs), of 
approx. 1 µm size were detected with the help of this method. Therefore, a new flow cytometer 
(hs-FCM, Apogee) of high resolution, that means of high sensitivity, was implemented in the PL-
EV analysis, that turned out to be able to detect smaller cell-derived vesicles of the equal size 
down to 400 nm (214). The assumption that the hs-FCM is able to recognize smaller vesicles 
was confirmed by the comparing results of the PL-EV-ratio measured by both systems. The 
ratio analyzed by the new system was 10-fold higher than the ratio of PL-EV to platelets 
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measured by the standard FCM. It has to be kept in mind, that the high resolution for small 
particles does not comprise the capture of normal sized PLTs.  
Furthermore, the additional technique, applied to determine the vesicle size with the use of the 
nanoparticle tracking analysis (NTA, NS-500, NanoSight) demonstrates that there is a 
surprisingly high amount of vesicles of decreasing size down to 50 nm. These smaller vesicles 
also include lipid vesicles, protein aggregates and immune complexes. The recent knowledge 
and the results of the present study demonstrate that the size of PL-EVs is cell-specific 
measurable for a certainty down to 400 nm but not down to 50 nm. More investigations with 
labeled PL-EVs, measurable by NTA, are crucial in order to satisfactorily solve the size issue. 
With regard to the detection of size by NTA, the validation of method results in obtaining high 
accuracy and recovery of both, monodispers and polydisperse polystyrene bead solutions. The 
results proving intra-assay precision in the determination of size (coefficient of variation [CV] of 
approx. 10.8% for PCs on day 7) and concentration (coefficients of variations up to 25.9% for 
PCs on day 7), were satisfactory.  
Similarly, as in the case of the method which bases on the effects of physical characteristics of 
scattering light on flow cytometry, the NTA method uses scattered light for tracking illuminated 
vesicles and it calculates the size using the rapidity of movement due to the Brownian motion. 
Here, the scattered light of NTA rather limits the simultaneous analysis of high polydisperse 
body fluids or solutions of cell-derived vesicles. During the analysis, larger vesicles scatter more 
light than the smaller ones and smaller vesicles are underestimated by adapted instrument 
settings, i.e. low camera level. Conversely, large vesicle population is undetectable in high 
dilution and with the instrument settings for small vesicles. One of the inventors of the technique 
(Dr. B. Carr) pointed out, that particles of the same size, regardless of which material, i.e. gold 
or plastic spheres, exhibiting certain mathematical and physical properties, show the same 
Brownian motions under the same conditions (such as temperature or viscosity of suspension). 
Therefore, the question of measurement of cell-derived EVs may be answered using NTA for 
detection of accurate complementary size relating to the illuminated moving particles.  
The question of EV-concentration could not be answered with the help of this method, because 
it was unclear, whether the camera was able to capture within one shot all vesicles in the 
continuum of size. The manufacturer’s advice on the optimized determination of particle 
concentration in a solution (per mL) was confirmed by results during validation of the method. In 
order to guarantee linearity in reproducibility of values, the recommended particle concentration 
ranging between 10
8
/ mL and 10
9
/ mL had to be achieved. As such, elution of larger particles 
must be mentioned again. However, during the first measurement, the particle concentration of 
a new sample is unknown. In body fluids and samples from PCs, the vesicle concentration 
varies individually and it depends on steps in sample preparation before analysis. Mostly, body 
fluid samples are highly polydisperse with vesicles in a size range of less or equal 50 nm up to 
1000 nm and more. In order to capture all movements of the particles by NTA, a three stage 
Discussion  118 
 
  
setting should be used: at first, low dilution of the sample and lower incidence of light should be 
applied; secondly, medium dilution with medium incidence of light should be administered and 
finally, high dilution with a high incidence of light should be used to capture even the smallest 
particles, which scatter less light due to their size. This measurement record proved to be the 
best one employed in order to acquire a high reproducibility of data, however it also turned out 
to be time-consuming.  
In the first tests with immunolabeled PL-EVs using NTA only for a short time, i.e. for less than 2 
seconds, PL-EVs were visualized in the fluorescent mode by NTA. Detected plasma vesicles 
from PCs are likely to contain PL-EVs, but the green laser bleached the conventional 
fluorescent monoclonal antibodies, i.e. CD61-PC7. This effect occurs due to the light exposure 
which stimulates the molecules into fluorescing, but otherwise diminishes them. Although, it has 
not been mentioned in this study, the labeling of vesicles with sypro-red dye which stains 
proteins and glycoproteins as well, was stable for minutes and showed a huge amount of intact 
cell-derived vesicles. It is important that more investigations employing photobleaching-stable 
and cell-specific fluorochromes and the use of a syringe pump for very long captures should be 
carried out in order to analyze the absolute PL-EV concentration by NTA. Without a platelet-
specific labeling and without additional preparation steps, as density gradient centrifugation of 
prepared exosomes, determination of vesicle size and vesicle concentration by NTA is not 
completed. Although, the proof of linearity of plasma vesicle concentration from PCs by NTA 
was demonstrated, the fact concerning the lack of specificity of PL-EVs provokes more 
investigations and prompts questions of the discrepancy between PL-EV concentration 
measured by hs-FCM (Apogee) and plasma vesicle concentration from PCs analyzed by NTA.  
Regardless of the fact, whether blood samples or PC samples were analyzed, the concentration 
of PL-EVs was controversially documented in literature (see Table VI-1). Differences were 
reported not only among several flow cytometers, but also between flow cytometry as a method 
and other detection techniques, i.e. atomic force microscopy (AFM) and electron microscopy 
(EM), to name a few. In this study, the standard method of PL-EV-analysis was a 
semiquantitative method with an indication of a PL-EV ratio according to the platelet events. As 
depicted in Table VI-1, the PL-EV ratio amounting to approximately six percent on day 1 was 
similar to the PL-EV ratio reported in literature. The concentration of CD61-positive PL-EVs 
measured by semiquantitative method was not comparable with the absolute concentration of 
CD61-positive PL-EVs measured with hs-FCM. Nevertheless, the reported PL-EV concentration 
in PCs also varied even if measured with the same hs-FCM method (256) and there is no 
common pre-analytical standard applicable to the analysis of PC samples. A standard protocol 
of EV analysis in samples stemming from several body fluids has been recently presented 
(267). This protocol was revised in the current study and was successfully employed in a 
running metacentric study conducted in four transfusion centers for QC of PCs.   
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Table VI-1: Comparison of PL-EV concentration from PCs on day 0 or day 1 reported in recent 
literature 
Material Flow cytometer Concentration References 
Buffy coat-derived PCs; 
PFP 
Apogee 24,2 x10
3
/ µL 
≡ 24200 x10
6
/ L 
CD42b+ (streptavidin-AF 
647nm-R-PE) 
(256) 
Plateletpheresis 
concentrate; 
PPP 
? 1264 x106/ L 
CD42b+ (1% Paraformaldehyd 
in PBS) 
 
(257) 
Plateletpheresis 
concentrate; 
After freeze: PFP 
FACScan (BD) 10000 x106/ L 
CD61+ 
day 1 
 
(15) 
Buffy coat-derived PCs; 
Ionophore-stimulated 
PRP  
FACScalibur (BD) PL-EV ratio 
approx.  5% 
day 1 
(258) 
 
 
The semiquantitative method could be a useful parameter of the comparison of the results of a 
metacentric study because the performance with sd-FCM may allow the most centers to 
participate in this investigation. Further, the PL-EV ratio may be acceptable as a quality control 
parameter because the platelet events determined by sd-FCM correlate to the platelet count 
measured by an automated blood cell counter (Sysmex); no significant changes in the count 
during storage during 5 days were observed. Therefore, the change of the PL-EV-ratio during 
storage, despite of the stable PLT count, may be the earliest and quickest test for a 
standardized detection of vesiculation in a QC program. In fresh, non-irradiated PCs, the PL-EV 
averaged 6.1 percent in contrast to the mean value of 7.1 percent for PL-EVs in PCs after 
expiry. In irradiated PCs, the values averaged 6.8 percent on day 0 and 11.8 percent on day 5 
(that means day 6 after preparation), confirming the QC test. It is not clear, whether the higher 
vesiculation rate during storage affects the viability of PLTs after application of PCs in vivo, but 
coherence between PL-EVs and the activatability of PLTs is very probable. The effects of 
storage on the externalization of p-selectin (CD62P) at the surface of PLTs are described in 
detail later.  
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Further, investigations of sd-FCM with count beads are recommended in order to compare the 
results obtained with quantitative methods of PL-EV analysis. As a means to confirm linearity, 
small-count beads, exhibiting the most similar characteristics to membrane vesicles, i.e. silica 
beads, could be applied instead of physiological, cell-derived reference control beads for spiking 
samples. With the purpose of improving the method, it has to be mentioned, that the chosen 
monoclonal antibody CD61 binds in a reduced form to HPA-1b (human platelet antigen-1b), 
which is one of the expressed forms of the two P1A alleles of the glycoprotein (GP) IIb/IIIa gene 
(268). This results in stronger mean fluorescence intensity (MFI) of the P1A1/P1A1 variation in 
platelets and less MFI values of the P1A1/P1A2 polymorphism. The CD61-positive events of 
vesicles and platelets analyzed by this method originate from the same donor and, therefore, it 
is assumable that PLTs and PL-EVs show the equal CD61 expression at their membrane 
surface, without interference with the PL-EV-ratio.  
PLTs are known to convey cytoplasmic mRNA as a molecular tool for protein biosynthesis and 
they are able to synthesize GPIIIa during 7-day storage (269). In case, PL-EVs containing 
mRNA are not able to synthesize proteins in amount equivalent to the amount of proteins 
synthesized by platelets, the volume of PLTs for semiquantitative CD61 positive PL-EV-ratio 
analysis will be overestimated, in contrast to the volume of PL-EVs from stored PCs. Moreover, 
integrin signaling, which influences protein biosynthesis during storage of PCs, indicates a link 
to the pathways of PSL (269). During the storage of platelets, alterations in talin, tubulin and 
thrombospondin were found (30, 270). In respect to the microparticle formation, generally and 
specifically for PL-EVs, talin, as degraded cytoskeleton molecule, beside myosin, and Ras-
related protein 1 (Rap1) effector RIAM (Rap1–GTP-interacting adapter molecule), plays an 
important role in an agonist stimulation in integrin αIIbβ3 binding and activation (271). 
Additionally, Rap1 activation was diminished in an inhibitor-induced study targeting PI3-kinase, 
accompanied by reduction of integrin αIIbβ3 activation and release of α-granules (22, 272). 
Therefore, it is assumed that the agonist stimulation of platelets, leading to integrin activation 
and Rap1-induced formation of an integrin activation complex, is involved in vesicle 
development in apoptosis or alteration during storage.  
As far as an optimized QC analysis is concerned, the correlating proteomic data, i.e. data on 
increase of cytoskeleton element talin, vinculin and moesin, as well as on signal transduction 
proteins 14-3-3, RhoGDI (Rho GDP-dissociation inhibitor) and Rap1, were suggested as a 
profile to predict PC quality (273). In this research, the decrease of these proteins translated to 
a poor platelet recovery and survival. In addition to protein profiling analysis and a research 
aiming to avoid expensive und extravagant radiolabeled survival-tests in vivo, the PL-EV 
analysis and, furthermore, proteomic data on PL-EV study should be integrated in a forward-
looking QC process. 
Surface antigens on PL-EVs such as CD41, CD42b, CD63, annexin V, phosphatidylserine (PS) 
and cleaved filamentin A (9, 256) were also detected during PL-EV analysis, however, the 
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antigens could not be detected with the standard method applied to this study. First 
measurements permit to remark, that 50-60 percentage of all PL-EVs are annexin V-positive. 
Further investigations to enclose the potentially changing immunophenotype of PL-EVs by a 
day-by-day analysis for QC tests are necessary. 
Inconsistent results gathered from different NTA and FCM methods, carried out either with fresh 
PCs or with irradiated PCs after expiry, were also expected. Interestingly, Canto™ II, a standard 
FCM method similar to Navios™, was able to recognize silica beads according to the forward 
scatter (FSC) size determination down to 240 nm. As a result of the comparison of the three 
FCMs (Navios™, Canto™ II and Apogee) and samples from PCs on day 4, similar PL-EV-ratios 
were obtained in an intra-assay test with CV about 6.2%. The results of the analysis of the 
samples from the seventh day exceed the acceptance criteria (set to ≤ 15% and they amounted 
to CV=16.2%. On day 7, Apogee (hs-FCM) detected more vesicles than the other both flow 
cytometers. This can be explained by the fact that the amount of smaller vesicles grows after 
expiry. Moreover, the vesicles are platelet-specific and detectable only by hs-FCM with a 
resolution for PL-EV smaller than 240nm. Results of NTA analysis confirmed the thesis; the 
mean size distribution does not reflect the increased amount of smaller vesicles, though. The 
changes of PL-EVs during the relevant time of applicability (day 1 to day 4) have to be analyzed 
separately based on the validated protocol for PL-EV-measurement. 
Before PL-EV analysis was performed with the use of fresh samples from PCs and samples 
after expiry, the thesis on platelet activation in relationship to vesiculation had been confirmed. 
In response to the activation by thrombin-receptor-activating-peptide 6 (TRAP-6) or by 
application of shear stress as a second mechanical activator (induced by a strong sampling), of 
a separated group of PC samples, an increased shedding of PL-EVs from platelets was 
induced. Activation by TRAP-6 generated an average increase of ¼ more PL-EVs in fresh PCs 
than in the same PC samples without mechanical activation. Beside the strong agonist, TRAP-
6, shear stress is also known as a platelet activator that induces vesiculation (230). The data on 
PL-EVs in this study showed no statistically significant differences between the activated and 
non-activated platelets of different sampling types, but the results demonstrated clear 
differences in the correlation between PL-EVs and the CD62P expression after activation with 
TRAP-6. CD62P was used as a gold standard to show the activatability of platelets. On the one 
hand, PL-EVs positively affected the activatability of unstressed platelets and, on the other 
hand, there was a negative effect influenced by the rigorous type of a sampling. The results, 
collected within 144 hours after sampling, were completely opposing between activated and 
non-activated platelets and it is likely that activated platelets underwent shape change 
accompanied by an increased vesiculation that negatively influences the activatability. Activated 
platelets were not able to reach the resting state as in case of the platelets in unstimulated 
samples from the same PCs. Results from the rebound phenomenon test let suppose that, 
despite shear stress during production, the functionality of platelets recurred. Further, the more 
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PL-EVs are shedded after 24 hours, the more positive relationship with the platelet function is 
assumable in samples not subjected to shear stress. By contrast, more PL-EVs and platelet 
function is assumably negative related in samples with stressed platelets. Inadequate activation 
of platelets during manufacturing process leads to reduction of their functionality accompanied 
by a higher PL-EV amount, especially four hours after sampling. 
According to the QC standard, samples with abnormally high CD62P values and a higher 
amount of PL-EVs on the day of apheresis imply lower quality of platelets in PCs. PL-EVs are 
useful as plausibility check in QC. This confirms the thesis, that there are different ways of 
platelet vesiculation within different types of PL-EVs and resting platelets exhibit less 
vesiculation (15). It remains obscure, whether PLTs originating from different manufacturing 
technologies vary in their in vitro functional activities (274). Additionally, it would be of great 
interest to investigate, whether PL-EV functional activity might be independent on their 
concentration. More researches applying other agonists are necessary to be conducted with a 
purpose of detection other ways of vesicle formation from platelets, indicative of different 
functionality of PL-EVs.  
With the help of impedance aggregometry used in this study, it was possible to confirm the 
results reported in 1967 by Wolf (8). The PL-EVs were originally called “platelet dust” and it was 
possible to prove their coagulant properties with the help of the clotting time measurement. 
Recently, it has been also possible to demonstrate by means of Impedance Aggregometry that 
PL-EVs cause aggregation in platelet-free plasma (PFP). Even platelet-derived exosomes (PL-
EXs) exhibited this phenomenon. However, the control samples, EV-free plasma alone or PBS 
manifested no coagulant properties and did not provoke any measurable aggregation. Results 
showed significantly increased aggregation in PL-EV-rich samples in comparison to the control. 
Therefore, the method of aggregometry has been rejected as a method of improved PC quality 
control. Different components of PCs, platelets, plasma and PL-EVs are not distinguishable in 
relation to function by this method and the results of aggregometry do not imply the activatability 
of platelets. Aggregometry does not reflect specific platelet activation because of the artificial 
procoagulant activity of PL-EVs. 
The donor-specific and preparation-specific values include the most relevant results that 
showed coherence to the PL-EV amount from PCs. No gender-, or age-related differences of 
PL-EVs were recognized, neither on day 0 nor day 5, confirmed by the recent results reported in 
literature (15). Moreover, the age of donors might positively affect the CD62P expression on 
platelets on day 0. Subsequent positive coherence was demonstrated between the CD62P 
expression and BMI (body mass index) for both, CD62P values at the time after apheresis and 
at the time after expiry. Interestingly, this phenomenon was accompanied by a negative 
correlation to PL-EVs after expiry. The high BMI, in general, is parallel to elevated cholesterol 
levels and elevated LDL-levels. However, as it negatively correlates to the amount of PL-EVs, 
the relevant coherence between the BMI and the PL-EVs is questionable. Nevertheless, 
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elevated cholesterol and LDL levels positively correlated to the CD62P expression. These 
results disprove the significantly higher BMI values found in a low-responder group for PLT 
responsiveness of activation in contrast to midrange or high-responder groups reported by 
Garner et al. (275). Mean BMI of the low-responder group accounted for 30.1 in contrast to the 
mean BMI of 24.5 found in the course of this study. Within the cohort of healthy donors, the low-
responder group was characterized by a minimum of platelet response after stimulation with 
adenosine diphosphate (ADP) and cross-linked collagen-related peptide. Fibrinogen binding 
and CD62P expression were determined as activation markers. It is likely that there is no 
coherence between BMI values and platelet activation due to the fact that the cohorts differ too 
much in their BMI values. However, in fact, BMI as a standard value of case history and clinical 
examination before apheresis could be useful for estimation of activatability of platelets from 
PCs.  
Another parameter, also called the immature platelet factor (IPF) of donors’ pre-donation 
samples, was discussed. Immature, young or so-called reticulated PLTs containing residual 
RNA are present in circulation after release from megakaryocytes in bone marrow. This 
parameter reflects the stage of megakaryocyte proliferation. A significant negative relationship 
between IPF and PL-EVs is assumable on day 0, whereas positive relationship among IPF, PL-
EV and platelet count was observed on day 5. The negative relationship between IPF and PL-
EVs within fresh PCs may demonstrate a high turnover and younger PLTs with either less 
vesiculation of PLTs in the peripheral blood or more viable, activatable PLTs pooled in the 
spleen (275). The coherence in altered PCs may indicate that some donors have particularly 
susceptible PLTs that are more viable during storage and are more capable of vesiculation in 
contrast to the apparent genetic determinants influencing modification of PLT function. 
It is also worth discussing whether all PC-derived CD61-positive vesicles originate from platelets 
or from megakaryocytes of plasma of healthy volunteers (276). This would result in coherence 
between IPF and PL-EV amount in the donor’s plasma, but it still cannot explain the negative 
relationship between IPF and PL-EVs from PCs. More investigations are necessary in order to 
characterize the phenotype of PL-EVs. 
As far as the preparation-related differences within PL-EVs are concerned, very interesting 
results were obtained for single-needle and double-needle systems. As a result of the 
application of single-needle-system during apheresis process, a lower activatability of platelets 
and decreased CD62P expression on day 0 and on day 5 were noticed. Further, an increased 
citrate concentration and, consequently, a decreased pH within PCs were evaluated because of 
the higher demand for anticoagulation when apheresis time was shorter, when single-needle 
system was used. Neither single-needle nor double-needle systems affected PL-EVs 
statistically significant; however, a typical imbalance in PLT count occurred. Application of 
double-needle system of lower flow rates requires longer time of apheresis; yet, the resulting 
collection of platelets above the buffy coat is likely to be more effective and leads to higher PLT 
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count. Aggregation of PL-EVs and forming larger particles, and detection of false positives 
within platelet populations may explain why both apheresis systems generate similar amount of 
PL-EVs in PCs. However, higher citrate consumption in concentrates obtained in the course of 
single-needle procedure speaks against aggregation of PL-EVs.  
The rebound phenomenon tests did not confirm any discrepancies within PC-derived PL-EVs, 
which were subjected to shear stress of varied intensity and manufactured by single-needle or 
double-needle systems (5.1.5). Additionally, PL-EV populations did not significantly differ from 
one another, however, the PL-EV concentration negatively correlated to CD62P expression in 
samples drawn under greater shear stress. Therefore, PL-EVs are not applicable as a single 
parameter of QC; rather they may serve as a marker of the plausibility check of platelet 
activatability. 
The variation within PL-EVs could be evaluated solely with the help of instruments employing 
double-needle system. With regard to different cell separators, it was previously shown that the 
instruments variably influence induction of PLT activation (277) and longer processing times are 
associated with increased activation. Among all instruments applied, there was only one 
separator whose measurements indicated considerably higher levels of PL-EV ratio on day 0. 
The amount of processed PCs was equal. Provided, that PL-EVs originate from the platelets 
enclosed within PCs, only, and not from the donor plasma obtained during apheresis (15), 
specific settings of apheresis apparatus affect the activation of platelets through shear stress or 
another non-physiological, mechanical stress. In the case of this particular instrument, the 
CD62P expression was decreased after TRAP-6 activation, accompanied by elevated levels of 
PL-EVs. Therefore, with regard to the quality control (QC) management, PL-EVs are applicable 
as an indicator of unfavorable apheresis settings and, consequently, lower activatability of 
platelets, originating from PCs. Therefore, prior to the launch of the method applying PCs, 
further research on the influence of the aforementioned instrument on other QC parameters is 
essential. 
Commonly accepted quality defining criteria for PCs, i.e. platelet count, sterility on day 5 or pH, 
do not exceed the reference levels for the approval of concentrates used in this study. Only one 
PC exceeded platelet count defined by the reference levels and, thus, it did not meet the 
requirements. Therefore, the quality of PCs used in this study is acceptable. The expression of 
CD62P on day 0 averaged 1094.7 percent after activation with TRAP-6 and it dropped to 547.3 
percent on day 5 after activation with TRAP-6, as compared with the control values. CD62P 
expression at the platelet surface is one of the most common markers of platelet activation in 
PCs and there were standardized protocols established to compare the activation of platelets 
during storage with increased CD62P level over time (37, 278-280). Reported in literature, data 
on increased CD62P level, not influenced by an additional activating stimulus, were obtained 
from partly fixed platelets, not stimulated by TRAP-6. Our data confirmed these results of 
increased basal CD62P values during the storage. Until today, no in vitro test has received 
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exclusive approval as a standard test. In general, it is accepted that agonists induce alterations 
in platelet shape and surface antigen expression. They are useful for protocols on platelet 
function tests in QC of PCs (5, 281).  
In the present study, this criterion was fixed as a gold standard for the evaluation of PL-EV 
levels as a quality control approach.  
Unlike the level of PC-derived plasma vesicles measured by NTA, the concentration of PL-EVs 
evaluated by flow cytometry has been revealed in the recent literature (15). The concentration 
was computed with the help of a formula by Berckman (86) employing PL-EV concentration of 
approx. 10000 x10
6
/ L on day 1 and approx. 7500 x10
6
/ L on day 5 (data of CD61 positive MP 
events obtained on the base of published figures, not written-out). Another study, reported in 
literature, demonstrated values of PC-derived PL-EVs labeled with CD42b moAbs. The 
concentration of PL-EVs in PCs reached the level of approx. 1264 x10
6
/ L and the level of 
approx. 1702 x10
6
/ L on day 0 and day 5, respectively. In order to compare the data 
aforementioned and data from the current study, numerous aspects have to be discussed.  
At first, the formula by Berckman is not applicable to the semiquantitative PL-EV analysis by 
Navios™. Secondly, the PL-EV concentration analyzed by hs-FCM (Apogee) corresponds to 
the presence of small, medium and large-sized vesicles ranging from 180 nm to 500 nm. PL-EV 
concentration measured by hs-FCM in this study was 450 fold higher [4509150x10
6
/ L; 
10000x10
6
/ L] than the concentration obtained by Rank et al., and more than 3500 fold higher 
than the PL-EV level  reported by Nollet et.al. (257). This indicates that there are differences in 
statements of PL-EV concentration in PCs varying from approx. 1000 to millions of PL-EVs per 
liter. Of course, different instruments were used in analysis by FCM, but until today, it has 
conveyed an impression of measuring ballpark figures. The values of PL-EV concentration of 
the largest subpopulation (300 nm to 500 nm), as determined by hs-FCM in this study, are not 
comparable to the results obtained by the aforementioned research groups, either. Further 
investigations are necessary to standardize techniques and methods of analysis of PL-EVs from 
PCs. However, the high resolution flow cytometer is likely to separate much more PL-EV 
vesicles than previously predicted. Even with the help of the analysis with optical single particle 
tracking, it is allowed obtaining higher concentrations of vesicles within PCs. 
Concluding, the PL-EV concentration, exemplarily on day 0, measured by hs-FCM [approx. 
4500 x10
6
/ mL] constitutes 1.5 percent of the total amount of plasma vesicles determined by 
NTA [approx. 300000 x10
6
/ mL]. This result is comparable with the results acquired from PFP, 
labeled with cell-tracker dye and two decimal power lower cell-derived vesicles, which are in 
fluorescent modus versus all measured plasma vesicles (248).  
The size of cell-derived vesicles from PFP ranged from 50 nm to 300 nm with a peak size 
around 80 nm. According to a general expectation that the majority of vesicles in human plasma 
derive from platelets (15, 142), these results conform to the size of PL-EVs. Another group 
reported that PL-EVs are expected to be of a size of approx. 125 nm in diameter as measured 
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by atomic force microscopy (282). Although, the average size of the plasma vesicles amounts to 
approx. 150 nm, it does not refer to the size of PL-EVs. Additionally, Dragovic et al., assumed, 
that the majority of plasma vesicles are lipid vesicles (248), which may influence the dimensions 
of the structures constituting PCs. Even some additional EV particles, i.e. high-density 
lipoproteins (HDL), cannot be isolated from EVs by means of sucrose gradient 
ultracentrifugation, due to the fact that their densities overlap (283). Large protein aggregates, 
which constitute other contaminating structures in plasma-containing samples, are not 
distinguished from PL-EVs by NTA based on the phenomenon of Brownian motion (267). In 
fact, the current literature does not provide enough information and no consensus on the exact 
size and concentration of PL-EVs from PCs determined by hs-FCM and NTA. This study implies 
existence of platelet-derived vesicles, stained with CD61 moAbs, of a size between 180 nm and 
1 µm. 
Further, two groups of PC samples were compared for QC testing. Samples from tubes from the 
apheresis container, filled with PC content on the day of preparation, and samples from the 
whole PCs constituted the investigated groups. The results of the comparison demonstrate that 
the material from the tubes is not useful for QC analysis. When comparing the data on platelet 
count, CD62P expression on platelets and on the amount of PL-EVs, it was noticed that the 
samples originating from the same platelet concentrate differ from one another what is likely to 
be caused by the presence of inadequate mixture of the tubing system. As a result, the 
equivalence was rejected. However, standardized stripping prior to sampling process may 
prevent the rejection. Extreme discrepancies in results of the material originating from the tubes, 
obtained for the latter specified parameters, reflect this assumption. Flexibility in standardized 
sampling of QC analysis would prevent the destruction of worthwhile pharmaceuticals. The 
process needs further validation and approval by regulatory authorities.  
In order to fulfill requirements for the evaluation of qualified PC samples corresponding to the 
real content of PC, the results of PL-EV analysis were interpreted only on the base of samples 
of the whole PC.  
The present study investigated a potential effect of gamma irradiation on platelets originating 
from fresh PCs and on vesiculation and PLT activation. This issue appeared to be more 
interesting than expected at the beginning of this research, due to the fact that, more than 50 
percent of the administered PCs at the University Hospital Regensburg underwent irradiation in 
the past year. Gamma irradiation of 25 Gy exposed to PCs prevents the proliferation of 
leukocytes before transfusion (284, 285). This process reduces the potential life-threatening 
transfusion associated graft-versus-host disease (TA-GvHD) in immunocompromised patients. 
Provided that RNA-containing platelets and even PL-EVs translate functional proteins during 
alteration, UVA gamma irradiation may inhibit PSL-linked protein production. With the help of 
PL-EV proteomic analysis by LC-MS/MS it has been discovered that five percent of proteins 
involved in molecular function belong to transcription and translation processes (286). Taking 
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into consideration that the aim of this study is to obtain long-lasting products, the methods of 
protein and PL-EV analysis are certainly subject for improvement. Results presented in the 
current literature do not confirm any obvious changes in platelet count observed between 
irradiated (with 20 to 25 Gy) non-irradiated platelets (29, 280, 287), but results obtained in the 
course of this study show significant differences in the platelet count between the two groups on 
day 0. The dosed gamma irradiation used in this research was constant and not subject to 
change. The fact, that diverse blood cell counters (i.e. ModelZM, Coulter; Cell-Dyn 4000, 
Abbott; analyzer from Rock et.al. not known) were applied to three mentioned studies, is likely 
to be a reason of discrepancies between the results obtained in the aforementioned studies and 
in the analysis by Sysmex XE-5000. Generally, an analysis of platelet count performed with 
automated hematology analyzer is validated with the help of blood samples but rarely validated 
with the help of samples from PCs. PLT count analysis of PCs with Sysmex XE-5000 was 
based on the earlier validation performed with samples originating from PCs. The evaluation of 
platelet count of irradiated PCs versus non-irradiated PCs during monthly QC analysis has to be 
continued. However, platelet count performed by hs-FCM approved the results of elevated 
platelet count after irradiation on day 0.  
Beside the change of the CD62P expression, no differences were found between irradiated or 
non-irradiated PCs, confirming the common assumption reported in the recent literature (29, 
280). The results of platelet vesiculation in PCs after γ-radiation have not been presented in the 
literature. Nevertheless, it was reported that human and mouse lung cancer cell lines subjected 
to irradiation with 10 Gy secreted up to four times more microvesicles (MVs) after 24 to 48 hours 
without affecting the viability of cells (288). These cells are nucleated in contrast to platelets, 
which remain unaffected by irradiation. However, the data suggest an influence of irradiation on 
the amount of PL-EVs. The sd-FCM and the hs-FCM showed significantly altered PL-EV ratio 
after irradiation of PCs.  
In aspect of vesiculation depending on storage effects to platelets, with the help of hs-FCM it 
was possible to determine the differences of PL-EV amount accompanied by lowered PL-EV 
ratio on day 0, whereas the results of sd-FCM showed significant changes after expiry of the 
PCs only, in form of elevated PL-EV ratio. These results, however, are not quite contradicting 
one another. The grow of platelet amount should lead to lower PL-EV/ PLT-ratio as measured 
by hs-FCM on day 0 in contrast to not significantly elevated (n=15) or stable (n=30) PL-EV/ 
PLT-ratio as determined by sd-FCM. This discrepancy on day 0 is based on the overestimated 
or underestimated platelet count by different FCM instruments, bearing in mind that the sd-FCM 
is a semiquantitative method. Platelet events detected by sd-FCM, are 10-fold more frequent 
than PL-EV events, whereas the platelet events detected by hs-FCM are only twice that 
frequent than PL-EVs. Changes in platelet events, measured by hs-FCM, lead to the fact that 
the PL-EV ratio is more susceptible to alteration. Latest results do not include the comparison of 
PL-EV ratio (estimated by hs-FCM) between non-irradiated and irradiated PCs on day 5. 
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However, it is supposed that the absent data would confirm the elevated PL-EV ratio measured 
by sd-FCM during storage. Anyway, the concentration of the main vesicle fraction, the lipid 
vesicles, does not change after irradiation of fresh PCs. In conclusion, it has been noticed that 
the platelets vesiculation is the sole phenomenon, which could explain adverse effects after 
transfusion of irradiated PCs. PL-EV ratio is the only indicator which changed after irradiation 
and more investigations of this topic are necessary to estimate modifications after irradiation of 
PCs with the hs-FCM and labeled PL-EVs by NTA. 
In order to prove the quality of the storage conditions of PCs, e.g. the storage temperature, 
agitation, storage containers, solution and anticoagulants, the measured stable platelet count 
was used as a positive, predictive indicator of proper conditions  The platelet count is one of the 
variables of approval and delivery according to the standard test and acceptance certificates in 
plateletpheresis manufacturing. These results were reported earlier and stay consistent with our 
data (25, 280). The pH values, which correspond to the metabolic processes under non-
physiological condition during storage after removing PLTs from the circulation, also match the 
reported data (279) (5). In this study, pH does not exceed the reference level at any time of 
storage. Our data on expression of CD62P on platelets during storage are also conformed to 
general findings. Disclosed data mainly demonstrated increased level of basal CD62P surface 
expression (37, 278-280), observed in platelets which were not stimulated and their activation is 
solely a result of the non-physiological conditions in storage container. The initial increase of 
CD62P was confirmed by our data; nevertheless, it was of interest to search whether the 
activatability of platelets at the beginning and the end of storage may serve as an applicable 
indicator of in vivo viability. In another study, similar changes of CD62P expression after TRAP-
6 activation during storage of PCs over 12 days were recognized, even accompanied by a 
complete loss of responsiveness after that time (258). The loss of platelet activatability during 
five days of storage time obviously appeared and did not depend on irradiation of PCs on day 0. 
This loss of activatability and an increased basal CD62P exposure indicate one of the effects 
called platelet storage lesion and this effect served as a gold standard of functionality. 
Therefore, it is plausible to employ the standard as a basis for evaluation of PL-EVs as a QC 
approach.  
PL-EV increased also during storage, independently of the irradiation. In literature, there are 
discrepant results. Decreased level of PL-EVs labeled with CD61 moAbs (15) was reported  as 
well as increased concentration of PL-EV labeled with CD42b moAbs (257) and increased level 
of PL-EV labeled with CD61 moAbs (258) over time. In our study, the analysis by hs-FCM 
confirms the results by sd-FCM at least, as far as elevated PL-EV ratio during storage in 
irradiated PCs is concerned. Further, the PL-EV ratio on day 0, as determined by sd-FCM, 
correlates to the PL-EV ratio from the fifth day. This may indicate that the PC-derived platelets 
undergo vesiculation already at the beginning of storage and this notion could facilitate a 
decision whether specific PCs should be applied in a therapy prior to other PCs.  
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Plasma vesicle concentration determined by NTA does not change during storage, as expected, 
due to the fact that PL-EVs translate to 1.5 percent of all plasma vesicles measured in PCs.  
The increase of PC-derived IPF is another noticeable change during storage. This phenomenon 
stays consistent with previous data and was explained by mainly unspecific binding of nucleic 
acid dyes to the membrane surface of platelets or residuals of mRNA (25). In addition, the fact 
that similar results of IPF increase and stable platelet count over time were acquired, the 
interpretation of the data of this study allows suggesting coherence between elevated IPF 
values and increased PL-EVs in PCs. This coherence could be explained based on the 
supposition that PL-EVs contain nucleic acid, i.e. RNA that is labeled similarly to IPF and, thus, 
provides false results. Furthermore, it was demonstrated that there is a relation among IPF, PL-
EV and CD62P on the fifth day of storage, only; further analysis is required, though. 
The correlation between the expressions of CD62P, employed as a QC gold standard of platelet 
activatability during storage and PL-EVs from the PCs was in focus. The question was whether 
PL-EVs might be useful as an indicator of the platelet activatability.  
According to the results obtained, PL-EVs were confirmed as a marker of fresh, non-irradiated 
PCs and irradiated PCs after expiry on the fifth day as determined by sd-FCM. With knowledge 
of several experiments described in literature in last years, it is assumable that sd-FCM used in 
this study distinguishes the size of PL-EVs of approx. 0.5 to 1 µm (214).  
First, the sd-FCM without high resolution is able to determine particles of approx. 300 nm (246, 
247) and secondly, the vesicle gate for the tests was adjusted to smaller or equal size of 0.5 µm 
calibration beads consisting of polystyrene. It is conceivable that the PL-EV analysis by sd-
FCM, performed in this study, covered more microvesicles than exosomes derived from 
platelets. Otherwise, one cannot rule out the possibility that vesicles of a size of exosomes are 
detected as ‘swarm within the iceberg’ (49, 255).  
The results of correlation and linear regression are significant for the coherence between PL-
EVs and CD62P in fresh, non-irradiated PCs showing a considerably lower expression of 
CD62P, after activation with TRAP-6, reaching approx. 51.5 percent due to the 1 percent 
increase in PL-EV ratio. The significantly lower activatability of platelets from irradiated PCs 
after expiry reached approx. 16.9 percent in parallel to 1 percent increase of PL-EV ratio. The 
same negative correlation between TRAP-6 stimulated CD62P and PL-EV amount was 
previously evaluated, but it was of no significance (258).  
What are the reasons for this coherence? We know that the platelet count was stable during five 
days of storage and the count itself is not responsible for changes in PL-EV ratio. Further, we 
know that PL-EVs are likely to originate from platelets, accumulated in the storage container, 
but not from the donor plasma gathered during preparation (15). Thirdly, platelets of PC origin 
change their shape upon activation, produce more vesicles through blebbing and form less 
vesicles under the condition when platelet activation inhibitors are added to the storage 
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containers (14). Fourthly, during storage, the PC-derived PL-EVs are less involved in apoptosis 
than in activation (258). Finally, the loss of responsiveness to TRAP-6 and reduced CD62P 
expression is a sign of exhaustion, affected by secretion of granules after activation and 
senescence or early apoptosis. This exhaustion was demonstrated in fresh activated platelets 
which were present under non-physiological and extracorporeal conditions. This may lead to a 
conclusion that PL-EVs in PCs provide a helpful predictor of platelet responsiveness. To 
summarize, one reason for the negative PL-EV/ CD62P coherence is the degranulation of 
activated platelets. Activation starts with response of platelet receptors to agonists, with 
crosslinking of receptors or changes of membrane integrity. Activation signaling occurs as 
‘outside-in’ and ‘inside-out’ signaling (289) and is associated, among others, with secretion of 
granules and membrane-derived vesicles. Former activated platelets form vesicles and are less 
responsive to reactivation. 
Moreover, nowadays, the interest in identification of signs of PSL process during storage in PCs 
is not limited to the amount of derived vesicles only. Proteomics of PLTs has gained importance 
as a tool to address pathways involved in the loss of morphologic, biochemical and functional 
changes during storage of blood products (269). Recently it has been found that approximately 
three percent of the cytosolic PLT proteome underwent changes within nine days of storage 
(20). An increase in the concentrations of septin 2, ß-actin and gelsolin was observed, however 
the proteins were not among those 587 proteins which were identified in PL-EVs (290), 
research on http://evpedia.info/). Nevertheless, it may happen that the changes in proteomics, 
found in platelets during storage, might be also identified in stored PL-EVs. 
One of the aims of the present study was to prove with the help of the obtained results the 
speculated relationship between the platelet activatability and the vesicle production. 
Additionally, new systems of PL-EV analysis with high-resolution FCM (Apogee) and the optical 
single particle tracking analysis (NTA) were favored as recent supporting techniques in the QC 
program of PCs. The results of PL-EV analysis by sd-FCM were compared to the results of both 
new systems. As far as both cytometric methods (the semi-quantitative (sd-FCM) and 
quantitative analysis (hs-FCM) are concerned, the ratio of PL-EVs to platelets was calculated 
based on the positive labeled CD61 events. The FCM methods delivered outstanding results 
comparing one another, which demonstrated a positive correlation of PL-EV ratios to CD62 
expression in all analyzed samples from fresh PCs. There was a significant coherence between 
the non-irradiated (cc=0.72**) and the irradiated PCs (cc=0.80**). In contrast, no significant 
coherence was detected between both systems determining the amount of PL-EVs after a 
storage period of five days under blood banking conditions. The fact that a considerable 
coherence has not been observed might be controversial because other, additionally acquired 
by a new system, parameters correlated very well. These parameters refer to the concentration 
of PL-EVs as CD61-positive events per µL.  
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The hs-FCM can distinguish among several subpopulations among PL-EVs from PCs. No 
attention was paid to the fraction of small PL-EVs with diameter lower than 180 nm. It is uneasy 
to separate the events from the background noise and this may be one of the subsequent 
reasons for a low concentration of small PL-EVs and for an attained detection limit for human 
membrane vesicles with a refractive index of 1.39 in the size of 180 nm (214) personal 
communication with O. Kenyon). Despite the fact that the PL-EV ratio failed to reach a 
significant correlation between the standard and new systems for expired PCs, the 
concentration of all PL-EVs from PCs and large PL-EVs (300 to 500 nm) showed significant 
coherence to the PL-EV ratio as assessed by standard system for PCs applied regardless of the 
maturity of PCs. The concentration of the medium-sized PL-EVs (180 to 300 nm) did not match 
the PL-EV ratio of expired PCs in significance of correlation to the standard system. This can be 
explained by the fact that during storage of platelets the more small formed vesicles are 
underestimated and, thus, do not influence the PL-EV ratio.  
The notion can be confirmed by an experience in application of the NTA methods to 
measurement of “old samples from PCs” characterized by an enormous increase of very small 
particles which escaped the analysis in the current dilution protocol. Although the plasma 
vesicles of the expired PCs were in average larger as measured by NTA, more peaks of vesicle 
smaller than 100 nm were recognized. The analysis by NTA does not show any correlation to a 
completely different method of flow cytometry at any step of the investigation. The method is for 
a certainty well suited for the estimation of all vesicles in PC samples, even for the plasma 
samples comprising high amounts of lipid vesicles and protein aggregates, and it provides a tool 
to determine the size of particles or vesicles in the samples. Recent investigations showed 
vesicle determination in PCs with a similar method, dynamic light scattering with 
ThromboLUX®, to define good quality of products (291). Labrie et al. involved microparticles in 
a scoring system according to platelet increment after application of PCs and concluded that all 
microparticles have to be excluded from PCs to guarantee sufficient product quality. In order to 
different origins of vesicles (i.e. proteins, cells, lipids, immuncomplexes) it was not examined, if 
separated vesicles may provide additional transfusion related functions. Nevertheless, without 
any categorical labeling of platelet-derived or membrane-derived vesicles, the specificity of the 
NTA method in this study is not congruent with the requirements of QC analysis of cell 
components or any other pharmaceutical product.  
Taking into consideration the fact that hs-FCM may be applied as a possible method of PL-EV 
analysis in PC control, it has to be addressed, whether the PL-EV ratio or the PL-EV 
concentration are reliably coherent to a gold standard of QC analysis. Without exception, the 
PL-EV levels measured by hs-FCM, negatively correlate to the expression of CD62P after its 
activation with TRAP-6. The method is suitable as a predictive test of the quality of platelets 
derived from both fresh and expired PCs. Therefore, it is necessary to continue investigation 
elucidating the fact whether the PL-EV ratio, the concentration of medium, larger or all PL-EVs 
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are the most effective predictors. To sum up, the new FCM system can be accepted as a future 
method of choice in vesicle analysis in QC program of PCs. The method could be fast and 
easily implemented in routine QC tests in parallel to gold standard platelet function analysis. It is 
more useful than sd-FCM to detect the relationship between former activation of platelets/ loss 
of responsiveness and their vesicle secretion.   
As mentioned above, PL-EVs or membrane-derived vesicles may constitute the most abundant 
components in the composition of all vesicles in human body fluids (248) and, as far as this 
study is concerned in PCs. As the results of the present research and further investigations of 
cell-derived vesicles from PCs demonstrate, no contamination with leukocyte-derived or red 
blood cell-derived vesicles was found (146).  
More than 95 percent of all PC vesicles detected with the sd-FCM method originated from 
platelets. The storage of platelets and the vesiculation of residual erythrocytes or leukocytes in 
PCs over time do not affect the aforementioned amount. It is speculated that leukocyte-derived 
vesicles in PC samples are hardly detectable and, consequently, underestimated by sd-FCM 
analysis. Additional researches are of importance in order to improve the identification of 
residual vesicles of remaining external cells. However, in the present study these vesicles were 
not in focus of interest as a component of vesicle population of PCs.  
In contrast, parallel tests on red blood cell (RBC) units which were analyzed in terms of vesicle 
composition, showed enormous contamination with foreign membrane vesicles, i.e. platelet-
derived. In undiluted RBC units, approx. 20 percent of PL-EVs were detected by sd-FCM. One 
can question these results and criticize inadequate pre-analytical preparation of the samples 
from RBC units exhibiting too high concentration of RBCs for a valid measurement by flow 
cytometry. However, the more RBC units were diluted, the more percent of PL-EV were 
obtained. Interestingly, the preparation of exosome fraction by ultra-centrifugation showed, 
particularly in the third pellet after preparation, cell-derived vesicles originated from other cell-
types primary not included in the concentrates. This aspect needs to be further investigated. 
However, it needs urgent research whether PL-EVs derived from RBC units are useful as 
procoagulant vesicles transferred during the application of RBC units to anemia patients or are 
carriers of specific proteins that affect both, red blood cells in concentrates and patient response 
after transfusion, thus causing adverse effects,  
Despite of the fact that every milliliter of concentrate gained in apheresis is extremely valuable, 
further investigations are necessary with the purpose of determination of extracellular vesicles 
in concentrates of peripheral blood stem cell apheresis.  
It is true that some cell-derived vesicles, for example, erythrocyte-derived vesicles (47), may be 
less influenced by washing steps or activation during centrifugation and they could be 
interpreted as false positive contamination of the blood concentrate of foreign cell type lineage; 
yet, the fact remains that type-specific vesicles are not the only structures found in the 
appropriate concentrates. They could appear due to the cell stress during apheresis as well as 
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due to other preparation techniques and they may be implemented in the plasma components 
of apheresis concentrates. Otherwise, the residual erythrocytes and residual leukocytes are 
sufficient to form MVE (multivesicular endosomes) and their secretion or degradation might be 
the only longer living breath of cells in vitro.  
On the whole, findings of EVs in blood components raise an important clinical question in 
context of the application of blood products to patients, namely, whether activation of PLTs and 
procoagulant PL-EVs in PCs are more effective in general or applicable to a selective group of 
patients only. For example, patients with severe hematologic-oncologic diseases need 
concentrates with less activated and less shedded PLTs for prophylactic treatment. These 
platelets may exhibit longer survival and viability in circulation and are not subjected to rapid 
clearance. In contrast, patients with polytraumata settings, with sepsis or MODS may benefit 
from more coagulant PCs consisting of differentially affected PLTs. The application of various 
types of vesicles may influence the clinical treatment as there is a choice between fresh PCs 
and altered PLTs/ PL-EVs.  
Finally, it has to be kept in mind that PCs comprise different amount of PL-EVs. PL-EVs range 
in size between approx. 70 nm and 550 nm. Moreover, considering the results of this study, it 
would be of importance to elucidate what kind of platelet activatability is to be expected after 
five days of storage. Such information could be obtained through a simple, applicable analysis 
of PL-EV amount in concentrates.  
In conclusion, many different aspects affecting the activation of PLTs from PCs and, 
consequently, EV production were presented and discussed in this dissertation. The amount of 
PL-EVs in PCs may be influenced by numerous factors such as donor-specific variables, the 
course of the manufacturing process and storage, pre-analytical factors and level of 
responsiveness of PLTs. Thus, it is crucial to gather more information on PL-EVs concerning 
their phenotype, formation process, proteomics and functional genomics in order to unravel 
mechanisms of coagulation of PL-EVs in PCs. The same information should be provided in 
order to transfusion that is more successful.   
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VII Summary 
Platelet-derived extracellular vesicles (PL-EVs) constitute the major part of circulating EVs in 
blood. They are also present in platelet concentrates (PCs) and may influence the quality of 
PCs as recent reports implicate significant pro-thrombotic and pro-coagulant activities of PL-
EVs. The aim of the present study was to analyze PC-derived PL-EVs and to correlate them 
with standard quality control (QC) parameters of PCs (e.g. functional capacity of platelets, 
duration of hemapheresis) and with donor-specific laboratory parameters (e.g. BMI, immature 
platelet fraction). 
PL-EVs, shed from activated and senescent platelets, were analyzed by nanoparticle tracking 
analysis (NTA) and standard (Navios™) as well as by advanced high sensitivity (Apogee 50M) 
flow cytometry. A hematology analyzer was applied to the determination of the platelet count 
and immature platelet fraction (IPF). Functional capacity of platelets (i.e. externalization of 
CD62P in response to standard TRAP-6 activation) was measured by flow cytometry. Standard 
QC parameters were recorded during platelet hemapheresis. All in vitro measurements were 
carried out on day 0 (PC-production, ‘fresh platelets’) and on day 5 (after PC expiry, ‘senescent 
platelets’). Altogether, n=106 PC-samples were investigated and n=42 (15 of them were 
irradiated with 25 Gy on day 0) were included in the specific statistical analysis. 
The externalization of CD62P, indicative for intact platelet function in PCs, significantly 
decreased during in vitro platelet senescence and this was inversely correlated with the 
significant increase of PL-EVs concentration. The size of PL-EVs varied in all PCs investigated, 
ranging from approx. 70 nm to 550 nm, suggesting that the size spectrum of PL-EVs depends 
on different vesicle formation mechanisms based on corresponding PLT condition.  
Interestingly, in fresh PCs it was found that there is a significant correlation between PL-EVs 
and PC-production with different hemapheresis instruments, duration of platelet apheresis and 
the IPF count in peripheral blood of the donor prior to apheresis. In senescent PCs, the BMI of 
donors inversely correlated with the PL-EV counts. 
Accurate measurement of PL-EVs is highly recommended in the regular QC of PCs as a 
plausibility check of platelet function. Shedding of PL-EVs in PCs depends on shear stress in 
hemapheresis and diverse pre-analytical conditions, leading to a conclusion that the quality of 
platelet concentrates is strongly influenced by PL-EVs. 
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VIII Zusammenfassung 
Im zirkulierenden Blut des Menschen stammt der überwiegende Anteil der extrazellulären 
Vesikel (EVs) von Thrombozyten und Megakaryozyten ab. Die thrombozytären EVs kommen 
ebenfalls in Apheresekonzentraten, wie beispielsweise Thrombozytapheresekonzentraten (TKs) 
vor und beeinflussen die Qualität der Blutprodukte auf unterschiedliche, noch nicht umfassend 
geklärte Weise. Unter anderem haben thrombozytäre EVs erwiesenermaßen pro-thrombotische 
und pro-koagulatorische Eigenschaften, die damit auch die pharmazeutische Wirkung der 
Blutprodukte beeinflussen.  
Ziel der vorliegenden Studie war, den qualitativen und quantitativen Nachweis von 
thrombozytären EVs in TKs mit den aktuell standardisierten Parametern der Qualitätskontrolle 
(QK) zu korrelieren. Standardtests umfassten dabei unter anderem die funktionelle Kapazität 
von Thrombozyten im TK und die Apheresedauer bei Herstellung der TKs und die damit 
verbundene Aktivierung der Plättchen durch Scherkräfte. Es wurden ebenfalls Spender-
spezifische Laborparameter, wie Glukose, Thrombozytenzahl vor Apherese oder unreife 
Thrombozytenfraktion, als auch klinisch orientierende Parameter (z.B. Body Mass Index, BMI) 
auf einen Zusammenhang mit dem Nachweis von thrombozytären EVs hin untersucht. 
Thrombozytäre EVs werden von der Membran aktivierter und/ oder alternder Plättchen 
abgeschnürt. Diese wurden mittels eines Nanoparticle Tracking Analysis (NTA)-Verfahrens, 
eines Standard Durchflusszytometers (Navios™), als auch mit einem hochauflösenden  
Durchflusszytometer (Apogee 50M) gemessen. Die Thrombozytenzahl und Fraktion unreifer 
Thrombozyten wurde mit einem automatisierten Hämatologie-Automaten bestimmt. Die 
funktionelle Kapazität von Thrombozyten anhand der Expression von P-Selectin (CD62P) nach 
Aktivierung mit TRAP-6-Reagenz wurde durchflusszytometrisch erfasst. Die übrigen Standard-
Parameter für die QK wurden während der Aphereseprozedur ermittelt. Alle in vitro Tests 
wurden an frischen Thrombozyten am Tag der Herstellung (Tag 0) und mit gealterten 
Thrombozyten bei sachgerechter Lagerung der Konzentrate nach Ablauf der Haltbarkeit (Tag 5) 
durchgeführt. Insgesamt wurden 106 TK-Proben untersucht. Von allen Proben wurden 42 TKs, 
darunter 15 bestrahlte TKs (25 Gy am Tag der Herstellung), in die spezielle Auswertung 
eingeschlossen. 
Die Expression von CD62P als Indikator für intakte, funktionsfähige Thrombozyten, nahm 
während der in vitro Lagerung der TKs über einen Zeitraum von 5 Tagen signifikant ab. Diese 
Funktionsabnahme der Plättchen korrelierte signifikant invers mit der Zunahme von 
thrombozytären EVs pro Thrombozytenzahl. Die Größe der thrombozytären EVs der 
untersuchten TKs variierte heterogen in einem Bereich von 70 - 550 nm, was darauf schließen 
lässt, dass verschiedene Mechanismen der Produktion von EVs zu Grunde liegen. 
Interessanterweise zeigten sich signifikante Unterschiede des EV-Gehaltes in frischen TKs 
durch den Einsatz unterschiedlicher Apherese-Maschinen, durch die unterschiedliche 
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Apheresedauer und die Fraktion unreifer Thrombozyten aus peripherem Blut der Spender vor 
der Apherese. In TKs mit gealterten Thrombozyten korrelierte der Anteil thrombozytärer EVs 
invers mit dem BMI der Spender. 
Die Messung des Anteils an thrombozytären EVs in TKs ist als sinnvoller Plausibilitätstests zur 
Funktionalität der Thrombozyten in der regulären QK zu empfehlen. Die Vesikulation von 
thrombozytären EVs in TKs ist abhängig vom Scherstress der Thrombozyten während der 
Herstellung und ist abhängig von verschiedenen anderen präanalytischen und Spender-
spezifischen Faktoren. Demzufolge beeinflusst der Anteil an thrombozytären EVs die Qualität 
von Thrombozytapheresekonzentraten.  
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